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1 Summary
Cellular phenotype plasticity is a hallmark of embryonic development in order to achieve
cell type specification from precursor populations. The molecular mechanisms orches-
trating phenotypic plasticity are of interest because they may also help to understand
how its dysregulation contributes to disease development, in particular cancer. The
neural crest is an embryonic cell population that is well known for its migratory capacity
and phenotypic plasticity. Malignant melanoma, an aggressive type of skin cancer, is
a neural crest-related malignancy originating from the pigment producing melanocytes
in the epidermis. In the recent years, it became clear to the field of neural crest biol-
ogists that melanoma is an ideal model system to study basic principles of phenotype
plasticity of the neural crest cell lineage. Melanoma cells are highly prone to phenotype
switching and this is linked to the expression level of MITF (Microphthalmia-associated
transcription factor), the master transcription factor of the melanocyte cell lineage that
induces the expression of pigmentation-related genes among other effects. On this ba-
sis, melanoma cell state transitions have been classified as a binary switch between a
differentiated MITFhigh proliferative phenotype and a dedifferentiated MITFlow invasive
phenotype. However, intermediate melanoma cell states, as well as the detailed molec-
ular mechanisms concerting the transitions remain elusive.
In this study we identified a novel nascent invasive cell state in melanoma. This pheno-
type exhibits early inflammatory and early invasive signaling programs although keeping
the differentiation signature. Expression of the cell surface 5'ectonucleotidase CD73
was revealed as a marker for nascent invasiveness and further increased upon full dedif-
ferentiation. Interestingly, CD73 is not only known as a mesenchymal stem cell marker,
but also involved in tumor immunosuppression and therefore emerges as a target for
cancer immunotherapy. Computational and in vitro studies confirmed a critical co-
operation of mitogenic growth factors and pro-inflammatory cytokines inducing CD73
expression. This was dependent on the MEK-ERK signaling cascade and coordinated
by the transcription factor c-Jun, which critically bound to an intronic enhancer within
the CD73 genomic locus. The findings reported in this thesis provide novel mechanistic
insight into neural crest plasticity, melanoma cell state transitions and the regulation of
a CD73-dependent immunosuppressive tumor microenvironment.
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2 Zusammenfassung
Phänotypische Plastizität ist ein entscheidender Mechanismus in der Embryonalentwick-
lung um die Vielzahl von Zelltypen aus Vorläuferpopulationen zu erzeugen. Die zugrunde
liegenden molekularen Mechanismen sind von grofler Bedeutung, da sie auch unser
Verständnis von Pathomechanismen verbessern wie z.B. bei Krebs. Die Neuralleiste
ist eine embryonale Vorläuferzellpopulation, bekannt für eine hohe Migrationsaktivität
und phänotypische Plastizität. Das maligne Melanom, ein aggressiver Hautkrebs, ist
ein Abkömmling der Neuralleiste und entsteht aus den Melanozyten in der Epider-
mis. Im Feld der Neuralleistenbiologie ist es in den letzten Jahre klar geworden, dass
das Melanom ein ideales Modell ist für die Untersuchung der phänotypischen Plastiz-
ität. Melanomzellen neigen stark zu Phänotypveränderungen und zentral ist dabei die
Expression von MITF (Mikrophthalmie-assoziierter Transkriptionsfaktor), dem Schlüs-
seltranskriptionsfaktor der melanozytären Zellreiche. Bisher wurden Zellzustände in
Melanomzellen daher binär in einen differenzierten MITF-reichen und proliferativen
Phänotyp sowie einen de-differenzierten MITF-armen und invasiven Phänotyp eingeteilt.
Jedoch verbleiben Zwischenzustände sowie die genauen molekularen Mechanismen, die
diese übergänge kontrollieren, unzureichend erforscht.
In dieser Studie konnten wir einen neuartigen früh-invasiven Zellzustand in Melanomzellen
identifizieren, der durch einen Anstieg entzündlicher und invasiver Signalprogramme in
einer Subpopulation von differenzierten Melanomzellen gekennzeichnet ist. Wir fanden
heraus, dass die membranständige 5'Ektonukleotidase CD73 einen Marker für diese früh-
invasive Zellpopulation darstellt und bei vollständiger invasiver Phänotypumschaltung
von Melanomzellen weiter hochreguliert wird. CD73 nicht nur als Marker mesenchy-
maler Stammzellen bekannt, sondern auch bedeutsam für Tumor-Immunsuppression
und damit ein potentielles Ziel für Immuntherapien gegen Krebs. Bioinformatische
Analysen und in vitro Studien wiesen auf ein kritisches Zusammenspiel von mitogenen
Wachstumsfaktorenund pro- inflammatorischen Zytokinen bei der Induktion von CD73
hin. Die Induktion von CD73 war dabei abhängig von der MEK-ERK-Signalkaskade
und wurde koordiniert von dem Transkriptionsfaktor c-Jun über Bindung an einen in-
tronischen Enhancer im CD73 Gen. Die Ergebnisse dieser Arbeit bieten neue Einblicke
in Prozesse welche Plastizität der Neuralleiste und im Melanom steuern, insbesondere
in die Regulation eines CD73-abhängigen immunsuppressiven Tumormikromilieus, und
erleichtern damit die rationale Entwicklung zukünftiger kombinatorischer Immunthera-
pien.
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3 Introduction
3.1 Melanoma - causes and consequences
3.1.1 Origin and development of melanoma
Melanoma arises from malignant transformation of melanocytes, the pigment producing
cells of the skin. Because of its neural crest origin it forms an highly aggressive and early
metastasizing form of cancer. Melanoma cells display high invasiveness, adaptivity and
chemoresistence leading to poor clinical outcome and death if not diagnosed at an early
stage. In contrast to local restricted and early stage melanoma, which can be cured by
surgical excision in most cases [227], advanced melanoma leads to death within 6-12
months [254]. Hence, even though melanomas make up only about 5% of skin cancers,
they cause most of skin cancer related death [188]. Alarmingly, in contrast to other
cancer entities, melanoma incidence in the western world is still rising and expected to
double every 10 - 20 years [154, 85].
During development, transitory and highly invasive cells of the neural crest migrate
throughout the body to build the peripheral nervous system as neurons and Schwann
cells, and constitute cells of the endocrine system, facial cartilage and smooth mus-
cle [244]. Within hair follicles and the basal layer of the skin, they form melanocytes
[247, 94]. The function of melanocytes is to protect the DNA at those outer parts
of the body from DNA damage by highly energetic ultraviolet (UV) radiation (Fig-
ure 3.1). Damaged DNA from keratinocytes stimulates the production and secretion
of melanosome vesicles in melanocytes, which contain the pigment molecule melanin.
Melanin protects cellular DNA from reactive oxygen species (ROS) and functions like
a shield around the nucleus of keratinocytes in the skin, causing the effect of tanning
[247, 94].
The Clark Model on melanoma development proposes several sequential steps during
melanocyte transformation (Figure 3.1) [43]: A cell that is encountering DNA damage
accumulates errors during DNA repair, leading to an increase in mutational load. In
case tumor-suppressor genes or proto-oncogenes become affected, this results in aber-
rant proliferation and the development of a hyperplastic lesion. Still, cell cycle control
mechanisms curtail uncontrolled growth and mediate oncogene-induced cellular senes-
cence, resulting in a benign melanocytic nevus that may remain dormant or progress
5
3 Introduction
after prolonged time [165]. In contrast, dysplastic nevi are associated with rapid, ir-
regular growth and contingent malignant progression [95]. Bypass of senescence is the
consequence of further somatic mutations or genetic predispositions leading to cell cy-
cle deregulation [20]. Melanoma first spreads horizontally within the epidermis, termed
radial growth phase (RGP). Upon progression it comes to loss of adhesion and gain of
migratory capacities initiating a vertical growth phase (VGF) that allows escape from
tight control by keratinocytes. Vertical migration via stromal cell interactions into the
dermis passes the basement membrane, and eventually leads to metastatic dissemination
[93]. Today we know that only about 20-30% of melanoma arise from transformation
of benign melanocytic or dysplastic nevi, yet the majority of 70-80% develop de novo
from melanocytes with no previously detected hyperplastic lesion [16] (Figure 3.1, blue
dotted lines). Transformation from RGP to VGP has major impact on melanoma malig-
nancy, hence tumor thickness as measured by Breslow Depth is still the best prognostic
parameter [28, 254].
Benign 
Nevus
Metastatic 
Melanoma
Melanocyte
Basement membrane
Ep
id
er
m
is
De
rm
is
Melanoma development
RGP VGPKeratinocytes
Vasculature
Dyplastic
Nevus
Figure 3.1: Melanocyte function and the Clark Model for development and progression of
melanoma Melanocytes are located in the basement membrane and, upon UV radiation transfer
melanin pigment to keratinocytes via dendrite processes. Melanin located around the nucleus is scat-
tering energetic light in order to protect from DNA damage. Oncogenic mutations cause hyperplastic
proliferation of melanocytes, resulting induction of senescence and benign melanocytic or dysplastic
nevi. Upon cell cycle deregulation horizontal spreading in a radial growth phase (RGP) follows. Malig-
nancy of melanoma is achieved upon progression to a vertical growth phase (VGP), eventually resulting
in metastasis. Dotted arrows indicate potential conversions in melanoma development.
3.1.2 Risk factors for melanoma
The major known risk factor for the development of melanoma is intermittent and heavy
UV radiation, especially during childhood [150]. Especially UVB radiation is highly geno-
toxic by causing cyclobutane pyrimidine dimers (CPDs) between adjacent cytosine (C)
and thymine (T) residues. Those alterations are error-prone in repair, and lead to the
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characteristic UVB signature mutations CT or CC into TT. Therefore melanomas exhibit
the highest mutational load across all tumor entities with more than 10 mutations per
DNA megabase [156, 6]. UV radiation also provokes microenvironmental changes such
as the release of growth hormones and immune remodeling factors by keratinocytes,
shaping and impairing proper immune cell functions and vice versa provoking gain of
an embryonic, aggressive phenotype in the transforming melanocytes [13, 156]. Addi-
tional risk factors for the development of melanoma are summarized in Figure 3.2, and
include a family history of melanoma [16], personal history of melanoma [95], increased
occurrence of nevi [84] as well as drug-related [153] and age-related immunosupression
[253]. Pale, fair-skinned and, most of all, red-haired individuals are at highest risk
of developing cutaneous melanoma [82]. Accordingly, in Australian and New Zealand
inhabitants melanoma manifests with an incidence rate of approximately 60 cases per
100,000 in a year, whereas 1 in 100,000 dark-skinned African people develops cutaneous
melanoma [67]. Additionally, there is a gender dependent preferential location of cuta-
neous melanoma: Males are more likely to develop melanoma on the back, melanomas
in females are more often found on the legs [210].
Risk 
factors
sun burn
age
genetic pre-
disposition
immuno-
suppression
elevated 
nevi counts
pale 
complexion
intermittent 
UV
red 
hair
Melanocyte
Melanoma
Figure 3.2: Risks factors for melanoma Schematic overview on the major risk factors for melanoma
development.
3.1.3 The genetics of melanoma
Genetic alternations promoting melanoma development can be splitted into germline
and somatic mutations and are depicted in Figure 3.3, A. About 10% of melanoma
cases trace back to familiar genetic defects in the CDKN2A or CDK4 genes leading to
a deregulated cell cycle or in the MC1R locus disturbing central melanocytic signaling
cascades and leading to impaired pigmentation, pale skin and red hair [40]. Interestingly,
individuals with germline mutations in p53, who are highly prone to cancer development,
are only rarely affected by melanoma [158]. About 50% of familiar melanoma lack a
clear genetic basis so far [16]. Sporadic somatic mutations in combination with environ-
mental factors account for 90% of cutaneous melanomas in individuals with no familiar
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predisposition (Figure 3.3, A). In 85% of those melanomas, primary driver mutations
are found to alter mitogen-activated protein kinases (MAPK) pathway activity[5, 132].
The MAPK signaling cascade is essential for melanoma growth and progression [72]. It
mediates signaling downstream of receptor tyrosine kinases (RTKs), i.e, cMET, FGFR
and cKIT in melanoma, as well as G protein coupled receptors (GPCRs) [72]. It is com-
posed of several sequential kinase modules that specify, modify and amplify signaling
transmission for regulation of target gene transcription as schematically illustrated in
Figure 3.3, B. Ligand induced receptor trans-phosphorylation promotes RAS activation
by GDP to GTP exchange. RAS-GTP, if not instantly inactivated by NF1, activates ki-
nase signal transmission by phosphorylation of RAF, which in turn phosphorylates MEK,
that phosphorylates ERK. pERK finally translocates to the nucleus and modulates tar-
get transcription factor (TF) activity. About 50% of melanoma harbor alterations in
the rapidly accelerated fibrosarcoma protein kinase B (BRAF) gene causing constitu-
tive signaling activation independent from RAS [50]. BRAFV600E accounts for 90%
of those genetic abberations, overall leading to an 600x hyper-activation in comparison
to wildtype (WT) BRAF [266]. Mutually exclusive to deregulated BRAF are MAPK
hyper-activating mutations in the neuroblastoma RAS viral oncogene homolog (NRAS)
gene, which occur in 20% of melanoma and most commonly affect the position Q61
[115]. Interestingly, common BRAF and NRAS mutations do not exhibit a characteristic
UV signature and are believed to result from UV induced genotoxic stress, such as ROS
[105, 63]. Recently, the era of deep sequencing revealed NF1 inactivation mutations in
about 15% of melanomas to constitute the third frequent driver mutation, leaving 15%
BRAF/NRAS/NF1 triple WT melanomas that harbor rare, or so far unknown primary
driver mutations [132, 105].
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Figure 3.3: Genetic drivers of melanoma. (A): Illustration on the genetics of melanoma develop-
ment, with primary somatic driver mutations leading to MAPK hyper-activation and main secondary
driver mutations, which are important for overcoming oncogene-induced senescence. Germline muta-
tions which predispose for melanoma are indicated below. 3x WT = BRAF/NRAS/NF1 triple wildtype.
Right side: 90% of melanoma sporadic, 10% of familiar predisposition. (B): Schematic overview on
molecular signal transduction by the MAPK cascade. P = phosphorylation.
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Sole constitutive MAPK pathway activation causes oncogene-induced senescence [54],
which is giving an explanation for about 80% of benign melanocytic nevi harboring
BRAF mutations [187]. Secondary driver mutations in melanoma that bypass senes-
cence cause the loss of p16INK4a, p14ARF or p53 [184]. Also, an hyper-activation of AKT
/ phosphatidylinositol-3-kinases (PI3K) signaling is observed in up to 40% of melanoma,
predominately due to inactivating mutations in the negative regulator PTEN, but also
due to amplification of AKT [228]. Besides MITF amplification and overexpression is
found in 4-21% of melanoma patients [105, 86].
3.2 Therapy of melanoma
Prognosis and therapy of melanoma largely depends on its stage. As long as melanoma
growth is locally restricted surgical excision presents the first choice of treatment and a 5
year survival rate of 98% is encouraging [227] (Figure 3.4, A). However, metastasizing
melanomas evolve rapidly and unnoticed due to their small size, leading to a rapid
drop of the 5 year survival rate with less than 10% for treated patients [83]. Poor
survival was also a result of the limited and poorly effective options for treatment.
Only 10-15% of patients benefit from DNA-alkylating chemotherapy by Dacarbazine,
which for a long time represented the only FDA approved treatment for advanced
melanoma, but still did not improve the overall survival [254]. Also, high dose IFN
therapy, that was introduced as adjuvant treatment after surgery, did not show a clear
improvement of overall survival, while substantial side-effects had to be tolerated [128,
127]. High dose of IL2, that was introduced subsequently, achieved significant responses
in a small subset of patients, yet showed high toxicity [12]. After a long time of fruitless
research, therapy of advanced melanoma was revolutionized twice by the introduction
of targeted therapy and immune checkpoint blockade in the early 2010s (Figure 3.4, B
and C).
3.2.1 Targeted therapy
In the year 2002, the discovery of mutant BRAF driving melanoma proliferation and
survival in half of all patients pushed the development of targeted therapy by MAPK
cascade small molecule inhibitors [269, 50]. In 2011, Vermurafenib was the first FDA
approved inhibitor targeting mutant BRAF, leading to rapid remission of multiple metas-
tases in patients suffering from metastatic melanoma with significant improved overall
survival and response rates of 84% and 48% after 6 month, respectively. In comparison,
in the Dacarbazine control arm, only 5% of patients responded to the treatment and
after 6 months only 64% were still alive [37, 124]. In 2013, Dabrafenib as a further
inhibitor of mutant BRAF and Trametinib as a non-competitive inhibitor of MEK1/2,
were approved for the treatment of advanced melanoma, both showing similar benefits
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like Vemurafenib [97, 78]. ERK inhibitors, such as SCH772984, are under clinical in-
vestigation currently. Despite the great enthusiasm from initial therapeutic responses,
major drawback occurred by the nearly imperative acquired resistance after 5-12 months
and the development of additional metastases [37, 97, 157]. Several targeted therapy
combinatorial treatment approaches were tested in clinical trails with the hope to cir-
cumvent common resistance pathways. Even though achieving an increased overall
and progression free survival, therapy resistance, relapse and death of patients occurred
eventually [137, 145, 77].
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Further options of targeting PI3K-AKT-mTOR signaling in melanoma are of high in-
terest, especially for patients suffering from NRAS mutant melanoma with so far no
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established targeted therapy and for patients suffering from BRAF mutant melanoma
with primary resistance to BRAF inhibition (BRAFi) by loss of PTEN [254]. Com-
bining MAPK inhibition (MAPKi) and PI3K inhibition (PI3Ki) has achieved promising
results, overcoming resistance development in vitro [92] and clinical trials are under de-
velopment. Even though targeting cKIT by Imatinib in previously unselected advanced
melanoma has failed to achieve significant results in clinical trails [258], ongoing studies
on patients selected on melanoma with rare KIT mutations are promising [35]. An
overview on currently available targeted therapies for advanced melanoma and drugs
that are in clinical testing is given in Figure 3.4, C.
3.2.2 Cancer immunoediting and checkpoint immune
blockade
The idea that the immune system detects and fights malignant transformation has been
proposed already in 1957 by Paul Ehrlich and MacFarlane Burnet [65, 30]. In the follow-
ing decades, evidence on the existence of tumor-associated antigens and tumor-specific
immune cells accumulated. The identification of melanoma-associated-antigens pro-
vided suitable targets for therapeutical stimulation of an anti-tumor immune response.
Melanoma-associated-antigens include melanocytic proteins that are expressed in high
abundance in melanoma, such as Melan-A, gp100, TRP1 and TRP2, and the cancer
testis antigens MAGE-1, MAGE-2 and NY-ESO-1. With respect to these findings, highly
personalized and labor-intensive adoptive T cell transfer (ACT) therapies have been de-
veloped. ACT involves the ex vivo activation and expansion of a patient’s tumor-specific
T cells, for strengthening anti-tumor immune responses upon re-infusion and has dis-
played durable clinical effects in a fraction of melanoma patients [204]. Latest research
focusses on the development of genetically engineered chimeric antigen receptor (CAR)
T cells, allowing the bypass of tumor immunosuppression and HLA restricted antigen
detection [61].
Immune checkpoint blockade brought major advances for the therapy of advanced
melanoma and for the first time, long term effective responses and durable remissions
were seen [104, 212]. It is based on Schreiber’s model, which proposes a pre-existing
anti-tumor immune response that has been shut off by the tumor in a co-evolutionary
process of tumor immunoediting [60, 59]. Tumor immunoediting harnesses the ver-
satile mechanisms of the immune system to control excess inflammation and prevent
auto-immunity, in order to hide from immune recognition [60, 59]. Blocking negative
immune checkpoints aims on intrinsic reactivation of the patient’s own anti-tumor im-
mune response, as summarized in Figure 3.4, B [200]. The first immune checkpoint
inhibitor for melanoma therapy was Ipilimumab, a fully humanized blocking antibody
against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is a negative im-
mune checkpoint receptor highly expressed on dysfunctional T cells in the tumor [104].
Under physiological conditions, CTLA-4 prevents self-recognition of T cells after thy-
mus maturation. With respect to this, it prohibits the activation of naïve T-cells in the
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lymph node by interfering with co-stimulatory CD28-B7 signaling during T cell - anti-
gen presenting cells (APC) interactions and leading to T cell anergy (Figure 3.4, B left
side) [134, 265]. Subsequent clinical studies directed against the programmed cell death
protein 1 (PD-1) / programmed cell death protein 1 ligand 1 (PD-L1) axis, achieved
even more remarkable results and lead to accelerated FDA approval of the PD-1 mon-
oclonal blocking antibodies Nivolumab and Pembrolizumab [202, 203, 251, 42]. PD-1
is expressed on activated T cells, B cells and myeloid cells and operates in the effector
phase of an immune response within peripheral tissues by ligation to either PD-L2 on B
cells and macrophages, or PD-L1, which can be induced by IFNγ during inflammation
in a variety of tissues, including tumors (Figure 3.4, B right side) [17]. PD-1 - PD-L1/
PD-L2 interaction terminates T cell responses and leads to an exhausted phenotype,
which is important for the establishment of peripheral tolerance and at the same time a
mechanism commonly harnessed by tumor cells [76, 270].
With the FDA approval of Ipilimumab, Nivolumab and Pembrolizumab the treatment
scheme of advanced melanoma was restructured and immune checkpoint therapy was
set as the new frontline, replacing Dacarbacine chemotherapy [202, 203, 251, 104, 42].
Considering the immunogenic effects that have been attributed to MAPK blockade in
melanoma, a combination of targeted therapy and checkpoint immune therapy seems
highly promising [31, 26]. However, first approaches in this direction, combining BRAFi
and CTLA-4 blockade were unsuccessful in clinical trials due to toxicity issues [199].
Further attempts, combining MEKi and PD-1 blockade seems to be able to circumvent
BRAFi-mediated paradoxical T cell reactivation and associated toxicity [21]. Investi-
gations on a triple blockade of MEK, BRAF and PD-1 are currently ongoing [198].
Long-term follow-up studies on immune checkpoint inhibitors reveal enduring complete
remission in a fraction of metastatic melanoma patients [212]. The ongoing success of
immune checkpoint blockade has unleashed the dream of curing advanced melanoma
and current research focusses on the evaluation of further immunomodulatory molecules
as targets for combinatorial immunotherapy.
3.2.3 Therapy resistance and tumor heterogeneity
Tumor heterogeneity is the main obstacle during cancer therapy and a major cause for
therapy resistance [75]. In melanoma both, spatial and temporal heterogeneity, have
been described [219, 141]. On a histomorphological level melanoma heterogeneity is
readily observable by the presence or absence of pigmentation [14]. Moreover, the broad
histomorphological spectrum can complicate diagnosis, as melanomas can even adopt
morphologies of schwannomas or neurofibromas [211, 109].
One part of tumor heterogeneity and resulting consequences for therapy resistance is ex-
plained by the gene-centric theory of clonal evolution, which follows the darwinistic prin-
ciple "survival of the fittest". During cancer development genomic instability together
with unlimited proliferation facilitates the accumulation of mutations [75, 161, 173].
This leads to high genetic diversification of the offspring and establishes the basis of an
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iterative selection process in favor of cancer cells with optimal environmental adaptation
[75, 161, 173]. Branching of clones rather than linear clonal evolution generates high
diversity in coexisting tumor cell clones with individual mutational signatures [89]. Ac-
cording to this concept, therapy resistance is the result of selection for tumor cell clones
with genetic aberrations enabling the bypass of treatment.
One can discriminate between primary therapy resistance, defined by a given predisposi-
tion of a tumor to escape from therapy, and acquired therapy resistance, that describes
de novo changes arising under therapy. As an example, primary resistance against tar-
geted therapy in melanoma is associated with the expression of BCL2A1 [96], loss of
PTEN [183], activation of CCND1 [229] or mutations in CDKN2A and CDK4 [40].
Acquired therapy resistance is caused by MAPK signaling re-activating mutations in
about 70% of cases, and in 22% by mutations activating the PI3K/AKT pathway
[225].
Clearly, selection on cancer cells with survival benefits due to genetic traits is decisive
for therapy resistance, yet not sufficient to explain the complete spectrum of treat-
ment responses, in both targeted therapy and immunotherapeutic approaches. In the
recent years, we have realized that both, phenotypic and genetic diversity contributes
to tumor heterogeneity. Reciprocal interactions between tumor cell subpopulations
and cells of the tumor microenvironment impact on the phenotype and behavior of
a tumor, enabling rapid adaptation to environmental changes during therapeutic in-
terventions [159]. Non-genetic heterogeneity relates to differences in tumor cell dif-
ferentiation, metabolic and transcriptional programs, tumor cell immunogenicity and
composition of the tumor microenvironment [155]. Today we know that such pheno-
typic heterogeneity explains up to 40% of existence or emergence of therapy resistance
[225, 260, 264]. In this regard, it has been shown that a dedifferentiated gene expression
signature is associated with resistance to targeted therapy in melanoma [167, 129] and
melanoma escape from immunotherapy by undergoing inflammation-induced dediffer-
entiation [136]. On the contrary, the melanocytic lineage program has also emerged in
promoting therapy resistance [117], hinting on complex phenotype - therapy resistance
relations.
3.3 Melanoma phenotype switching
3.3.1 Concepts of phenotypic heterogeneity
Initially, a rare slow-cycling cancer stem cell (CSC) within the rapidly proliferating bulk
of cancer cells has been highlighted in non-genetic heterogeneity causing therapy resis-
tance. Therapy resistant CSCs are believed to populate the tumor bulk in a hierarchical
manner by giving rise to highly proliferative and more differentiated offsprings [155]. In
melanoma, the expression of several neural-crest associated markers has been suggested
for the identification of CSCs. Among them are nerve growth factor receptor (NGFR)
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/ CD271 [25], CD133 [164], ALDH1 [27], ABCB5 [213] and the B cell marker CD20
[71]. Estimates on the frequency suggested stem cell properties in a highly rare fraction
of 0.0001% of melanoma cells [213]. An interesting study by Quintana et al. showed
that about 25% of melanoma cells were able to initiate tumor growth irrespective of
CSC marker expression when injected into highly immunocompromised mice, thereby
questioning the hierarchical concept of CSCs [191]. Another study by Shackleton and
colleagues showed that both CD133 positive and CD133 negative melanoma cell sub-
populations are equally tumorigenic and recapitulate the initial spectrum of CD133 ex-
pression in developing tumors [220]. The unidirectional CSC model was revised and more
emphasis was set on reciprocal interactions between tumor cells and cells of the tumor
microenvironment. Presently, CSCs are rather seen as distinct cancer cell phenotypes
that arise non-hierarchically by stochastic fluctuation.
Differentiated cells, which revert their phenotype and temporarily switch back to a
pluripotent cell state in physiological processes, have been first observed in the phe-
nomenon of epithelial to mesenchymal transition (EMT) or in the other direction in
mesenchymal to epithelial transition (MET) [99]. Epithelial cells that undergo EMT
reorganize signaling programs, lose apical-basal polarity and adhesion. In parallel, they
acquire features of motile invasive mesenchymal cells. This process is essential during
development and wound healing, but also an integral feature during fibrosis and cancer
progression [246, 245]. The capacity to revert differentiation in response to microen-
vironmental cues is especially manifest for cells of neuroectodermal origin, as they are
determined to undergo EMT-like changes during development in order to leave the
neural crest and invade the body. As an example, it has been shown that activation
of NOTCH signaling in terminally differentiated melanocytes initiated reprogramming
to a neural-crest like stem cell state [185]. Furthermore, expression of EMT-related
TFs, such as ZEB2 and SLUG as well as the mesenchymal related markers CDH2 and
Vimentin, can still be detected in terminally differentiated melanocytes to some extent
[126].
3.3.2 Phenotypic plasticity in melanoma
Gene expression analyses in large collections of melanoma cell lines and cohorts of pri-
mary and metastatic tumors from melanoma patients yielded substantial insights into
the taxonomy of melanoma phenotypes [24, 107]. Two distinct, mutually exclusive
transcriptional profiles of melanoma cells emerged, which set the basis for classification
of the MITFhigh proliferative and MITFlow invasive phenotypes in melanoma [107, 34].
MITFhigh proliferative cells are attributed with a high rate of proliferation and a high
degree of differentiation, including expression of melanocytic antigens, which usually
enables identification already on a visual level by the black pigment melanin [34]. On
the contrary, MITFlow invasive cells are missing pigmentation, and adapt a slow-cycling
de-differentiated cell state with an increased migratory potential. This phenotype is
prone to invasion and metastatic dissemination [34]. Importantly, MITF has evolved
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not only as a marker the proliferative phenotype, but has also been assigned the cen-
tral regulator of melanoma phenotypic plasticity [39]. MITF comprises nine isoforms
and belongs to the Myc-related family of basic helix-loop-helix (bHLH) leucine zipper
TFs [139]. MITF-M (in the following termed MITF) is the shortest isoform and exclu-
sively expressed in melanocytes [34]. During melanocyte differentiation MITF promotes
melanoblast survival and proliferation and prevents trans-differentiation into glial and
neuronal lineages [179]. In melanoma, MITF is termed the melanoma lineage onco-
gene, as it is overexpressed in many melanomas and induction of MITF in melanocytes
has been shown to overcome oncogene induced senescence [52]. The Rheostat Model
explains lineage dependent expression in melanoma and compensation for loss of MITF
expression [34]. It proposes that melanomas with high levels of MITF are differenti-
ated though highly proliferative. However, cells will initiate final differentiation upon
enforced elevation of MITF. Low levels of MITF are only tolerated when a stem cell like
phenotype is acquired, on the contrary acute MITF depletion is leading to senescence
and cell death [86].
Direct evidence for in vivo melanoma cell phenotype switching came from a study by
Hoek et al., who showed that both proliferative and invasive melanoma cell lines were
capable to form tumors in immunocompromised mice [106]. Additionally, tumors of
both MITFlow invasive and MITFhigh proliferative cell lines revealed similar heterogenous
expression of MITF and the proliferation marker Ki67 in immunohistochemical analyses
of the established tumors [106]. Importantly, single cell RNA sequencing (scRNA-
seq) of melanoma cells derived from human melanoma revealed that even within a
single tumor of the proliferative phenotype, cells with an invasive signature coexist,
indicating that stochastic phenotype switching is present in vivo [248, 88]. While MITF
expression clearly defines a proliferative phenotype in melanoma, several markers have
been proposed to identify an invasive melanoma cell state. Most research has been
performed on the neural crest marker NGFR, which was first assigned to play a role as
a CSC marker in melanoma [25]. The RTK AXL is frequently over-expressed in invasive
melanoma cell lines and plays a direct role for melanoma cell migration and survival
[218, 167]. A switch from CDH1 to CDH2 is a well accepted feature of disseminating
melanoma cells during formation of metastasis, and hence CDH2 expression has been
used to study melanoma cell dedifferentiation.
3.3.3 The tumor microenvironment shapes melanoma cell
states
Reciprocal interactions between tumor cells and their microenvironment had already
been noticed by Paget in 1889, when he postulated his theory on "Seed and Soil"
for cancer cell dissemination: A cancer cell seed will only survive and form metastasis
at a distant site when the site of implantation provides adequate soil for its nidation
and growth [180]. Initial evidence for microenvironmental driven metastatic phenotype
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switching in melanoma was provided by a study which showed reversible transdifferen-
tiation and acquisition of invasive features in melanocytes, which were cultured side by
side with metastatic melanoma cells [217]. Since then, data showing the importance of
the tumor microenvironment for shaping cancer cell phenotypes has accumulated [2].
An overview on microenvironmental stress triggers, cell type interactions and signaling
molecules involved in reciprocally shaping tumor and bystander cell phenotypes is given
in Figure 3.5, and will be described in detail below.
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Figure 3.5: Melanoma plasticity is a result of tumor cell - microenvironment interactions
Figure adapted from Reinhardt et al. [194]. Mediators of inflammation and therapy-induced stress
are depicted that change the tumor-microenvironment, melanoma cell characteristics, and reciprocally
influence cancer and cancer-associated-cells’ phenotypes. Inflammation promotes phenotype switching
from a MITFhigh proliferative melanoma cell state (brown) to a MITFlow invasive phenotype (red). An
anti-tumoral immune response (blue immune and stromal cells) is remodeled to chronic pro-tumorigenic
inflammation (green immune and stromal cells). Red and brown arrows highlight reversible phenotype
switching. CTLs: Cytotoxic T lymphocytes, CAFs: Cancer-associated fibroblasts, ECM: extracellular
matrix, EMT: Epithelial-mesenchymal transition, MET: Mesenchymal-epithelial transition.
During phenotype switching melanoma cells respond and adapt to cellular stress in order
to cope with intracellular imbalance and ensure survival. Stress can be caused by many
triggers, such as energy shortage that requires modulation of metabolism, genotoxic
stress induced by DNA damage, toxic stress affecting proper protein functions and
inflammation [70, 175, 136, 38]. Hypoxia represents a further stress condition and
a hallmark of the developing tumor. Phenotype switching of melanoma cells towards
an invasive cell state and metastatic dissemination in response to hypoxia has been
repetitively shown [38, 271, 74]. On the contrary, oxidative stress is a main burden
during metastatic dissemination. Melanoma cells have been shown to adopt to hostile
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conditions while circulating by changing metabolic pathways [186]. An effective therapy
represents a strong impulse for phenotype switching, as it involves all kinds of stress
triggers. Stress impulses that promote phenotype switching are not only provided by
environmental triggers, but also by tumor cells, which has been recently demonstrated
in a study by Obenauf et al., who found that melanoma cells protect neighboring
melanoma cells by a therapy-induced secretome [175].
Within the tumor microenvironment altered stromal cells constitute an important source
of factors that shape melanoma cell states (Figure 3.5, upper part). For example, it
has been shown that components of the extracellular matrix (ECM), which are secreted
by cancer-associated fibroblasts (CAFs), such as Fibronection, TenascinC and THBS1,
can modulate and activate melanoma cell PI3K signaling and the focal adhesion ki-
nase (FAK) via integrins, thereby leading to transcriptional rewiring and conferring
therapy resistance [73, 103]. Fibroblasts that secrete HGF are involved in remodeling
melanoma signaling programs upon BRAFi [238]. HGF derived from keratinocytes
has been demonstrated to down-regulate melanoma cell CDH1 expression, thereby
increasing invasiveness [140]. Another way keratinocytes are promoting melanoma
cell invasive phenotype switching involves NOTCH signaling and subsequent down-
regulation of MITF in melanoma [90]. Furthermore, fibroblasts in an aged microen-
vironment were found to promote melanoma cell invasiveness by secretion of sFRP2,
an inhibitor of canonical WNT signaling [121, 123]. Of note, this finding provides
an explanation for the poor prognosis observed for melanoma in the elderly [149]. In
return, phenotype switching from invasive to proliferative is required during seeding
of metastasis. Addressing this aspect, a recent study in a zebrafish model provided
interesting results on the involvement of Endothelin-3 at the site of metastasis to pro-
mote MET-like switching in melanoma cells and thus allowing metastatic dissemination
[125].
Understanding inflammation-induced phenotype switching during the development of
therapy resistance has come into focus by the recent advances in targeted therapy
and anti-cancer immunotherapy. Effective immunotherapies elicit a strong anti-tumoral
inflammatory response within the tumor accompanied by infiltration of myeloids, neu-
trophils, cytotoxic T cells and NK cells that promote high tumoral concentrations of
IFNγ and TNFα. Long lasting tumoral inflammation initiates remodeling processes and
converts an acute into a chronic pro-tumorigenic inflammation [47]. As an example, in a
syngeneic melanoma mouse model for ACT, TNFα promoted reversible dedifferentiation
of melanoma cells, accompanied by loss of target antigen, leading to ablated anti-tumor
T cell recognition and therapy resistance [136]. A recent study found that besides T
cells, NK cells provide a source of TNFα within the tumor microenvironment, medi-
ating invasive phenotype switching of melanoma cells [280]. In another model, TNFα
released in the course of neutrophilic inflammation in response to intermittent UV expo-
sure promoted melanoma cell switching to an angiotrophic phenotype and perivascular
metastatic invasion [13]. Additionally, TNFα mediated melanoma cell dedifferentiation
has been implicated in resistance to targeted therapy [129]. Vice versa, invasive pheno-
type switching in melanoma counter-impacts on the composition of immune cells within
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the tumor microenvironment. A summary of tumor-immune cell interactions that re-
ciprocally shape the tumor microenvironment is illustrated in the lower part of Figure
3.5. Melanoma cell invasive phenotype switching is accompanied by up-regulation of
NFκB target genes in melanoma cells and recruitment of pro-tumorigenic myeloid cells
via CCL2, CCL5 and CXCL1/2 chemokine secretion [201]. Inflammation-associated
phenotype switching has been associated with inflammatory niches build by CAFs and
myeloid cells that secrete CXCR2 ligands and Il1β, respectively [278]. In line with
experimental evidence for the importance of inflammation in phenotype switching and
therapy resistance, clinical data show failure of immune checkpoint blockade to correlate
with an invasive phenotype in melanoma [113].
3.3.4 A regulatory network of melanoma phenotype
switching
An important mechanism in melanoma phenotype switching is the reciprocal antago-
nism of proliferative and invasive signaling hubs, which are controlled by a plentitude
of stress triggers. An overview on the main stress triggers that comprise hypoxia, star-
vation, cellular stress, inflammation, therapeutic intervention, molecular mediators, and
antagonistic signaling pathways is given in Figure 3.6.
MITF in melanocytes is regulated by αMSH binding to MC1R, which leads to accu-
mulation of cAMP and induction of MITF expression via CREB in cooperation with
the neural-crest specific TF SOX10 [189, 112]. Furthermore, canonical WNT sig-
naling via WNT1/3a and stabilization of βcatenin is driving MITF expression [241].
Constitutive expression of MITF promotes melanoma cell proliferation, survival and
is orchestrating differentiation genes, altogether driving the proliferative phenotype
[139]. At the same time, MITF expression is inhibiting invasive phenotype switch-
ing [39, 34]. Carreira et al. have shown Dia1 as a central regulator in that process [34].
More recent studies reveal metabolic remodeling by MITF leading to an impairment
of RHO-GTPases, which are essential for invasion [23]. Importantly, in previous work
we could show that MITF directly antagonizes JUN, central player of inflammation-
and stress-triggered phenotype switching through binding in the JUN enhancer region
[201]. Furthermore, there is evidence, that CDH1 impairs JUN at post-translational
level [234].
In return, invasive signaling hubs antagonize MITF and a proliferative cell state in many
ways. Several stem cell-associated and neural crest signaling pathways have been im-
plicated. Most relevant are WNT5a mediating non-canonical WNT signaling, TGFβ
signaling and inflammatory pathway activation [176]. Hypoxia leads to stabilization of
HIF1α inducing BHLHB2 expression which in return represses MITF [38, 271]. Further-
more, hypoxia augments an invasive phenotype by a switch from ROR1 to ROR2 expres-
sion, thereby promoting non-canonical WNT signaling via WNT5a [176]. Repression of
MITF by non-canonical WNT signaling is mediated by activation of Stat3, that represses
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Pax3, which is an inducer of MITF expression, in summary lowering MITF expression
[56]. In addition, non-canonical WNT signaling leads to the induction of invasive signa-
ture genes and EMT TFs, such as Vimentin and Snail [57].
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from Reinhardt et al. [194]. Schematic overview adapted from Reinhardt et al. depicting known
molecular mechanisms involved in melanoma phenotype switching due to environmental stress triggers
as indicated.
We recently showed that JUN induces invasive phenotype switching, while at the same
time counteracting MITF on a transcriptional and translational level by so far unknown
mechanisms [201]. Various stress impulses via p38, JNK, and NFκB signaling can
converge on, or cooperate with AP1/ JUN to orchestrate melanoma cell plasticity. Ad-
ditionally, under MAPKi therapy, elevated JUN levels have been repetitively observed
causing phenotype switching, resulting in therapy resistance [51, 69, 192, 249]. So far,
JunB/ATF2 heterodimers have been reported to down-regulate MITF expression by
interfering with SOX10 [222]. Another study, that performed transcriptomic and epige-
netic analyses on melanoma culture panels, confirmed MITF/SOX10 and AP1/TEAD
as regulators for proliferative and invasive melanoma cells, respectively [262]. In addi-
tion to JUN, the TFs Brn-2, Gli-2, Zeb1 have been identified to oppose MITF and a
proliferative phenotype, while inducing invasive signature genes [91, 116, 33, 192, 201].
In detail, Brn-2 has been shown to repress MITF, while at the same time promoting
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melanoma cell dedifferentiation [91].
Translational reprogramming represents another recently highlighted feature of melanoma
phenotype switching. Rapid growth of tumor cells imperatively leads to nutrient de-
privation. With respect to this, Falletta and colleagues showed massive translational
reprogramming in melanoma cells in a situation of glutamine starvation, which was
initiated by blockade of the translation initiation factor eIF2B and led to invasive phe-
notype switching. In parallel, an integrated stress response was observed to block MITF
via ATF4. Intriguingly, the group was able to show similar effects when treating the
cells with TNFα providing further insides on the mechanisms of inflammation-induced
dedifferentiation of melanoma cells [70].
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4 Objectives of this study
Phenotypic plasticity endows cancer cells to rapidly adapt to and bypass potential harm-
ful conditions, impacting on cell survival, tumor growth, metastasis and mediating ther-
apy resistance. However, despite all the progress made in recent years, we are only
beginning to decode the regulatory network of melanoma phenotype switching. Inflam-
mation and stress signaling in the tumor represent key determinants of an effective
therapeutic response [2]. The fact that both are also key triggers for melanoma pheno-
type switching bridges the gap to plasticity-related therapy resistance and underlines the
importance for understanding inflammation-induced cell state transitions in melanoma
on a functional and molecular level. Enhanced understanding of the underlying molec-
ular mechanisms eventually provides control of phenotype switching with the goal to
forestall therapy resistance and prevent metastatic spread. Initial attempts for directed
phenotype switching during melanoma therapy have already shown promising results
[208, 230].
The central hypothesis of this thesis claims the existence of additional transition cell
states in melanoma between the well characterized opposing phenotypes defined by the
presence or absence of melanocytic differentiation programs or invasive dedifferentiation
signatures. In order gain a more detailed understanding on the trajectory of melanoma
phenotypes and to allow insights into process of interconversion, three specific aims are
defined:
1. To identify transitory cell states by bioinformatic investigation of inflammatory
signature marks on large melanoma expression data and to evaluate markers for
molecular and functional characterization of transition cell states (see chapter
6.1).
2. To characterize molecular pathways that are orchestrating intermediate cell state
interconversion and that are regulating intermediate cell state marker expression
(see chapter 6.2).
3. To dissect transcription factor binding sites controlling melanoma phenotype
switching using functional genomics (see chapter 6.3 and 6.4).
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5 Material and methods
5.1 General laboratory equipment
5.1.1 Instruments and equipment
Table 5.1: Instruments and equipment
Instrument Company
Axio Vert A1 Microscope Biorad
BD FACS ARIA III cell sorter BD Biosciences
BD FACS Canto II flow cytometer BD Biosciences
Branson analog sonifier 250 Branson Ultrasonics
Centrifuges (5417R, 5424, 5810K) Eppendorf
Excella® E24 incubator shaker New Brunswick Scientific
Freezer -80°C MDF-U55V-PE Panasonic
HERAcell® 240 CO2 incubator Thermo Fisher Scientific
HERAsafe® KS laminar air flow cabinet Thermo Fisher Scientific
Heraeus® microbiological incubator Thermo Fisher Scientific
Julabo TW8 waterbath Julabo
InGenius3 gel documentation system Syngene
Light Cycler® 480 II Roche
Magnetic stirrer Stuart™ stirplate SB161 Sigma-Aldrich
Mini-PROTEAN® electrophoresis cell Biorad
Micropipettes Pipet-Lite LTS Rainin/ Mettler-Toledo
MiSeq sequencer Illumina
Mr Frosty™ freezing container Thermo Fisher Scientific
Multistep pipettor VWR
NanoDrop 2000 spectrophotometer Thermo Fisher Scientific
Odyssey® SA imaging system LI-COR® Bioscience
PerfectBLUE™ gel system Peqlab
pH meter Hanna® pH 21 Woonsocket
Pipetboy pipetting aid Integra Biosciences
Power Source VWR, Radnor, PA, USA
Scale TE601 Sartorius
Spectrometer Ultrospec 10 Amersham Biosciences
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Table 5.1: Instruments and equipment
TC10™ automated cell counter Biorad
ThermoMixer® R Eppendorf
T100 thermal cycler Biorad, Hercules
Ultraviolet transilluminator GelVue Syngene
VV3 vortexer VWR
5.1.2 Software
Table 5.2: Software
Software Developer/ Company
ApE V2.0.50 M. Wayne Davis
FACS Diva V6.1.1 BD Biosciences
FV10-ASW Viewer Olympus
FlowJo® V8.7.3 Tree star, Inc.
GenSys V1.5.4.0 Syngene
UCSC genome browser Kent et al. [122]
GraphPad Prism7 GraphPad Software, Inc.
javaGSEA desktop application V3.0 BROAD Institute, MIT
LATEX Leslie Lamport
Light Cycler® 480 Software V1.5.1.62 Roche
Maggelan V7.1 SP Tecan
Microsoft Office for Mac 2011 Microsoft Corporation
NanoDrop 2000/2000C V1.4.2 Thermo Fisher Scientific
Odyssey® Sa Application Software V1.1 LI-COR® Bioscience
Outknocker.org V1.31 Jonathan L. Schmid-Burgk [215]
R V3.3.3 R foundation, R Development
RStudio V1.0.153 RStudio, Inc.
TexShop V3.84 Richard Koch
ZEN light microscopy software Zeiss
5.1.3 Consumables and plasticware
Table 5.3: Consumables and plasticware
Article Company
Blotting paper VWR
Cell culture flasks (T25, T75) Sarstedt
Cell culture dishes (10 cm, 15 cm) Sarstedt
Centrifuge tubes (5 ml) Eppendorf
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Table 5.3: Consumables and plasticware
Centrifuge tubes (15 ml, 50 ml) Sarstedt
Falcon™ Cell strainers (70 µm) Thermo Fisher Scientific
Flow cytometry tubes Sarstedt
Micropipette tips Starlab
Micropipette tips, with filter Starlab
Multidispenser tips (5 ml, 12.5 ml) VWR
Nitrocellulose membrane (0.45 µm) GE Healthcare
Parafilm® M Brand
Pasteur glas pipettes VWR
PCR adhesive seals Sarstedt
PCR plates (96well) Sarstedt
PCR stripes and lids (8well) Axygen
Petri dishes Sarstedt
qPCR adhesive seals Biozym Scientific GmbH
qPCR plates Biozym Scientific GmbH
Reagent reservoirs Labomedic
Round bottom test plates (96well) Geiner Bio-One
Serological pipettes (5 ml, 10 ml, 25 ml) Corning
Spin columns for DNA preparation Centric Biotec
Spin columns for RNA preparation Zymo Research Group
Syringes (5 ml, 10 ml, 20 ml) B. Braun Melsungen AG
Syringe pore filters (0.2 µm, 0.45 µm) VWR
Tissue culture test plates (6well, 12well,
24well, 96well)
Techno Plastic Products AG
5.1.4 Chemicals
Table 5.4: Chemicals
Substance Company
Acetic acid (C2H4O2) Carl Roth GmbH
Agar Agar, Kobe I Carl Roth GmbH
Agarose Powder Invitrogen, Thermo Fisher Scientific
Ampicillin Carl Roth GmbH
Ampuwa® ultrapure water Fresenius Kabi GmbH
Ammonium persulfat ((NH4)2S2O8) Carl Roth GmbH
Bovine Serum Albumine (BSA) Carl Roth GmbH
Albumin Fraction V
Bromphenolblue (C19H10Br4O5S) Carl Roth GmbH
Calcium chloride (CaCl2) Carl Roth GmbH
Dimethylsulfoxide (DMSO) (C2H6OS) Carl Roth GmbH
Disodium phosphate (Na2HPO4) Carl Roth GmbH
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Table 5.4: Chemicals
Dithiothreitol (DTT) (C4H10O2S2) Carl Roth GmbH
Doxycycline monohydrate Sigma-Aldrich
(C22H24H2O8 · H2O )
Ethanol, absolute (C2H6O) Carl Roth GmbH
Ethanol, 70%, denatured Otto Fischar GmbH & Co. KG
Ethidium bromide (EtBr) (C21H20BrN3) Carl Roth GmbH
Ethylenediaminetetraacetic acid (EDTA)
(C10H16H2O8)
Carl Roth GmbH
D-Glucose (C6H12O6) Carl Roth GmbH
Glycerol (C3H8O3C) Carl Roth GmbH
Glycogen Carl Roth GmbH
Guanidinium chloride (CH6ClH3) Carl Roth GmbH
HEPES (C8H18N2O4S) Carl Roth GmbH
Hydrochloric acid (HCl) 32% Carl Roth GmbH
Hydrochloric acid (HCl) 37% Carl Roth GmbH
Isopropanol (C3H8O) Carl Roth GmbH
LB medium powder Lennox Carl Roth GmbH
Magnesium choride (MgCl2) Merck Millipore
Magnesium sulfate (MgSO4) Carl Roth GmbH
Methanol (CH4O) Carl Roth GmbH
Monopotassium phosphate (KH2PO4) Carl Roth GmbH
Potassium acetate (CH3CO2K) Carl Roth GmbH
Potassium chloride (KCl) Carl Roth GmbH
Rotiphorese Gel30, Carl Roth GmbH
30% solution of Acrylamide (C3H5NO)/
Bisacrylamide (C7H10N2O2) (37.5:1)
Sodium acetate (C2H3NaO2) Carl Roth GmbH
Sodium azide (NaN3) AppliChem
Sodium chloride (NaCl) Carl Roth GmbH
Sodium dodecyl sulfate (SDS) pellets Carl Roth GmbH
(NaC12H25SO4)
Sodium hydroxide (NaOH) Carl Roth GmbH
Tetramethylethylenediamine (TEMED) Carl Roth GmbH
Tris-HCl Carl Roth GmbH
Triton X-100 Sigma-Aldrich
Tween 20 Carl Roth GmbH
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5.1.5 Cell culture substances
Table 5.5: Cell culture substances
Substance Company
Blasticidine S hydrochloride Sigma-Aldrich
Dulbecco’s modified eagles medium Gibco Life Tech, Thermo Scientific
(DMEM)
Dulbecco’s phosphate buffered saline Gibco Life Tech, Thermo Scientific
(DPBS)
Fetal Bovine Serum (FBS) Gibco Life Tech, Thermo Scientific
GlutaMAX™ Gibco Life Tech, Thermo Scientific
L-Glutamine (200 mM) Invitrogen, Thermo Scientific
Opti-MEM™ Gibco Life Tech, Thermo Scientific
Penicillin/Streptomycin (100x) Invitrogen, Thermo Scientific
Puromycine dihydrochloride Sigma-Aldrich
RPMI 1640 medium Gibco Life Tech, Thermo Scientific
Sodium pyruvate (100 mM) Gibco Life Tech, Thermo Scientific
Trypsin-EDTA (0.05 %) Gibco Life Tech, Thermo Scientific
5.1.6 Recombinant proteins and peptidases
Table 5.6: Recombinant proteins and peptidases
Name Dilutent Stock Working Company
conc. conc.
HGF Ampuwa® 100 µg/ml 50 ng/ml Peprotech
TNFα Ampuwa® 1000 U/µl 1000 U/ml Peprotech
5.1.7 Cell culture stimulants and inhibitors
Table 5.7: Cell culture stimulants and inhibitors
Name Dilutent Stock Working Company
conc. conc.
Aphidicolin DMSO 10 mg/ml 1 µg/ml Sigma Aldrich
5-Azacytidine DMSO 10 mM 1-10 µM Sigma Aldrich
BEZ235 DMSO 14.9 mM 1 µM SelleckChem
MK2206 DMSO 20 mM 1 µM SelleckChem
Phorbol-12- DMSO 1 mg/ml 100 ng/ml Sigma Aldrich
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Table 5.7: Cell culture stimulants and inhibitors
myristat-
13-acetat
(PMA)
SCH772984 DMSO 10 mM 1 µM SelleckChem
Sotrastaurin DMSO 10 mM 1 µM SelleckChem
SP600125 DMSO 10 mM 20 µM SelleckChem
Trametinib DMSO 1 mM 50 nM SelleckChem
5.1.8 Commercially available kits, reagents and enzymes
Table 5.8: Commercially available kits, reagents and enzymes
Reagent Company
All-in-One cDNA Synthesis SuperMix Biotool
BbsI (5,000 U/ml) NEB
Broad range protein marker sc-2361 Santa Cruz
cOmplete™ protease inhibitor cocktail Roche
Desoxynucleotide(dNTPs) solution mix,
10 mM
Thermo Scientific
DreamTaq™ DNA polymerase Thermo Scientific
Evagreen® qPCR-Mix II (ROX) Biobudget
EZ DNA Methylation-Direct kit Zymo Research
FACSFlow™ BD Biosciences
FastDigest™ AvrII Thermo Scientific
FastDigest™ BamHI Thermo Scientific
FastDigest™ NheI Thermo Scientific
Fugene® HD transfection reagent Promega
GeneRuler™ 1 kb DNA ladder Thermo Scientific
GFP-Trap® MA ChromoTek GmbH
InnuPREP gel extraction kit Analytik Jena
InnuPREP PCRpure kit Analytik Jena
MluI (10,000 U/ml) NEB
Propidium iodide solution (50 µ/ml) #
556463
BD Bioscience
Proteinase K (800 U/ml) NEB
PureLink™ HiPure Plasmid MidiPrep kit Thermo Scientific
PureLink™ RNase A (20 mg/ml) Thermo Scientific
Phusion® High-Fidelity DNA polymerase NEB
SalI-HF (20,000 U/ml) NEB
SimpleChIP® enzymatic chromatin IP kit CellSignaling
RLT lysis buffer Qiagen
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Table 5.8: Commercially available kits, reagents and enzymes
RW1 RNA wash buffer Qiagen
T4 DNA Ligase (40,0000 U/ml) NEB
Zymo RNA wash buffer Zymo Research
5.1.9 Primary antibodies for immunoblot
Table 5.9: Primary antibodies for immunoblot
Directed Produced Dilution Clone Company Catalog
against in number
AKT mouse 1:2000 40D4 CellSignaling CS#2920
βActin mouse 1:500 C-4 Santa Cruz SC-47778
CD73 rabbit 1:1000 D7F9A CellSignaling CS#13160
C-FOS rabbit 1:1000 9F6 CellSignaling CS#2250
JUN rabbit 1:1000 60A8 CellSignaling CS#9165
ERK1/2 rabbit 1:1000 polyclonal CellSignaling CS#9102
FOSL1 rabbit 1:200 R-20 Santa Cruz SC-604
GFP mouse 1:200 B-2 Santa Cruz SC-9996
IκBα rabbit 1:1000 L35A5 CellSignaling CS#4814
JUNB mouse 1:200 C-11 Santa Cruz SC-8051
MITF rabbit 1:250 polyclonal Atlas HPA
Antibodies 003259
pAKT rabbit 1:2000 D7E CellSignaling CS#4060
(Ser473)
pMET rabbit 1:1000 D26 CellSignaling CS#3077
(Tyr1234/1235)
pERK mouse 1:200 E-4 Santa Cruz SC-7383
(Tyr204)
p38 rabbit 1:1000 D13E1 CellSignaling CS#8690
pp38 rabbit 1:1000 D3F9 CellSignaling CS#4511
(Thr180/Tyr182)
5.1.10 Secondary antibodies for immunoblot
Table 5.10: Secondary antibodies for immunoblot
Dye Directed Produced Dilution Company
against in
IRDye680LT mouse donkey 1:15,000 LI-COR
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Table 5.10: Secondary Antibodies for Immunoblot
IRDye680LT rabbit donkey 1:15,000 LI-COR
IRDye800CW mouse donkey 1:15,000 LI-COR
IRDye800CW rabbit donkey 1:15,000 LI-COR
5.1.11 Antibodies for flow cytometry
Table 5.11: Antibodies for flow cytometry
Dye Directed Produced Dilution Clone Company
against in
Brilliant CD73 mouse 1:100 AD2 Biolegend
Vilolet
421™
5.1.12 Molecular biology - buffers, media and agar
10x phosphate buffered saline (PBS):
80 g NaCl
11.6 g Na2HPO4
2 g KH2PO4
2 g KCL
add up to 1 l with ddH2O
1x PBS:
100 ml 10x PBS
add up to 1 l with ddH2O
1x TAE:
dissolve in ddH2O
40 mM Tris-HCl
20 mM acetic acid
1 mM EDTA
6x loading dye:
dissolve in ddH2O
10 mM Tris HCl pH 7.6
0.03% (w/v) Bromophenol Blue
60% (v/v) Glycerol
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EtBr agarose gels:
Table 5.12: Preparation of EtBr agarose gels
1% gel 1.5% gel 2% gel
Agarose powder 1.5 g 2.25 g 1.3 g
1x TAE 150 ml 150 ml 150 ml
Boil until dissolved
EtBr 5 µl 5 µl 5 µl
Annealing buffer:
dissolve in Ampuwa® H2O
100 nM NaCl
50 mM HEPES
NaOH to adjust pH to 7.4
Lysogeny Broth (LB) medium:
20 g LB medium powder Lennox
5 g NaCl
30g Agar Agar Kobe I
add up to 1 l ddH2O
autoclave for 15min at 121°C
cool down to room temperature (RT)
100 mg/l Ampicillin
Agar bacterial plates:
20 g LB medium powder Lennox
5 g NaCl
add up to 1 l ddH2O
autoclave for 15min at 121°C
cool down to RT
100 mg/l Ampicillin
pour 8ml per petri dish
Resuspension buffer P1:
dissolve in Ampuwa® H2O
50 mM Tris-HCl pH 8.0
10 mM EDTA
100 µg/ml RNaseA
store at 4°C
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Neutralisation buffer N3:
dissolve in Ampuwa® H2O
4.2 M Guanidinium chloride
0.9 M Potassium acetate
32% HCl to adjust pH to 4.8
Wash buffer PE:
dissolve in Ampuwa® H2O:
10 mM Tris-HCl pH 7.5
80% (v/v) ethanol
5.1.13 Cell culture media and buffers
Complete RPMI:
Gibco® RPMI 1640
10% (v/v) heat-inactivated (60 min,56°C) FCS
1% (v/v) Penicillin/Streptomycin
1% (v/v) L-Glutamine
store at 4°C
THP1 medium:
Gibco® RPMI 1640
10% (v/v) heat-inactivated (60 min,56°C) FCS
1% (v/v) Penicillin/Streptomycin
1% (v/v) Sodium pyruvate
store at 4°C
Complete DMEM:
Gibco® DMEM
10% (v/v) heat-inactivated (60 min,56°C) FCS
1% (v/v) Penicillin/Streptomycin
1% (v/v) L-Glutamine
store at 4°C
2x freezing medium:
Gibco® DMEM
40% (v/v) medium of respective cell line to be frozen
50% (v/v) FBS
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20% (v/v) DMSO
store at 4°C
2x HBS:
dissolve in Ampuwa® H2O:
274 mM NaCl
10 mM KCl
1.4 mM Na2HPO4
42 mM HEPES
15 mM D-Glucose
NaOH adjust pH to 7.05
Fluorescence-activated cell sorting (FACS) buffer:
dissolve in DPBS
2% (v/v) FBS
0.1% (w/v) Sodium azide
store at 4°C
5.1.14 Lysis buffers
Direct Lysis Buffer (DLB):
dissolve in Ampuwa® H2O:
10 mM Tris-HCl
1 mM CaCl2
1 mM MgCl2
1 mM EDTA
1% (v/v) Triton X 100
32% HCl to adjust pH to 7.5
store at 4°C
prior use freshly add 100 µg/ml Proteinase K
Lysis buffer for gDNA isolation:
dissolve in Ampuwa® H2O:
100 mM Tris-HCl pH 8.0
5 mM EDTA pH 8.0
200 mM NaCl
0.2% (w/v) SDS
prior use freshly add 100 µg/ml Proteinase K
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Lysis buffer P2:
dissolve in Ampuwa® H2O: 100 mM Tris-HCl pH 8.0
200 mM NaOH
1% (w/v) SDS
prior use freshly add 100 µg/ml Proteinase K
1x Lämmli buffer:
dissolve in Ampuwa® H2O:
120nM Tris-HCl pH 6.8
4% (w/v) SDS
20% (v/v) Glycerol
0.02% (w/v) Bromophenolblue
20 mM DTT
5.1.15 Immunoblot buffers and preparation of SDS PAGE
gels
1 M Tris pH 6.8:
121.1 g Tris-HCl
stir and warm until dissolved
32% HCL to adjust to pH 6.8
add up to 1 l with ddH2O
1 M Tris pH 8.8:
121.1 g Tris-HCl
stir and warm until dissolved
32% HCL to adjust to pH 8.8
add up to 1 l with ddH2O
10x SDS running buffer:
29 g Tris-HCl
144 g Glycine
10 g SDS
stir and warm until dissolved
add up to 1 l with ddH2O
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10x Tris-Glyine buffer:
29 g Tris-HCl
144 g Glycine
add up to 1 l with ddH2O
1x Transfer buffer:
100 ml 10x Tris-Glycine buffer
200 ml Methanol
add up to 1 l with ddH2O
10x TBS:
80 g NaCl
30 g Tris-HCl
37% HCl to adjust to pH 7.6
add up to 1 l with ddH2O
1x TBS:
100 ml 10x TBS
add up to 1 l with ddH2O
1x TBS-T:
100 ml 10x TBS
500 µl Tween-20
add up to 1 l with ddH2O
SDS PAGE gels:
Table 5.13: Preparation of SDS PAGE gels
6% gel 10% gel 12% gel
ddH2O 4.00 ml 2.71 ml 2.04 ml
Rotiphorese® Gel30 2.00 ml 3.33 ml 4.00 ml
1M Tris-HCl (pH 8.8) 3.75 ml 3.75 ml 3.75 ml
10% SDS 0.1 ml 0.1 ml 0.1 ml
10% APS 0.1 ml 0.1 ml 0.1 ml
TEMED 8 µl 8 µl 8 µl
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SDS polyacrylamide gelelectropheresis (PAGE) 3% stacking gel:
2.26 ml ddH2O
0.3 ml Rotiphorese® Gel30
0.38 ml 1M Tris-HCl (pH 6.8)
30 µl 10% SDS
30 µl 10% APS
3 µl TEMED
5.1.16 Cell lines and bacteria
Table 5.14: Cell lines and bacteria
Cell line/ bacteria Obtained from
HEK293T cells ATCC® CRL-3216™ purchased from
ATCC, Mannassas, VA, USA
Escherichia coli(e. coli) DH10β V. Hornung, Bonn, Germany
MaMel human melanoma cell lines D. Schadendorf, Essen, Germany. Gener-
ation described by Ugurel et al [259].
MZ7 melanoma cells T. Wölfel, Mainz, Germany
SK.Mel28 melanoma cells T. Wölfel, Mainz, Germany
THP1 monocyte cells V. Hornung, Bonn, Germany
5.1.17 Primer sequences
All primers were purchased from Microsynth AG (Balgach, Switzerland).
Primers for cloning:
Table 5.15: Primers for cloning
Primer name Primer sequence (5’-3’) Application
Seq-pLV-tetO-fwd TGATAGAGAACGTATGTCGAGG Sequencing
Seq-pLV-tetO-rev GCAGCGTATCCACATAGCGTAAA Sequencing
Seq-pRp-fwd GGAGACGCCATCCACGCTG Sequencing
Seq-pRp-rev CTGACCTTGATCTGAACTTCTC Sequencing
pRpCitrine- TGCATGACGCGTATGGTGAGCAAGGGCGAGGAGCT PCR
MluI-fwd
pRpCirine- ACTTCAGTCGACCTACTTGTACAGCTCGTCCATGCCG PCR
SalI-rev
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Table 5.15: Primers for cloning
pRpcJUN- TGCATGACGCGTATGACTGCAAAGATGGAAACGAC PCR
MluI-fwd
Px330- TCTAGAGCCATTTGTCTGCAG PCR
gRNA-rev1
Px330-U6-start GAGGGCCTATTTCCCATGATTC PCR/
Sequencing
Primers for analyzing mRNA expression in quantitative polymerase chain
reaction (qPCR):
Table 5.16: Primers for analyzing mRNA expression in qPCR
Primer Sequence of forward Sequence of reverse
name (fwd)-primer (5’-3’) (rev)-primer (5’-3’)
MITF AGGAGTTGCTGATGGTGAGG GAAATCTTGGGCTTGATGGA
MLANA TTCTTGTGGGCATCTTCTTG GCTCATCGGCTGTTGGTATT
NT5E GAGTGGCTCGATCAGTCCTT GGCACTATCTGGTTCACCGT
TYR CTTCTTGAAGAGGACGGTGC TGTCCCAGGTACAGGGATCT
UBC CAGGGTACGACCATCTTCCAG GGAGCCGAGTGACACCATTG
Primers for quantitative PCR of Chromatin Immunoprecipitation (ChIP):
Table 5.17: Primers for ChIP qPCR
Primer Sequence of Sequence of
name fwd-primer (5’-3’) rev-primer (5’-3’)
AP1-1 TGTTACTCTTTCCCTCTCTGCTGG GCCACATACAACCAGGGAGTCA
AP1-2 GCTGGCAGTGCTTCAGGAAATC GTGACTCAGCTTCATTGCCCAT
AP1-3 CTGCATCATGCATCCTACACTGC GGAAACTAGAGGGATGAGGCAGTA
AP1-4 CCTGTAAATGAATGCTGCCGTTGG CCTCCATCCTGGTTCCTGTGTTA
AP1-5 AGAGGAAACTGCGGTTCTGAGATG CCTCCAGCCTCATTCCTGACA
AP1-6 CCCAGTTAGGAGGCTGTGGTAG GTCAATAAAGCCAGAAGCCCTGG
AP1-7 ATGGGTTATGACCAGTAGTAGGGC CCTGGGGCTGTTCTTGACATCTTA
AP1-8 CCCATGTGCCTTTGATGAGTCAG CCCTTCCTTTCTCTCGTGTCCTT
Ctrl-1 ACCAAAGTCCAGGAAAGGAGGG CGGAGCTTTCATGCCCTACCT
Ctrl-2 TGCTCGCGGGATGTTACTCTG GCAGAGAGCCTGGCATGTAGTA
Ctrl-3 TTCAGGTGCCCTCAGTTCCAG GCTGATACACCAGAGACAGACGT
Ctrl-4 AGAGTCACAAGCTAGGATGCAGG CTGCTGTTCTGTGACTGTGGC
Ctrl-5 CCTGTGGTTTGTGTCCATCAGTG GGGAACAAAGGACAGGCTACAGA
Neg-Ctrl ATGGTTGCCACTGGGGATCT TGCCAAAGCCTAGGGGAAGA
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sgRNA oligonucleotide sequences targeting NT5E in intronic
c-JUN/AP1-sites and ctrl sites and NF1 in exon 4 and exon 27 for
annealing and cloning in px330:
Table 5.18: sgRNA oligonucleotide sequences
Oligo Top strand (TS) Bottom strand (BS)
name oligonucleotide sequence oligonucleotide sequence
(5’-3’) (5’-3’)
AP1-1 CACCTATGAGTGAATCACATCCTC AAACGAGGATGTGATTCACTCATA
AP1-2 CACCGGGGGCGGTGAGTCAAGC AAACGCTTGACTCACCGCCCCC
AP1-3 CACCGAGTCACAGTATAATCTGAG AAACCTCAGATTATACTGTGACTC
AP1-5 CACCGGCAAGTGCTGACTCAATAC AAACGTATTGAGTCAGCACTTGCC
AP1-6 CACCGCCAAGACAGTGAGTCAC AAACGTGACTCACTGTCTTGGC
Ctrl CACCGTGACACCAGGTGAGCTC AAACGAGCTCACCTGGTGTCAC
Primers for first level PCRs evaluating CpG methylation of bisulfite
converted DNA, clustered regularly interspaced short palindromic repeats
(CRISPR)/CRISPR-associated protein 9(Cas9) NT5E intronic AP1-site
targeting by deep sequencing:
Table 5.19: Primers for first level MiSeq PCR
Primer name Primer sequence (5’-3’)
AP1-1-NGS-fwd ACACTCTTTCCCTACACGACGctcttccgatct-
CACATACAACCAGGGAGTCAGCT
AP1-1-NGS-rev TGACTGGAGTTCAGACGTGTGctcttccgatct-
CTCCAGTTGCAGCCCCTAAAACA
AP1-2a-NGS-fwd ACACTCTTTCCCTACACGACGctcttccgatct-
AATGAAAATCCTGCCTCCGTCTG
AP1-2a-NGS-rev TGACTGGAGTTCAGACGTGTGctcttccgatct-
GTCTTGTTGCTCACACAAAGCCT
AP1-2b-NGS-fwd ACACTCTTTCCCTACACGACGctcttccgatct-
AGCCCTTCAGCTAGGTTTGCAGT
AP1-2b-NGS-rev TGACTGGAGTTCAGACGTGTGctcttccgatct-
CAGTGCTTCAGGAAATCGGGTGT
AP1-5-NGS-fwd ACACTCTTTCCCTACACGACGctcttccgatct-
GAGTGCAGTAAGAGTACCACCCT
AP1-5-NGS-rev TGACTGGAGTTCAGACGTGTGctcttccgatct-
CACCCCATAAAGTGTGAGGAAAC
AP1-6-NGS-fwd ACACTCTTTCCCTACACGACGctcttccgatct-
CCTGACGTCTAGATCTGTATGTC
AP1-6-NGS-rev TGACTGGAGTTCAGACGTGTGctcttccgatct-
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Table 5.19: Primers for first level MiSeq PCR
CACTAAGGCAGCAACAATAGGTG
Bisulf-NGS-CD73-fwd ACACTCTTTCCCTACACGACGctcttccgatct-
GTATTAGGGTATTATTTGGTTTAT
Bisulf-NGS-CD73-rev TGACTGGAGTTCAGACGTGTGctcttccgatct-
CTTACCACACTCTACCATCC
Ctrl1-NGS-fwd ACACTCTTTCCCTACACGACGctcttccgatct-
GGTTCACGCACCAAATCATACCA
Ctrl1-NGS-rev TGACTGGAGTTCAGACGTGTGctcttccgatct-
AGGTGTGACATCTTTGAGGTCTC
Ctrl2-NGS-fwd ACACTCTTTCCCTACACGACGctcttccgatct-
TGCTTGCCATGCTGGTGTCATCT
Ctrl2-NGS-rev TGACTGGAGTTCAGACGTGTGctcttccgatct-
TTGTTGGGGACTAGGGATGAGAG
Barcoding primers for second level PCRs for deep sequencing:
Table 5.20: Barcoding fwd-primers for second level MiSeq PCRs
Primer name Fwd primer sequence (5’-3’)
D501-long AATGATACGGCGACCACCGAGATCTACACTATAGCCTACA-
CTCTTTCCCTACACGACgct
D502-long AATGATACGGCGACCACCGAGATCTACACATAGAGGCACA-
CTCTTTCCCTACACGACgct
D503-long AATGATACGGCGACCACCGAGATCTACACCCTATCCTACA-
CTCTTTCCCTACACGACgct
D504-long AATGATACGGCGACCACCGAGATCTACACGGCTCTGAACA-
CTCTTTCCCTACACGACgct
D505-long AATGATACGGCGACCACCGAGATCTACACAGGCGAAGACA-
CTCTTTCCCTACACGACgct
D506-long AATGATACGGCGACCACCGAGATCTACACTAATCTTAACA-
CTCTTTCCCTACACGACgct
D507-long AATGATACGGCGACCACCGAGATCTACACCAGGACGTACA-
CTCTTTCCCTACACGACgct
D508-long AATGATACGGCGACCACCGAGATCTACACGTACTGACACA-
CTCTTTCCCTACACGACgct
Table 5.21: Barcoding rev-primers for second level MiSeq PCRs
Primer name Rev primer sequence (5’-3’)
D701-long CAAGCAGAAGACGGCATACGAGAT-
CGAGTAATGTGACTGGAGTTCAGACGTGTgct
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Table 5.21: Barcoding rev-primers for second level MiSeq PCRs
D702-long CAAGCAGAAGACGGCATACGAGAT-
TCTCCGGAGTGACTGGAGTTCAGACGTGTgct
D703-long CAAGCAGAAGACGGCATACGAGAT-
AATGAGCGGTGACTGGAGTTCAGACGTGTgct
D704-long CAAGCAGAAGACGGCATACGAGAT-
GGAATCTCGTGACTGGAGTTCAGACGTGTgct
D705-long CAAGCAGAAGACGGCATACGAGAT-
TTCTGAATGTGACTGGAGTTCAGACGTGTgct
D706-long CAAGCAGAAGACGGCATACGAGAT-
ACGAATTCGTGACTGGAGTTCAGACGTGTgct
D707-long CAAGCAGAAGACGGCATACGAGAT-
AGCTTCAGGTGACTGGAGTTCAGACGTGTgct
D708-long CAAGCAGAAGACGGCATACGAGAT-
GCGCATTAGTGACTGGAGTTCAGACGTGTgct
D709-long CAAGCAGAAGACGGCATACGAGAT-
CATAGCCGGTGACTGGAGTTCAGACGTGTgct
D710-long CAAGCAGAAGACGGCATACGAGAT-
TTCGCGGAGTGACTGGAGTTCAGACGTGTgct
D711-long CAAGCAGAAGACGGCATACGAGAT-
GCGCGAGAGTGACTGGAGTTCAGACGTGTgct
D712-long CAAGCAGAAGACGGCATACGAGAT-
CTATCGCTGTGACTGGAGTTCAGACGTGTgct
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5.2 Experimental procedures
5.2.1 Generation of expression vectors
Cloning of constitutive JUN-Citrine and conditional Citrine/JUN-Citrine
expression constructs
For constitutive expression constructs JUN open reading frames (ORF) was derived
from the Precision LentiORF Collection pLOC plasmids (Dharmacon, kindly provided
by E. Latz, Institute of Innate Immunity, Bonn, Germany). JUN (DQ896432) was
cut from pLOC using BamHI/NheI restriction enzymes, pRp235 (kindly provided by E.
Latz, Institute of Innate Immunity, Bonn, Germany) was cut by BamHI/AvrII. Fragments
were gelpurified, ligated and transformed into e. coli. Sequence of ready constructs was
validated using primers Seq-pRp-fwd and Seq-pRp-rev. Tetracycline inducible lentiviral
plasmid pLV-tetO and transactivator construct pRp rtTA (obtained from J. Uttikal,
DKFZ, Heidelberg, Germany) were used for conditional expression of JUN. JUN-Cirine
cDNA was amplified from pRp235 JUN. Fragments were gelpurified, digested, PCR-
column purified and cloned into pLV-tetO using SalI/MluI restriction sites. Sequence of
ready constructs was validated in Sanger sequencing using primers Seq-pLV-tetO-fwd
and Seq-pLV-tetO-rev.
PCR reaction:
5 µl Phusion® High-Fidelity buffer
0.5 µl dNTPs (10 mM stock)
1.25 µl pRpCitrine-MluI-fwd/ pRpJUN-MluI-fwd (10 µM stock)
1.25 µl pRpCitrine-SalI-rev (10 µM stock)
0.5 µl Phusion® polymerase
20 ng pRp235 JUN template DNA
PCR protocol:
98°C 3 min
98°C 20 s
60°C 20 s
72°C 45 s
repeat 30x (98°C 20 s, 60°C 20 s, 72°C 45 s)
72°C 3 min
Restriction enzyme-based cloning of sgRNAs for CRISPR/Cas9-based
genome editing
Single guide RNAs (sgRNAs) for targeting potential AP1 binding sites and control sites
in the NT5E first intronic enhancer were chosen according to ENCODE ChIP-seq anno-
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tated JUN binding sites in NT5E and localization of AP1 consensus binding site motifs
within and nearby NT5E. NF1 targeting sgRNAs for KO generation were directed to
exon 4 and exon 27 in order to cover all splice variants and control for off target ef-
fects. For design of sgRNAs rules described at http://www.genome-engineering.org
were obeyed and targeting sequences were cloned into px330-U6-Chimeric-BB-CBh-
hSpCas9 (px330, Addgene #42230) expressing Cas9. BbsI restriction digest was used
to generate custom-built overhangs in px330. Targeting sequences were purchased as
complementary oligonucleotides with predefined px330 cut BbsI matching overhangs
and dissolved at 3 mg/ml. For oligo-annealing 1 µl of each TS and BS oligonu-
cleotide was mixed in 48 µl annealing buffer and incubated at 95°C 4 min, 70°C 10
min, 70°C 1 min 30 s, decreasing 1°C per cycle for total 60 cycles. Annealed oligonu-
cleotides were ligated to BbsI digested and gelpurified px330 and transformed into e.
coli. Sequence of ready constructs was validated using primer px330-U6-start in Sanger
sequencing.
Restriction digest
5 µg of vector backbones was digested in 30 µl volume with 1.5 µl of each enzyme for
3 h at 37°C. In case of separate double-digestion, 3 µl of single enzymes were used.
Gelpurified PCR fragments were digested in a volume of 15 µl with 0.5 µl of each enzyme
for 3 h at 37°C. Reactions involving FastDigest™ enzymes AvrII, BamHI and NheI were
performed in FastDigest™ buffer. Digestion by MluI/SalI and BbsI was done in NEB3.1
buffer and NEB2.1 buffer, respectively.
Gel electrophoresis
Digested vector backbones and PCR reactions were mixed with 6x gel loading buffer and
separated on agarose gels in 1xTAE buffer at 140 V for 20 min. Addition of 5 µl ethidium
bromide (EtBr) per 150 ml gel solution enabled visualization of DNA fragments at an
InGenius3 Gel Documentation System. Fragment size was indicated by GeneRuler 1 kb
DNA ladder. 1%, 1.5% and 2% (w/v) agarose gel were used for DNA fragment sizes
of >1000 bp, 250-1000 bp and <250 bp, respectively.
Gelpurification of fragments
Following gel electrophoresis gel-pieces of fragments of interest were cut under visual-
ization at a UV transilluminator and purified using the InnuPREP Gel Extraction kit
according to the manufacturer's instructions. DNA was eluted in 10 µl Ampuwa®
H2O.
42
5 Material and methods
PCR column cleanup of fragments
For cleanup of digested PCR fragments the InnuPREP PCRpure kit was used ac-
cording to the manufacturer's instructions. DNA was eluted in 10 µl Ampuwa®
H2O.
Ligation of fragments
For ligation of digested and purified fragments vector backbone and insert DNA were
mixed in Ampuwa® H2O in a 3:1 molar ratio in 8 µl volume plus 1 µl 10x T4 DNA
Ligase buffer. 1 µl T4 DNA Ligase was added and ligation performed over night (O/N)
at 16°C. A control reaction without an insert was performed in parallel for every liga-
tion.
Transformation of ligated constructs into e. coli D10Hβ bacteria
Bacterial agar plates were pre-warmed at 37°C to allow easy absorbance of transformed
bacteria suspension. Transformation competent e. coli D10Hβ bacteria were thawed on
ice. For re-transformations of ready plasmids 0.5 ng of plasmid DNA, for transformation
of ligated constructs 5 µl of the ligation reaction was pipetted to 50 µl of competent
bacteria on ice, mixed by snipping and incubated for 15min. Heat shock was performed
at 42°C for 45 s, followed by immediate incubation on ice for 2 min. Re-transformed
bacteria were spread equally on pre-warmed bacterial agar plates and incubated upside
down at 37°C for 16 h. For transformations of ligated constructs heat shocked bacteria
suspension was transferred to 500 µl of LB medium without antibiotics and shaken
at 1000 rpm for 1 h at 37°C. Bacterial pre-culture was then pelleted at 6000 g for
10 min and 450 µl of supernatant was aspirated. Bacterial pellet was resuspended,
spread equally on pre-warmed bacterial agar plates and incubated upside down at 37°C
O/N.
Minipreparation
For small scale DNA preparation single colonies were picked from agar bacterial plates
and inoculated into 1.8 ml LB-medium containing 100 µg/ml Ampicillin. Culture was
shaken in a ThermoMixer® R at 1000 rpm, 37°C for O/N. Bacteria were pelleted by
centrifugation at 6000 g for 10 min and pellet was resuspended in 250 µl P1 resuspension
buffer containing 100 µg/ml RNase A. For lysis 250 µl of buffer P2 was added and mixed
by inversion. For neutralization 350 µl of buffer N3 was added and mixture inverted.
Precipitate was spun down at 20,000 g for 10 min and supernatant was transferred to
spin columns for DNA preparation. DNA was bound to column by centrifugation at
10,000 g for 60 s and washed twice by 750 µl PE wash buffer. After an additional spin
at 20,000 g to remove remaining wash buffer, DNA was eluted in 35 µl Ampuwa® H2O
and concentration was determined at a Nanodrop™ 2000 instrument using Ampuwa®
H2O as a blank.
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Midipreparation
For large scale DNA preparation single colonies were picked from agar plates or small
samples of bacterial glycerol stocks were transferred to Erlenmeyer flasks into 150 ml
LB medium containing 100 µg/ml Ampicilin and shaken at 180 rpm O/N. Bacteria
suspension was transferred to 50 ml centrifugation tubes and pelleted at 4500 g for 1 h.
DNA was isolated from bacteria pellet using the PureLink™ HiPure Plasmid MidiPrep
kit according to the manufacturer's instructions.
Preparation of glycerol stocks
500 µl of bacteria solution was removed immediately before Mini- or Midipreparation,
mixed in a screw cap cryovial with 500 µl of 60% v/v glycerol diluted in Ampuwa H2O
and directly frozen at -80°C for long term storage.
Sanger sequencing of ready constructs
Sanger sequencing was performed by Microsynth AG, samples were prepared in Ampuwa®
H2O according to the companies instructions and sent in a total volume of 15 µl with
700 ng plasmid DNA and 3 µl of 10 µM sequencing primer.
5.2.2 Cell culture and generation of cell lines
Cultivation of cell lines
All cell lines were kept in a humidified incubator at 37°C, 5% CO2 and were passaged
up to 3 months, then replaced by cryopreservations of younger passages. Adherent
MaMel cell lines were growth in complete RPMI medium. HEK293T cells were grown
in DMEM medium. For suspension culture of THP1 cells RPMI 1640-based THP1
medium was used. MaMel cell lines and HEK293T cells were passaged upon 80%
confluence according to the ratios indicated in table 5.22. First cells were washed once
with 5 ml of DPBS, then dislodged using 0.5 ml, 1 ml and 1.5 ml of 0.05% Trypsin-
EDTA for T25 culture flasks, 10 cm culture dishes and T75 culture flasks, respectively
and incubated for 5 min at 37°C, 5% CO2. Trypsin reaction was stopped by adding
appropriate amount of FBS-containing culture medium and splitted by removing the
respective volume of cell suspension. Then the equal amount of pre-warmed complete
RPMI medium was added to remaining cells in culture. THP1 suspension cells were
passaged twice a week by removing 3/4 of total cell suspension and readjusting volume
by addition of THP1 medium.
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Table 5.22: Passaging ratios and schemes for the individual cell lines
Cell line Splitting ratio Splitting frequency
HEK293T 1:10 2x/week
MaMel.04 1:3 1x/week
MaMel.15 1:4 2x/week
MaMel.27 1:2 1x/ 2nd week
MaMel.37a 1:3 2x/week
MaMel.48a 1:4 2x/week
MaMel.54a 1:10 2x/week
MaMel.65 1:10 2x/week
MaMel.67a 1:3 2x/week
MaMel.71 1:3 2x/week
MaMel.79b-e/-l 1:3 2x/week
MaMel.85 1:10 2x/week
MaMel.102 1:5 2x/week
MZ7 1:5 2x/week
SK.Mel28 1:10 2x/week
THP1 1:5 2x/week
Freezing and thawing of cell lines
Aliquots of about 5×106 cells were frozen in 1 ml volume. First, cell suspension was
harvested and pelleted at RT using 300 g for 5 min. Medium was aspirated, cell
pellet was resuspended in remaining 500 µl of culture medium and transferred to a
cryovial. After cooling down cell suspension for at least 5 min on ice, 500 µice cold 2x
freezing medium was added and briefly resuspended. Then, cryovials were immediately
transferred to a MrFrosty™ freezing container and kept closed at -80°C for at least
8 h to allow standardized cooling of -1°C/min. Frozen cells were placed to storage
boxes, for long-term storage cells were transferred to -150°C. For thawing frozen cryovial
from -80°C was incubated directly at 37°C in a waterbath until only small pieces of ice
remained in vial. Cell suspension was eventually homogenized by pipetting up and down
and added dropwise to 9 ml of pre-warmed culture medium in a centrifugation tube.
Cells were spun at 300 g for 5 min at RT, remaining freezing medium was aspirated and
cells resuspended and transferred to culture flask in an appropriate amount of culture
medium.
Retroviral and lentiviral transduction of cell lines
HEK293T cells were plated in complete DMEM medium at a density of 1.2×106 per 6
well in the morning and were allowed to attach for at least 8 h. Packaging plasmids and
plasmids encoding the gene of interest were transfected the same day in the evening by
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the Calciumphosphate method: A transfection mixture containing plasmids in 1x HBS
was prepared and mixed by brief vortexing. Then, 2.5 M CaCl2 was added quickly and
mixture immediately virtuously vortexed. After an incubation of 15 min at RT mixture
was added drop-wise to adherent HEK293T cells. For pRp-based expression plasmids
retroviral packaging constructs (gag-pol and pCMV VSV-G), for pLV-based expression
plasmids 3rd generation lentiviral packaging system consisting of pCMVdelta8.91 and
pCMV VSV-G were used. For every viral transduction a positive control transduction
was included consisting of pRpGFP for production of retroviral particles and kH1GFP
for production of lentivirus.
Transfection mixtures were prepared as follows:
Retroviral particles:
200 µl 1 x HBS
2 µg retroviral expression construct
2 µg gag-pol
220 ng pCMV VSV-G
10 µl 2.5 M CaCl2
Lentiviral particles:
200 µl 1 x HBS
2 µg lentiviral expression construct
1.5 µg pCMVdelta8.91
600 ng pCMV VSV-G
10 µl 2.5 M CaCl2
16 h after transfection medium on HEK293T cells was carefully replaced to pre-warmed
complete DMEM harvest medium and target cells were seeded into 6 well plates to
reach about 80 % of confluence at the time of infection. For infection harvest medium
was collected from virus-producing HEK293T cells 40 h after transfection and filtered
trough a 0.45 µm syringe filter unit. Medium of target cells was replaced by 2 ml
of undiluted virus supernatant per well and incubated for 24 h at 37°C, 5 % CO2.
In the meantime new complete DMEM harvest medium was added to virus-producing
HEK293T cells and a second round of infection was performed after 24 h for another 24
h. Finally viral supernatant was removed and complete RPMI medium added. Selection
was started 48 h after the last infection with either Puromycin (for all pRp-based
plasmids) at a concentration of 2 µg/ml or Blasticidine (for all pLV-based plasmids) at
a concentration of 10 µg/ml for at least 5 days. A negative control of non-infected
target cells was included for selection and selection was carried out until all cells in the
negative control wells were dead. Cells were frozen and experiments were started not
before transduced cells had been splitted three times and could be considered security
level 1(S1) organisms. For generation of MaMel.79blate lines with tetracycline inducible
expression of cJUN-Citrine and Citrine (named: MaMel.79blate inducible cJUN-Citrine
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and MaMel.79blate inducible Citrine), infection with pRp rtTA followed by Puromycin
selection was done prior to infection with pLV-tetO-cJUN-Cirtine or pLV-tetO-Citrine
and consecutive Blasticidine selection.
Generation of polyclonal CD73 intronic enhancer CRISPR/Cas9 targeted
cell lines
24 h prior to transfection target cells were seeded at a density of 5000 cells per 96well.
For AP1-site/ Control site targeting in the CD73 enhancer region of MaMel.79blateJUN-
CitrineDOX 150 ng of px330 containing the respective AP1-site/ Ctrl-site targeting
sgRNA (AP1-1 , AP1-2a, AP1-2b, AP-5, AP1-6 , Ctrl) was mixed with 50 ng of
pRp mTomato in 10 µl OptiMEM™ medium. For targeting MaMel.54a, MaMel.65,
MaMel.85 and SK.Mel28 a reduced set of AP1-site/ Ctrl-site targeting sgRNAs (AP1-
2a, AP1-5 and Ctrl) was used along with pRp GFP instead of pRp mTomato. 0.6 µl
of Fugene® HD transfection reagent was added per DNA-OptiMEM™ mixture, briefly
vortexed and incubated at RT for 15 min, then mixture was added to the cells. 48 h
post transfection cells were FACS sorted to enrich for successfully transfected cells by
either sorting on mTomato or GFP depending on the transfection mixture setup and
then further expanded in culture.
5.2.3 Stimulation and manipulation of cells
For seeding of cells cell number was determined using a TC10™ automated cell counter.
Cell solution was pre-diluted to fit a range of 5 x 104–1 x 107 5×104-1×107 cells/ml
and 10 µl of cell suspension applied per counting chamber. Singlet cells were ensured
by visual examination of the counting image.
For analysis on cell surface and total protein at baseline or treatment for up to 48 h
200,000 cells were seeded per well into 12 well plates 24 h prior analysis and handled
according to immunoblotting and flow cytometric procedures described in the respective
section below. For analysis on cell surface and total protein cells were seeded 24 h
prior analysis or further treatment and handled according to immunoblotting and flow
cytometry procedures described in the respective section below. For baseline expression
analysis and treatment for up to 48 h 200,000 cells were seeded per well into 12 well
plates. For 4 day or 5 day inhibitor treatment using DMSO, SP600125, Sotrastaurin
and MK2206 70,000 cells were seeded per 12 well. Interfering with MAPK cascade
signaling by Trametinib and SCH772984 as well as PI3K blockade by BEZ235 strongly
inhibited melanoma cell growth, therefore for 4 day or 5 day inhibition 200,000 cells
were seeded into 6 well plates. Inhibitors and cytokine/ growth factor stimuli were
applied according to the concentrations indicated in tables 5.7 and 5.6, respectively. In
case of long term cytokine/ growth factor stimulation treatment was renewed at day 3
for analysis on day 5.
For long term Trametinib inhibition for a total of 18 days, 200,000 cells were seeded
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to 3 and 6 additional 6 wells for analysis on day 10 and day 18, respectively. Inhibitor
solution was renewed every 5th day. For Trametinib withdrawal experiments cells were
washed two times with PBS following 4 days culture in Trametinib and culture medium
renewed after 5 days for analysis on day 12 post withdrawal. Again, separate 6 wells
for each time point of analysis was seeded.
THP1 SN was generated as described below and aliquots rapidly thawed in a waterbath.
For stimulation culture medium was supplemented with 50% v/v of either THP1 SN
or THP1 medium for analysis at day 5 on CD73 induction or within 24h for time line
experiments of TF accumulation and protein phosphorylation.
5-Azacytidine was dissolved in DMSO and stored at -80°C and used up to six months.
As specified for individual experiments, 1-10 µM 5-Azacytidine was used for 6 days to
achieve global demethylation and treatment renewed daily. Subsequently, the medium
was supplemented for 3 day stimulation with 1000 U/ml TNFα and 50 ng/ml HGF.
Generation of THP1 supernatant
For differentiation of THP1 cells 12×106 of suspension cells were seeded per 10 cm
dish in 100 ng/ml PMA for 48 h, which was generating a 70% confluent adherent
culture. For harvest of supernatant cells were washed twice with PBS, detached with 1
ml 0.05% Trypsin-EDTA for 5 min and re-plated on new 10 cm dishes in 10 ml THP1
cell medium. After 48 h medium was collected, remaining cells removed by 0.45 µm
syringe filtering and aliquots quick frozen in a dry ice/ isopropanol bath and stored at
-80°C until used for experiments.
5.2.4 RNA isolation, cDNA synthesis and qPCR
RNA isolation
Cells seeded in 12 wells at a confluence ranging from 30-100% (1×105-106 cells de-
pending on experimental set up) were lysed with 350 µl RLT lysis buffer and frozen at
-80°C for at least 5 minutes. RNA clean up protocol was adapted from Zymo RNA
Clean and Qiagen RNeasy kit protocols. All centrifugation steps were performed at RT.
Briefly, thawed lysates were mixed with 70% ethanol in Ampuwa® H2O, volume was
applied on a Zymo-SpinTM II column, following spin at 10,000 g for 60 s. Column was
washed first by 500 µl RW1 buffer, centrifuged 10000 g for 60 s, then by 500 µl Zymo
wash buffer, centrifuged 10,000 g for 60 s, remaining buffer was completely removed
with an additional spin at 20,000 g for 2 min. 20-40 µl of H2O was added directly
on column, incubated for 5 min at RT and RNA eluted at 10,000 g for 1 min. RNA
concentration was measured at a Nanodrop 2000 instrument and RNA was stored at
-80°C until further analysis.
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cDNA synthesis
300-1000 ng of total RNA was transcribed into cDNA in a 10 µl reaction using the All-
in-One cDNA synthesis SuperMix (contains a mix of oligo(dT) and random hexamer
primers) according to the manufacturer's instructions. For cDNA synthesis the extended
protocol guaranteeing higher quality of cDNA was chosen with incubations steps of 10
min at 25°C, followed by 30 min at 42°C and finally 5 min at 85°C. cDNA was stored
at -20°C until further analysis.
Quantitative Real-Time-PCR (qPCR)
cDNA was diluted 1:5 with Ampuwa® H2O and technical duplicates of diluted cDNA
probe were included in the qPCR run in a 96 well qPCR plate.
Per well a reaction mixture was set up as follows:
1 µl of diluted sample cDNA
2 µl EvaGreen® qPCR Mix II
0.6 µl fwd and rev qPCR primer mix of the transcript of interest (10 µM)
6.4 µl Ampuwa® H2O.
On a routine bases a standard curve of mixed cDNA from every experiment and primer
was included in every sample run to test on amplification efficiency. Primer specificity
was tested by melting curve analysis. Analysis of Ubiquitin expression was included
for every cDNA sample for normalization and relative mRNA expression. In case of
inhibitor treatment or stimulation relative gene expression are shown as referenced to
a control condition if not indicated otherwise. For relative quantification analysis the
Efficiency Method provided by the Light Cycler® 480 Software was applied with CP
analysis based on the Second Derivative Maximum method. mRNA expression was
expressed as normalized ratio of the relative concentrations (conc.) calculated for the
individual samples according to the formula:
Normalized Ratio =
(
conc. target
conc. reference
)
treated sample
:
(
conc. target
conc. reference
)
control treated
5.2.5 ChIP qPCR
For chromatin immunoprecipitation (ChIP) MaMel.79blateJUN-CitrineDOX
and MaMel.79blateCitrineDOX were cultured at a confluency of 80% on three 15 cm
dishes each. After 24 h treatment with 25 ng/ml Doxycycline Citrine and JUN-Citrine
induction was at peak. Using SimpleChIP® Enzymatic Chromatin IP Kit according to
the manufacturer's instructions chromatin was crosslinkesd, purified and digested using
optimized protocol of 3 µl of micrococcal nuclease per pooled sample. DNA fragmen-
tation into dinucleosomes was achieved by sonification with three times 20 pulses, each
20 s at 20% output and 20% duty cycle at a Branson Analog Sonifier 250. Proteinase
K digestion of a small test aliquot allowed quality control of DNA fragmentation by
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visualization on a 1% (w/v) agarose gel. DNA concentration of chromatin preparation
was measured at a Nanodrop 2000 spectrometer.
For immunoprecipitation 10 µg of chromatin was diluted into 500 µl 1x ChIP buffer
derived from the SimpleChIP® Enzymatic Chromatin IP Kit and a 2% Input sample
retained for qPCR allowing normalization and calculation of sample site occupancy.
Obeying the SimpleChIP® protocol 5 µl of IgG and 10 µl of anti-HistonH3 antibodies
were set up per ChIP as negative and positive control, respectively. For ChIP against
Citrine and JUN-Citrine 25 µl GFP-Trap® -MA beads (ChromoTek) were added. Ac-
cording to the GFP-Trap® -MA protocol GFP-Trap® -MA beads were incubated for
4 h at 4°C, control antibodies were incubated O/N at 4°C as indicated. Magnetic
bead separation, sample elution, reverse crosslinking, DNA column purification and elu-
tion of final DNA in 50 µl elution reagent C was performed as suggested. Samples
were run in technical duplicates in qPCR with each 1µl of sample input as described
above. A standard dilution of the input samples was included to adjust for amplification
efficiencies.
% Input was calculated as follows:
Input normalized IP value: (∆Ct) = (Ct[IP ]− (Ct[input]− log2DF ))
with DF [2% input fraction] = 50
% input =
(
2−∆Ct
)× 100
DF = dilution factor
Ct = cycle threshold
IP = Immunoprecipitation
5.2.6 Immunoblotting
In order not to interfere with phosphorylation states of signal transduction proteins cells
were lysed directly from culture dish in 1x Lämmli buffer (20,000 cells / 10 µl Lämmli
buffer) and proteins denatured at 95°C for 5 min. 15 µl of sample were run per lane
on a SDS PAGE gel. First gels were run at 100 V for 10 min, and then voltage was
increased to 140 V until loading front run out of gel. 6%, 10% and 12% SDS PAGE
gels were used for protein sizes of >100 kDa, 40-100 kDa and <40 kDa, respectively. A
wet blotting system and 20% (v/v) methanol containing transfer buffer were used and
protein transfer onto a 0.45 µM pore size nitrocellulose membrane was accomplished at
450 mA for 1.5 h (for large protein transfer from 6% gels 200 mA O/N). Membranes
were then blocked in 5% (w/v) BSA in TBS-T for 1h at RT before primary antibodies
were added in 5% (w/v) BSA and 0.02% (w/v) sodium acid (for antibody dilution
see table 5.9). All antibodies were incubated O/N at 4°C, except antibody directed
against Actin that was incubated for 1 h at RT. Following primary antibody incubation
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membrane was washed 3 times in TBS-T for 10 min and incubated with fluorescently
labeled secondary antibodies (1:15,000) in TBS-T containing 5% (w/v) BSA for 1 h
at RT in the dark. Membranes were washed twice in TBS-T and once in TBS for 10
min each and scanned on an Odyseey® Sa Imaging System from LI-COR®İn case of
harvesting cells from experiments involving differential cell growth or when combining
lysates from different cell lines an actin loading blot from 10 µl of lysate was run first and
loading was adjusted according to the actin signal strength. Therefore, actin signal was
quantified using the Odyseey® Sa Application Software.
5.2.7 Flow cytometry based methods
Flow cytometric analysis
For stimulation experiments cells were harvested from 12 wells by 150 µl of 0.05%
Trypsin-EDTA for 5 min at 37°C, 5% CO2, resuspended in 500 µl culture medium and
200,000 cells were seeded per round bottom 96 well test plate. An unstained control
was included for every single stimulation and inhibition condition and cell line. Cells
were pelleted at 420 g, 3 min, washed once with 200 µl FACS buffer and stained 30
min on ice in 50 µl FACS buffer with Brilliant Violet 421™ anti-CD73mAb 1:100 (clone
AD2, Biolegend). Antibody was removed by three times washing with 200 µl FACS
buffer, 420 g, 3 min. For 5-Azacytidine treated cells propidium iodide staining ( 5 µl
per test, BD Bioscience) was included immediately prior FACS analysis. 20,000 cells in
the P1 live gate were recorded on a FACS Canto II flow cytometer (BD Bioscience) and
analyzed using FloJo® software (TreeStar, V7.8 for Mac).
FACSorting on successfully transfected cells by CRISPR/Cas9 sgRNA
constructs
48h post CRISPR/CAS9 construct transfection, cells in 96 wells were washed once with
PBS and detached with a centered drop of 0.05% Trypsin-EDTA for 5 min at 37°C.
100 µl of growth medium were added and cell solution resuspended. pRp mTomato
and pRpGFP positive cell fractions for MaMel.79blateJUN-CitrineDOX and MaMel.54a/
MaMel.65/ MaMel.85 respectively were sorted on a FACS ARIA III cell sorter under
sterile conditions and replated in a 96 well formate for expansion.
FACSorting of polyclonal CD73 intronic enhancer CRISPR/Cas9 targeted
cell lines
In MaMel.79blateJUN-CitrineDOX CRISPR/Cas9 engineered cell lines CD73 expression
was induced by 25 ng/ml Doxycycline for 5 days. MaMel54a/ MaMel.65 and MaMel.85
CRISPR/Cas9 engineered cell lines were harvested directly for accession of baseline
CD73 levels. For FACSorting 8×106 individual cell lines were harvested and stained
according to the protocol described above, adjusted in volume to 2ml FACS buffer per
51
5 Material and methods
staining. FACS sorter machines were operated by Andreas Dolf and Peter Wurst in the
FACS core facility of the University Hospital, Bonn. Using a FACS INFLUX cell sorter
100,000 cells of each 10% most dim, 10% brightest and total CD73 positive fraction
were sorted in triplicates into FACS buffer, pelleted at 300 g for 5 min and resuspended
in 20 µl of DLB buffer containing 100 µg/ml Proteinase K and digested at 65°C for
1h, followed by inactivation at 95°C for 15 min. Lysate was further used as template
for dual barcoding PCRs for deep sequencing. Simultaneously, samples were read in at
FACS Canto II flow cytometer for recording of total cell population CD73 expression
levels.
5.2.8 Bisulfite conversion based methylation analysis by deep
sequencing
Bisulfite conversion spares methylated cytosine residues from conversion, but all native
cytosine residues in DNA are converted to uracil, enabling the detection of methylation
status a CpG island by subsequent sequencing procedures. Commonly, subcloning of
converted DNA and Sanger sequencing of several clones is used. However, here we
use deep sequencing for methylation quantification enabling considerable increase in
depth.
Isolation of genomic DNA (gDNA) for bisulfite conversion
5×106 were resuspended in 500 µl lysis buffer for gDNA extraction, Proteinase K added
at a final concentration of 100 µg/ml and incubated at 56°C, 900 rpm O/N. 166.7
µl of 5 M NaCl was mixed to the lysate and gDNA was precipitated by addition of
2 volumes of ethanol and heavily vortexed. gDNA was captured with a pipet tip,
transferred to a new reaction tube and washed in 70% ethanol. gDNA was pelleted at
20,000 g for 5 min at RT, supernatant removed completely, air-dried for 30 min and
dissolved in 50 µl Ampuwa® H2O. DNA concentration was measured at a NanoDrop
2000 system.
Bisulfite conversion assay
For conversion 500 ng of gDNA was included in the conversion reaction using the
EZ DNA-Methylation direct kit and the protocol was executed according to the man-
ufacturer's instructions. Bisulfite converted gDNA was eluted in a volume of 10 µl
Ampuwa® H2O and frozen at -80°C until further analysis.
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5.2.9 Sample preparation and running deep sequencing
Generation of whole cell lysates as template for DNA amplification
For deep sequencing analysis of CRISPR/Cas9-based targeting in a polyclonal cell
population 100,000 cells of the population of interest were lysed in 20 µl of DLB
buffer containing 100 µg/ml Proteinase K and incubated at 65°C for 1h, followed
by 95°C for 15 min. Lysates were directly used for PCR or stored at -20°C until
use.
PCR amplification of CRISPR/Cas9-targeted regions from genomic DNA of
whole cell lysates and bisulfite converted DNA for deep sequencing analysis
Two consecutive PCRs were set up. In a first step amplification of the region of interest
was performed with target region specific primers creating an amplicon of 200-250 bp
length and containing an adapter sequence for binding of second level barcoding primers.
For CRISPR/Cas9-targeted regions 19 cycles with an annealing temperature of 60°C,
for bisulfite converted DNA 34 cycles with an annealing temperature of 54°C were run
in first PCR. In a second level PCR an index for deep sequencing was introduced by
amplification with a barcoding primer pair binding to the adapter regions of the first
level PCR. For quality control 5 µl of second level PCR products were subjected to
gel electrophoresis on a 2% agarose gel. Remaining volume was then pooled for deep
sequencing proportionally to the individual PCR signal strengths on gel. If all samples
exhibited similar PCR signal strengths 4 µl of al PCR reactions were pooled for deep
sequencing.
Reaction mix for first level PCR:
5 µl Phusion® HF 5x buffer
0.5 µl dNTPs (10 mM stock)
1.25 µl target region specific fwd primer (10 µM stock)
1.25 µl target region specific rev primer (10 µM stock)
0.25 µl Phusion® polymerase
4 µl DLB cell lysate /1 µl bisulfite converted genomic DNA
add 25 µl H2O
Reaction mix for second level PCR:
2.5 µl Phusion® HF 5x buffer
0.25 µl dNTPs (10 mM stock)
1.25 µl barcoding fwd primer (5 µM stock)
1.25 µl barcoding region specific rev primer (5 µM stock)
0.25 µl Phusion® polymerase
2 µl first level PCR
5 µl H2O
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PCR protocol (first and second level PCR):
98°C 1 min
98°C 20 s
60°C 20 s
72°C 30 s
repeat 19x (95°C 20 s, 60°C 20 s, 72°C 30 s)
72°C 3 min
Sample pool clean up for deep sequencing analysis
For sample pool clean up of experiments aiming at analysis of monoclonal targeting
events separate sample pools were mixed in a single tube proportionally to the number
of clones. For experiments aiming at sequencing of polyclonal targeting sample pool
clean up was performed separately for each experiment. Preparation of sample DNA
was done in collaboration with Dr. Jonathan Schmid-Burgk and Dr. Tobias Schmidt
in the group of Prof. Dr. Veit Hornung, Bonn. Sample pools were run on a 1% (w/v)
agarose gel and PCR product bands from 300-400 bp length were purified by column-
based gelpurification. DNA was eluted in 200 µl H2O each sample. For precipitation 1
µl glycogen, 20 µl 3 M sodium acetate pH 5.2, 220 µl isopropanol was added, virtuously
mixed and incubated on ice for 20 min. DNA was pelleted at 20,000 g at 4°C for
5 min, supernatant was removed and pellet washed with 70% (v/v) ethanol. After
centrifugation at 20,000 g at 4°C for 5 min, liquid was completely removed and DNA
was air-dried. For recovery of DNA pellets were resuspended in 35 µl Ampuwa® H2O
and dissolved at 37°C, 900 rpm for 5 min in a ThermoMixer®. Finally, remaining
non-dissolvable remnants were pellet at 20,000 g for 5 min and 25 µl of supernatant
transferred to a new reaction tube. DNA concentration was measured twice on a
Nanodrop 2000 spectrometer instrument.
Deep sequencing at Illumina MiSeq
The MiSeq sample cassette was thawed in a waterbath and stored on ice until use. DNA
samples were mixed in Illumina hyb buffer according to the desired amount of reads
for the respective individual samples (500 and 10,000 reads per clone in monoclonal
and polyclonal samples) in a total volume of 350 µl. For calculation, 32 ng of sample
DNA were expected to yield 106 reads. 10 µl of sample mixure was denatured by 10
µl 0.2 N NaOH for 5 min. Thereafter 980 µl Illumina hyb buffer was added on ice.
For dilution 180 µl of denatured sample was mixed with 420 µl Illumina hyb buffer
and total volume applied to the Illumina cassette. Illumina MiSeq was started and run
according to the manufacturer's instructions using the single read protocol generating
data in FASTQ format for further analysis. MiSeq sequencing runs were conducted
by Dr. Jonathan Schmid-Burgk and Dr. Tobias Schmidt in the group of Prof. Veit
Hornung, Bonn or forwarded to the deep sequencing core facility of the University
Hospital Bonn.
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5.2.10 Bioinformatic analyses
Evaluation of deep sequencing data from CRISPR/Cas9-based FACSorting
enhancer screening
Deep sequencing data on CRISPR/Cas9-based FACSorting enhancer screening were
either analyzed on enrichment/ depletion of successful targeting for a predefined tar-
get side using the javascript web-based software outknocker.org [215] or by positional
mutation analysis for screening single basepair position-wise enrichment/ depletion of
targeting by an algorithm developed in the R programming environment that uses po-
sitional mutation tables text-files obtained from outknocker.org as input files.
For validation, technical triplicates of total cell pools of individual CRISPR/Cas9 tar-
geted cultures were sequenced 14 days post transfection and individual sgRNA genome
editing frequencies controlled on homogeneity across sgRNAs. Furthermore complexity
of the polyclonal cell pool was assured by checking on high diversity of genome edit-
ing within individual samples. From here consistency for subsequent was controlled.
Sample preparation and sequencing depth was adjusted to stably cover 10,000 cells in
input DNA by sequencing, affirming reliability of the fractional sorting and sequencing
procedure.
For outknocker.org based analysis AP1 consensus binding motifs targeted by the re-
spective JUN/ AP1 site sgRNAs were set as nuclease target site. Specification of the
nuclease target site to AP1 motif sequence coerced InDel frequency analysis to premise
InDels overlapping with the canonical AP1 binding motif. For control targeting total
guide sequence was used as recommended in the software’s instructions. For analysis,
percent mutated at target site was determined from the quotient of reads counted with
InDels at target site to total reference sequence aligned reads. Next normalization of
mutation frequency of CD73high and CD73low sorted samples to mutation frequency in
the CD73 total sorted sample was done in order to compensate for intra-experimental
differences in editing efficiency due to differential active sgRNAs.
Positional mutation analysis is based on data tables containing the counts of mutated
reads for every position across the reference sequence amplicon. Positional mutation
frequency was calculated by dividing counts of mutated reads for every single base po-
sition by the number of total deletion reads. In order to compensate for differences in
deletion lengths affecting the above introduced ratio, we integrated area under curve
(AUC) normalization by position-wise dividing positional mutation frequencies by the
sum of positional mutation frequencies across the total reference sequence. Biological
independent triplicates were then combined and position wise deviation illustrated by
error bars of SD.
R based positional mutation analysis enables automated calculation and ggplot based
visualization of positional mutation frequencies for a sequence window of CRSIPR/Cas9
predicted cutting site +/- 20 bp.
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Quantification of CpG island methylation in Bisulfite deep sequencing
approach
For quantification of CpG island methylation a specified, custom designed version of the
javascript-based Outknocker.org software was written and provided by Dr. Jonathan
Schmid-Burgk (BisulfiteSeq quant Table 1.0): Reference amplicon sequence is pasted
into the program and converted for all cytosine residues except CpG islands by the
program for alignment analysis. Next, deep sequencing raw reads are imported in
FASTQ format and aligned to the adjusted reference sequence while ignoring all CpG
islands. Positional counts of base frequencies were aggregated from successfully aligned
reads and displayed in an output table across the reference sequence. For generation
of sequence logos first 100 aligned amplicon sequences are provided by the software.
Percent of methylation was then calculated by the ratio of cytosine to thymidine residues
at the individual CpG islands and illustrated in pie charts.
UCSC genome browser and ENCODE regulatory tracks TF binding analysis
The UCSC Genome Browser human GRCh37/hg19 assembly from February 2009 was
accessed at http://www.genome.ucsc.edu/. Genomic sequence surrounding NT5E Ref-
Seq transcript was loaded and analyzed for chr6:86,108,517 to chr6:86,211,362. EN-
CODE regulation tracks used comprised layered H3K27Ac, H3K4Me3 and H3K4Me1
layered from 7 cell lines. DNAseI hypersensitivity clusters in 125 cell types and TF
ChIPseq from 161 TFs with Factorbook motifs in 91 cell types.
R based melanoma plasticity analyses
For bioinformatic analyses R programming (R version 3.3.3) was used within R Studio
(version 1.0.143). Visualization was based on ggplot, ggrepel and ggpubr packages. For
data processing packages useful, dplyr, reshape2 and tidyr were loaded.
Microarray datasets GSE51221(n = 17) [13] processed for variance stabilization and
normalization by vsn package (bioconductor), GSE4843 (n = 45) [107] and GSE7127
(n = 63) [118] were acquired from NCBI’s Gene Expression Omnibus (GEO) database
and loaded into R using the GEOquery package. For annotation hgu133a2.db and Anno-
tationDbi packages were applied. RMA-normalized data of the BROAD melanoma cell
line panel (n = 88) as published by Lin et al [142] was downloaded from the Melanoma
Genomics Portal (http://portals.broadinstitute.org/IGP/home) and imported into R.
Data was log2 transformed and probeIDs of individual genes aggregated on mean ex-
pression based on gene symbols for further analysis. Verfaillie invasive signature genes
were published by Verfaillie et al [262], Hoek invasive and proliferative signature genes
were obtained from Hoek et al [107] and TNF response signature we had generated
previously in our lab by Riesenberg et al [201] and consists of 237 individual genes with
more than 2 fold change in expression by 72h TNFα in 8 of 17 melanoma cell lines of
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the GSE51221 cohort [13].
In order to determine individual gene signatures, first, subsetting on probeIDs of genes
belonging the respective gene expression signature was performed. Then gene signatures
in individual samples were calculated by aggregating on mean expression of probeIDs of
the respective signature genes and averaging expression of all signature genes in a next
step.
Moving average (movAVG) calculation was adapted from Riesenberg et al [201] and
an improved version of the movAVG algorithm written. In brief, expression data of a
given panel is ranked according to marker gene or signature expression that is invasive
signature expression in the data presented in this study. Mean centered movAVG de-
scribes averaged gene expression of a gene of interest across this ranked data panel.
Importantly, averaged gene expression is calculated from a sample window with centered
mean stepwise moving across the data panel. Sample window is fixed to odd numbers
in the algorithm presented and a sample window of n = 13 had been used in this study
covering a panel size of n = 88.
For classifying the BROAD melanoma cell line panel into MITFhigh proliferative and
MITFlow invasive phenotypes cell lines were ranked according to invasive gene expres-
sion ranked and compartmentalized at inflection point of MITF expression. MITFhigh
proliferative cell lines were further divided based on NT5E expression upon nascent in-
vasiveness into MITFhigh CD73low proliferative cell lines and MITFhigh CD73high nascent
invasive cell lines and grouping reproduced by K-means clustering based on MITF and
NT5E expression as described below.
K-means clustering was conducted based on MITF and NT5E expression as collapsed
from individual gene probe IDs within the R environment using implemented default
Hartigan and Wong algorithm. Based on plasticity analyses by invasiveness ranking and
movAVG implementation three phenotypes were expected and clusters were set to k
= 3. Algorithm was rum with randomseed = 20 and nstart 0 =20. For visualization
normal confidence ellipses were drawn at a confidence level of 0.95.
Gene set enrichment analysis (GSEA)
Gene set enrichment analyses (GSEA) were run on the GSEA javascript based software
(v3.0) [240] downloaded from the BROAD institute website (http://software.broad-
institute.org/gsea/index.jsp). For analysis probeIDs of the BROAD melanoma cell line
panel expression dataset were collapsed to gene symbols as described above. Pheno-
type labels were generated on fly to cover cell lines of the MITFhigh nascent invasive
and MITFhigh proliferative phenotype that had been assigned by cell state interrogation.
Analysis on the C2 collection of curated gene sets (n = 2235) derived from the BROAD
Molecular Signature Database v.6.1 (MSigDB) (http://software.broadinstitute.org/gsea-
/msigdb/index.jsp) was performed with permutation type set to gene sets and keeping
the default of 1000 permutations to calculate enrichment scores for MITFhigh nascent
invasive phenotype versus MITFhigh proliferative phenotype. Impact of gene sets was
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determined by ranking according to normalized enrichment score (NES) and false dis-
covery rate (FDR) corrected p-values.
5.2.11 Statistics
If not indicated otherwise FACS and immunoblot data show representative experiments
of three replicates. qPCR, ChIP and enhancer screening data are depicted as means of
n=3 with error bars indicating SD.
Statistical tests performed are indicated in figure legends of the individual experiments.
If not indicated otherwise two-sided paired and un-paired Student’s T test were per-
formed in Excel. Boxplots comparing gene expression across melanoma phenotypes
were calculated and plotted within the R environment and evaluated by ggplot builtin
statistics in two-sided unpaired Student’s T-Tests with multiple comparison correction
according to Benjamini and Hochberg via FDR. For stimulation and inhibitor panels
comparing more that two groups ANOVA was run within the GraphPad Prism software
and Bonferroni post-hoc test used for multiple comparison correction comparing indi-
vidual treatment conditions to the respective DMSO control sample. For correlation
analysis Pearson correlation with 0.95 confidence level and two-sided testing on signif-
icance was used. Significance levels are indicated as follows: *, P<0.05; **, P<0.01;
***, P<0.001; n.s.=none significant.
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6.1 CD73 is a marker for melanoma cell plasticity
6.1.1 Bioinformatic analysis on a large panel of melanoma
cell lines reveals CD73 as a marker expressed upon
nascent invasiveness
The current concept of melanoma cell plasticity defines two opposing cell states: The
MITFhigh proliferative cell state is formed by a highly differentiated population of
melanoma cells and is opposed by a MITFlow invasive cell state [34, 107]. During
phenotype switching melanoma cells undergo dedifferentiation and acquire an invasive
gene expression signature. It has been shown that inflammation is a key trigger in that
process [136, 280]. In more detail, we were able to show that a MITF / JUN antag-
onism is involved in orchestrating phenotype switching on a mechanistic level [201].
However, the detailed mechanisms of plasticity remain largely unknown. Paradigms
have recently shifted from polarization into predefined phenotypes to understanding
plasticity as a continuum of cell polarization [226]. We speculated that melanoma cell
plasticity likely integrates into those paradigms and additional transition cell states such
as a nascent invasive phenotype should be found during melanoma phenotype switch-
ing. The description of any transition cell state would yield fundamental insights into
the mechanisms of melanoma cell plasticity.
In order to identify marker genes and mechanisms for such a nascent invasive melanoma
cell state we made use of mRNA expression data of the well-characterized BROAD panel
of melanoma cell lines (n = 88) [142] and ranked them according to their invasiveness,
as calculated by expression of an EMT-like invasive gene signature published by Verfaillie
et al. [262] (Figure 6.1 A). As expected, integration of MITF mRNA expression data
showed significant anti-correlation with melanoma cell invasiveness and clearly separated
MITFhigh invasive low from MITFlow invasivehigh cell lines into the hitherto described
melanoma phenotypes MITFhigh proliferative and MITFlow invasive (Figure 6.1 , A, left
diagram). As a control, cell line classification was confirmed by applying the widely
accepted invasive and proliferative gene signatures published by Hoek et al. [107]
(Figure 6.1 , A, right diagram).
For identification of an early plasticity marker we were especially interested in highly vari-
ably expressed genes within the MITFhigh proliferative cell lines. Based on our previous
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findings on inflammation priming melanoma cells for dedifferentiation and phenotype
switching [136] we hypothesized that inflammatory marker genes are suitable candidates
for indicating intrinsic inflammatory pathway activation and as such a nascent invasive
cell state. Confirmative, expression of the TNFα response gene signature highly cor-
related with both established invasive gene signatures in the analyzed cell line panel
(Figure 6.1, B). In the following, we filtered TNFα regulated genes that showed high
variability in gene expression in the MITF high cell line fraction (n = 57) (Figure 6.1,
C). Ranking according to variance in gene expression identified a small set of candidate
plasticity markers (Figure 6.1, D). Among them we were especially interested in NT5E
which encodes the 5'ectonucleotidase CD73 and constitutes a novel target in cancer
immunotherapy [98]. CD73 converts AMP to immunosuppressive adenosine and is
thereby shaping an anti-inflammatory tumor microenvironment [9]. Interestingly, CD73
is also an accepted marker for mesenchymal stem cells [58]. As a GPI-anchored plasma
membrane protein it constitutes a well accessible marker for detection and isolation of
cells.
In order to validate CD73 as a nascent invasive cell state marker we next analyzed
NT5E mRNA expression in our panel ranked by invasive signature (Figure 6.1, E).
Assuringly, we found CD73 to be diminished from MITFhigh proliferative cell lines with
low invasive signature. NT5E expression starts in a subpopulation of MITFhigh prolif-
erative cell lines upon nascent invasiveness and is further up-regulated in cell lines of
the MITFlow invasive phenotype exhibiting strong increase in invasive signature gene
expression. (Figure 6.1, E and F). Thereby, CD73 splits the MITFhigh proliferative
phenotype into two distinct phenotypes, a MITFhigh CD73low proliferative phenotype
that is none-invasive and a MITFhigh CD73high nascent invasive phenotype, which we
in the following classified as the MITFhigh proliferative and MITFhigh nascent invasive
phenotype, respectively.
Affirmatively, the three subsets of melanoma phenotypes were also found when applying
K-means clustering based on MITF and NT5E mRNA expression and defining three
cluster centers as depicted in Figure 6.1, G. Multiple comparison analyses between the
subsets showed that NT5E was robustly up-regulated already in the nascent invasive
cell state while MITF and proliferative signature genes were still expressed. Inflam-
matory and invasive gene expression signatures were significantly up-regulated upon to
the nascent invasive cell state (Figure 6.1, H). In contrast, other candidates of highly
variably expressed TNFα response genes did not validate as nascent invasive phenotype
marker but varied in gene expression within the MITFhigh proliferative cell lines indepen-
dent from their nascent invasiveness (data not shown).
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Figure 6.1: CD73 marks a nascent invasive phenotype in melanoma: Continued caption see next
page.
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Figure 6.1: CD73 marks a nascent invasive phenotype in melanoma (A): BROAD melanoma cell
line panel (n = 88) ranked by Verfaillie (left diagram) and Hoek (right diagram) invasive signature
gene expression. MITF expression as movAVG, bar charts indicating expression in individual samples.
Dashed lines separate MITFhigh invasive low (n = 57) and MITFlow invasive (n = 31) cell lines. Pearson
correlation with two-sided significance testing. (B): Same as (A) but implementing expression of
the TNF response gene signature [201]). (C): Schematic overview on the experimental strategy for
identification of nascent plasticity markers. (D): Variance of TNF response genes by individual gene
probes in MITFhigh proliferative cell lines (n = 57) and plasticity marker candidates with variance > 4.0
highlighted. (E): Same as (A) but implementing NT5E expression. Dashed line at left shows median
separation of MITFhigh proliferative (n = 28) and MITFhigh nascent invasive cell lines (n = 29). (F):
Dot plots of MITF and NT5E expression for the BROAD melanoma cell line panel (n = 88). Invasive
signature gene expression (INVsig) as blue color gradient. (G): same as (F) but applying K-means
clustering with k=3. Ellipses at 0.95 confidence level. (H): NT5E,MITF and signature gene expression
for the BROAD melanoma cell line panel (n = 88) clustered by phenotype as shown in (G) (inv. =
invasive, prol. = proliferative). Two-sided, un-paired Student’s T-Tests with multiple comparison
correction according to Benjamini & Hochberg (aka FDR). movAVG group size=13. Expression data
log2 transformed. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.00001.
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Figure 6.2: Common invasive phenotype markers fail to indicate early phenotype switching.
(A): BROAD melanoma cell line panel (n = 88) ranked by Verfaillie invasive signature and expression
of invasive phenotype markers implemented as indicated by movAVG and bars for individual cell lines’
marker expression. Dashed lines separate MITFhigh proliferative (n = 57) and MITFlow invasive cell
lines (n = 31). Pearson correlation with two-sided significance testing. (B): Dot plots of plasticity
marker gene expression as indicated in figure and MITF expression with invasive signature expression
(INVsig) as blue color gradient shown for the BROAD melanoma cell line panel (n = 88). movAVG
group size=13. Expression data log2 transformed. ****, P<0.00001.
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6.1.2 Established invasive phenotype markers in melanoma
are not suitable for describing a nascent invasive
phenotype
AXL, WNT5A and NGFR constitute common markers for describing melanoma cell
invasive phenotype switching. In a next approach we analyzed those invasive pheno-
type markers on their capability in discriminating between a MITFhigh proliferative and
MITFlow invasive cell state in our panel of melanoma cell lines. We found strong correla-
tion of invasive marker expression with melanoma cell invasiveness for all except NGFR,
which was highly variably expressed throughout all melanoma phenotypes (Figure 6.2,
A and B). NGFR expression was even reduced in the fraction of most dedifferentiated
melanoma cell lines. When checking on elevated marker expression upon nascent in-
vasiveness, we found up-regulated expression of AXL in some cell lines, however less
consistent than NT5E upregulation seen in the nascent invasive cell state (Figure 6.2,
A and Figure 6.1, E).
6.1.3 A nascent invasive phenotype is primed to phenotype
switching
Based on the above delineated concept, we next asked whether a nascent invasive phe-
notype is primed for inflammation-induced dedifferentiation and phenotype switching.
For addressing that issue, we referred to the GSE51221 mRNA microarray of melanoma
cell lines (n = 17). This dataset was generated in our lab by 72 h TNFα stimulation in
order to analyze intrinsic inflammatory pathway activation in melanoma [13]. Accord-
ing to expression of MITF and NT5E, cells were grouped into MITFhigh proliferative,
MITFhigh nascent invasive and MITFlow invasive phenotypes as introduced earlier (Figure
6.3, A). In agreement with our previous observations, we observed a significant increase
of NT5E expression in the group of MITFhigh nascent invasive cell lines when compared
to cell lines of the MITFhigh proliferative group (Figure 6.3, B). NT5E expression fur-
ther increased in the MITFlow invasive phenotype and MITF expression simulataneosly
decreased. Along, we found considerable, yet not significant increase in inflammatory
and invasive gene expression signatures in the MITFhigh nascent invasive compared to
the MITFhigh proliferative phenotype. Both signatures are further up-regulated in cell
lines of the MITFlow invasive phenotype.
Intriguingly, matching to the above introduced hypothesis, cell lines belonging to the
nascent invasive phenotype indeed show stronger dedifferentiation in response to TNFα
stimulation as monitored in decrease in MITF expression (Figure 6.3, B). In addition,
inflammatory TNFα signature genes are more prominently induced in MITFhigh nascent
invasive when compared to MITFhigh proliferative cell lines in response to TNFα stimula-
tion. As expected, NT5E expression is up-regulated by inflammatory TNFα stimulation
across all groups of cell lines (Figure 6.3, B).
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Figure 6.3: A nascent invasive phenotype is primed to phenotype switching. (A): Subset of
unstimulated cell lines of GSE51221 (n = 17) plotted for NT5E and MITF expression. (B): Boxplots
showing NT5E, MITF, TNF response signature (TNFsig) and Verfaillie invasive signature (INVsig)
expression in cell lines grouped as indicated by clusters in (A) +/- 72 h 1000 U/ml TNFα. Gene
expression log2 transformed. For statistics two-way ANOVA with Bonferroni multiple comparison
correction. *, P<0.05; ***, P<0.001; n.s.=none significant.
In summary, our data propose a novel nascent invasive phenotype in melanoma plasticity
which can be defined by the concurrent expression of CD73 and MITF. Furthermore, our
experiments suggest priming of nascent invasiveness in melanoma cells for inflammation-
triggered phenotype switching.
6.1.4 CD73 expression in nascent invasive melanoma cells is
associated with mitogenic and inflammatory signaling
pathways
Next, we wanted to explore pathways that are correlated with MITFhigh CD73high nascent
invasive phenotype in order to gain further insights into the regulation of CD73 expres-
sion in melanoma. In order to retrieve gene sets and pathways positively correlating
with CD73 expression in melanoma, we performed GSEA on MITFhigh nascent inva-
sive cell lines (n = 28) by comparing to MITFhigh proliferative cell lines (n = 28) of
the BROAD panel of melanoma cell lines (n = 88) using the C2 collection of curated
gene sets from the Molecular Signature Database v.6.1 (MSigDB) (Figure 6.4, A). All
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RANK NAME NES FDR*q,val
#1 CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN 2,98 0,0000
#2 SEIDEN_ONCOGENESIS_BY_MET 2,89 0,0000
#3 CHEN_HOXA5_TARGETS_9HR_UP 2,76 0,0000
#4 GHANDHI_BYSTANDER_IRRADIATION_UP 2,72 0,0000
#5 WINZEN_DEGRADED_VIA_KHSRP 2,69 0,0000
#6 SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP 2,61 0,0000
#7 CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN 2,58 0,0000
#8 MILI_PSEUDOPODIA_HAPTOTAXIS_UP 2,58 0,0000
#9 BILD_HRAS_ONCOGENIC_SIGNATURE 2,57 0,0000
#10 KAN_RESPONSE_TO_ARSENIC_TRIOXIDE 2,57 0,0000
#11 XU_HGF_SIGNALING_NOT_VIA_AKT1_6HR 2,56 0,0000
#12 PHONG_TNF_RESPONSE_VIA_P38_PARTIAL 2,55 0,0000
#13 SCHOEN_NFKB_SIGNALING 2,55 0,0000
#14 NUYTTEN_NIPP1_TARGETS_UP 2,53 0,0000
#15 RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP 2,53 0,0000
#16 PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN 2,52 0,0000
#17 DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN 2,51 0,0000
#18 MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN 2,48 0,0000
#19 PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2 2,48 0,0000
#20 BROWNE_HCMV_INFECTION_2HR_DN 2,48 0,0000
#21 ZHENG_RESPONSE_TO_ARSENITE_UP 2,48 0,0000
#22 PHONG_TNF_TARGETS_UP 2,47 0,0000
#23 LEE_LIVER_CANCER_HEPATOBLAST 2,47 0,0000
#24 LINDSTEDT_DENDRITIC_CELL_MATURATION_A 2,46 0,0001
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Figure 6.4: GSEA identifies mitogenic and inflammatory pathways in the regulation of
melanoma CD73 expression. (A): Overview of the bioinformatic analyses for pathways enrichment
in melanoma nascent invasive phenotype.
(B): Ranking of C2 collection of curated gene sets from MSigBD v.6.1 (n = 2235) according to FDR
corrected q-values and NES after GSEA on MITFhigh nascent invasive phenotype against MITFhigh
proliferative phenotype based on the BROAD melanoma cell line panel (n = 88). (C): List of top
rank 24 gene sets of analysis from (A). (D): Enrichment plots of mitogenic and inflammatory gene
sets of analysis from (A).
gene sets analyzed (n = 2235) were ranked according to NES and by increasing FDR
corrected p-values (Figure 6.4, B). In accordance with previous filtering on TNFα reg-
ulated genes for identification of CD73, we found an enrichment of NF-κB signaling
(rank #13) and TNFα targets (rank #12 and rank #22) in CD73 expressing MITFhigh
nascent invasive cell lines (Figure 6.4, C and D). However surprisingly, among the top
ranking gene expression signatures we also found mitogenic signaling gene sets, such as
HGF signaling on rank #12 and HRAS signaling on rank #9 and in especially gene sets
of oncogenic MET signaling (rank #2) to be highly enriched upon CD73 expression in
the MITFhigh nascent invasive phenotype.
In conclusion, our analysis show mitogenic signaling together with inflammatory path-
way activation to coincide with CD73 expression within a nascent invasive pheno-
type.
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6.2 Mitogenic inflammatory signaling drives CD73
expression in melanoma through the MAPK
pathway
6.2.1 A melanoma cell line panel as a model to study CD73
regulation in vitro
In the following we aimed to test this hypothesis by consecutive functional studies
on basis of a melanoma cell line panel available for cell culture in vitro analysis that
would represent the above delineated concept of melanoma phenotypic plasticity. For
that, we referred to the GSE51221 cohort of melanoma cell lines (n = 17) [13] and
integrated known MAPK signaling related driver mutation status, described by Hoek
et al. [107]. When we FACS analyzed a subset (n = 14) of cell lines for CD73
expression, we could confirm highly variable cell surface expression of CD73 (Figure 6.5,
A) that well corresponded to the phenotypes classified previously (Figure 6.3, A). We
recapitulated that CD73 was co-expressed along with MITF in a subgroup of melanoma
cell lines, and highly expressed in melanoma cell lines negative for MITF (Figure 6.5,
B).
Three cell lines of the MITFhigh proliferative phenotype showed complete absence of
CD73 expression: MaMel.27, MaMel.67a and MaMel.79bearly (MaMel.79b-e) (Figure
6.5, A and B). Based on reports describing epigenetic regulation of NT5E [267, 171],
we questioned if promoter silencing is present for the CD73low phenotype in that fraction
of melanoma cell lines. Bisulfite conversion assay followed by deep sequencing of the
CpG island within the 5'regulatory sequence at the end of NT5E exon 1 yielded detailed
information about the methylation status of the individual cell lines. It confirmed high
CpG island methylation exactly for those cell lines that were negative for CD73 expres-
sion (Figure 6.5, A). Interestingly, we were able to establish a subculture of one of those
cell lines, MaMel.79bearly, that showed phenotype switching and CD73 upregulation un-
der prolonged passaging (termed MaMel.79blate, MaMel79b-l). Bisulfite sequencing of
that culture confirms remodeling at the NT5E genomic locus by continuous decrease
of CpG island methylation (Figure 6.5, A).
Two cell lines, MaMel.15 and MaMel.71, did not show epigenetic silencing at the NT5E
locus, but still had low CD73 expression. These two cell lines were the only ones that
did not harbor any activating mutations in the MAPK signaling pathway (Figure 6.5,
A). In consequence, they exhibit low ERK phosphorylation levels when compared to
melanoma cell lines with positive MAPK driver mutation status (Figure 6.5, B). We
speculated that lack of CD73 expression in MaMel.15 and MaMel.71 might be the result
of insufficient MAPK signaling and hypothesized that both cell lines represent a suitable
model system for testing cooperative induction of CD73 by mitogenic and inflammatory
stimuli.
66
6 Results
M
M
79
b%
e'
M
M
27
'
M
M
67
a'
M
M
71
'
M
M
15
'
M
M
04
'
M
M
48
a'
M
Z7
'
M
M
10
2'
M
M
54
a'
M
M
85
'
M
M
65
'
Ac3n'
CD73'
MITF'
ERK'
pERK'
V600E/K
G459R
Q61K/L
stop/fs
missense
CD73
%
 o
f m
ax
MM27 MM67a MM79b-e MM15MM71 MM04 MM48a MM102
CD73
unstained
MM54aMM85 MM65
CpG-1
CpG-2
CpG-3
CpG-4
CpG-5
CpG-6
CpG-7
CpG-8
CpG-9
CpG-10
CpG-11
CpG-12
CpG-13
CpG-14
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
methylated
non-methylated
M
M
27
M
M
67
a
M
M
79
b
M
M
11
9
M
M
71
M
M
15
M
M
04
M
M
48
a
M
M
10
2
M
M
37
a
M
Z7
SK
M
el2
8
M
M
85
M
M
54
a
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
methylated
non-methylated
M
M
27
M
M
67
a
M
M
79
b
M
M
11
9
M
M
71
M
M
15
M
M
04
M
M
48
a
M
M
10
2
M
M
37
a
M
Z7
SK
M
el2
8
M
M
85
M
M
54
a
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
methylated
non-methylated
M
M
27
M
M
67
a
M
M
79
b
M
M
11
9
M
M
71
M
M
15
M
M
04
M
M
48
a
M
M
10
2
M
M
37
a
M
Z7
SK
M
el2
8
M
M
85
M
M
54
a
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG 1
CpG12
CpG13
CpG14
methylated
non-methylated
M
M
27
M
M
67
a
M
M
79
b
M
M
11
9
M
M
71
M
M
15
M
M
04
M
M
48
a
M
M
10
2
M
M
37
a
M
Z7
SK
M
el2
8
M
M
85
M
M
54
a
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
methylated
non-methylated
M
M
27
M
M
67
a
M
M
79
b
M
M
11
9
M
M
71
M
M
15
M
M
04
M
M
48
a
M
M
10
2
M
M
37
a
M
Z7
SK
M
el2
8
M
M
85
M
M
54
a
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
methylated
non-methylated
M
M
27
M
M
67
a
M
M
79
b
M
M
11
9
M
M
71
M
M
15
M
M
04
M
M
48
a
M
M
10
2
M
M
37
a
M
Z7
SK
M
el2
8
M
M
85
M
M
54
a
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
methylated
non-methylated
M
M
27
M
M
67
a
M
M
79
b
M
M
11
9
M
M
71
M
M
15
M
M
04
M
M
48
a
M
M
10
2
M
M
37
a
M
Z7
SK
M
el2
8
M
M
85
M
M
54
a
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
methylated
non-methylated
M
M
27
M
M
67
a
M
M
79
b
M
M
11
9
M
M
71
M
M
15
M
M
04
M
M
48
a
M
M
10
2
M
M
37
a
M
Z7
SK
M
el2
8
M
M
85
M
M
54
a
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
me hylated
non-me hylated
M
M
27
M
M
67
a
M
M
79
b
M
M
11
9
M
M
71
M
M
15
M
M
04
M
M
48
a
M
M
10
2
M
M
37
a
M
Z7
SK
M
el2
8
M
M
85
M
M
54
a
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
methylated
non-methylated
M
M
27
M
M
67
a
M
M
79
b
M
M
11
9
M
M
71
M
M
15
M
M
04
M
M
48
a
M
M
10
2
M
M
37
a
M
Z7
SK
M
el2
8
M
M
85
M
M
54
a
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
methylated
non-methylated
M
M
27
M
M
67
a
M
M
79
b
M
M
11
9
M
M
71
M
M
15
M
M
04
M
M
48
a
M
M
10
2
M
M
37
a
M
Z7
SK
M
el2
8
M
M
85
M
M
54
a
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
methylated
non-methylated
M
M
27
M
M
67
a
M
M
79
b
M
M
11
9
M
M
71
M
M
15
M
M
04
M
M
48
a
M
M
10
2
M
M
37
a
M
Z7
SK
M
el2
8
M
M
85
M
M
54
a
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
methylated
non-methylated
M
M
27
M
M
67
a
M
M
79
b
M
M
11
9
M
M
71
M
M
15
M
M
04
M
M
48
a
M
M
10
2
M
M
37
a
M
Z7
SK
M
el2
8
M
M
85
M
M
54
a
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
methylated
none-methylated
M
M
27
M
M
65
CpG1
CpG2
CpG3
CpG4
CpG5
CpG6
CpG7
CpG8
CpG9
CpG10
CpG11
CpG12
CpG13
CpG14
methylated
none-methylated
M
M
27
M
M
65
MZ7
BRAF:
NRAS
G12D
NF1
G13I
HRAS
methylated
none-
methylated
A
B
MITFlow''invasive'MITFhigh''nascent''invasive'MITFhigh''prolifera3ve'
MM37aMM79b-l
CD73NGFR_basal.jo Layout-5
18.04.2018 11:37 Uhr Page 1 of 1 (FlowJo v8.7)
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
MaMel04 MaMel102 MZ7MaMel48a SKMel28
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
MaMel54aMaMel65 MaMel85MaMel71 MaMel37aMaMel67aMaMel27
MaMel79b
0 102 103 104 105
0
20
40
60
80
100
MaMel79b_late
100 101 102 103 104
0
20
40
60
80
100
MaMel15 S 8
Figure 6.5: A melanoma cell line panel confirms in silico plasticity analyses in vitro. (A):
Melanoma cell lines (n = 14) from GSE51221 cohort (n = 17) depicted for CD73 in representative
FACS histograms (upper panel). MAPK driver mutation status from Hoek et al. [107] (middle panel).
Deep sequencing analysis on bisulfite conversion shows methylation status of CgG islands 1-14 in
NT5E regulatory sequence in pie charts (lower panel) (B): Representative immunoblots of melanoma
in vitro culture panel for CD73, MITF, total ERK, phosphorylated ERK and Actin. (C): Immunoblots
of melanoma cell lines after 20min/ 2h of 50 ng/ml HGF as indicated.
6.2.2 Inflammatory and mitogenic signaling cooperatively
induce CD73 expression
In order to investigate CD73 induction by inflammatory and mitogenic stimulation,
we monitored CD73 levels by FACS analysis, following treatment of MaMel.15 and
MaMel.71 with HGF and / or TNFα for 5 consecutive days. In fact, we saw a robust
induction of CD73 in both cell lines upon HGF treatment. Similarly, we achieved an
increase in CD73 expression in response to TNFα stimulation. Most interestingly, when
co-treating with inflammatory and mitogenic stimuli at once we found a very strong
and robust cooperative induction of surface CD73 expression in both cell lines (Figure
6.6).
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6 Results
In conclusion, mitogenic stimulation induces melanoma CD73 expression in differenti-
ated melanoma cells which exhibit insufficient MAPK signaling and CD73 induction is
strongly amplified in the combination with inflammatory triggers.
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Figure 6.6: Cooperative CD73 induction by mitogenic and inflammatory stimuli. (A): Repre-
sentative CD73 FACS histograms in MaMel.15 (A) and MaMel.71 (B)) after 5 days of 1000 U/ml
TNFα, 50 ng/ml HGF or combinatorial treatment.
6.2.3 Epigenetic remodeling at the NT5E locus is required
for induction of CD73
We next speculated whether epigenetic silencing of NT5E can be overcome by the co-
stimulation procedure and stimulated the CpG island methylated cell lines MaMel.27,
MaMel.67a and MaMel.79bearly according to the above introduced stimulation protocol.
However, we found no upregulation of CD73 by neither of the stimulation conditions
(Figure 6.7, A). These observations prompted us hypothesize that epigenetic remodeling
at the NT5E locus is required to allow induction of CD73 expression by inflammatory
and mitogenic signaling. Using 5-Azacytidine, we globally demethylated MaMel.79bearly
and MaMel.67a and simultaneously subjected the cultures to our co-stimulation ap-
proach. Deep sequencing-based bisulfite sequencing confirmed sufficient demethyla-
tion by 5-Azacytidine of the NT5E CpG island in both cell lines. Demethylation was
stronger in MaMel.79bearly with a further increase upon co-stimulation (Figure 6.7, B).
By FACS analysis we indeed observed induction of CD73 upon global demethylation in a
5-Azacytidine concentration dependent manner for both cell lines tested (Figure 6.7, C).
In accordance with the degree of demethylation, we saw stronger upregulation of CD73
in MaMel.79bearly, than in MaMel.67a. HGF / TNFα co-stimulation further amplified
CD73 expression in both cell lines, again with more pronounced induction observed for
the cell line showing more advanced demethylation under stimulation, MaMel.79bearly
(Figure 6.7, C).
In summary, we show epigenetic silencing at the 5'regulatory CpG island in NT5E in
some of the MITFhigh proliferative cell lines accounts for the absence of CD73 and
the resistance to up-regulate CD73 in response to mitogenic / inflammatory stimula-
tion.
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Figure 6.7: Epigenetic remodeling induces CD73 expression and susceptibility to mitogenic
inflammatory stimulation. (A): Representative CD73 FACS histograms for the cell lines indicated,
after 5 days of 1 0 U/ml TNFα, 50 ng/ml HGF or combinatorial treatment. (B):
Pie charts of deep sequencing based bisulfite sequencing analysis covering the NT5E CpG island within
in MaMel.67a (left) and MaMel.79bearly (right). Cells treated 6 days, daily with DMSO or 5-Azacytidine
and 3 more days by 1000 U/ml TNFα and 50 ng/ml HGF or mock. (C): Representative CD73 FACS
histograms f r MaMel.67a and MaMel.79bearly for the experimental procedure as described in (B).
MaMel.79bearly = MaMel.79b-e.
6.2.4 CD73 induction in melanoma by both mitogenic and
inflammatory stimuli depends on MAPK signaling
cascade activation
In a next step, we wondered whether which mitogenic signaling pathway is driving the
observed induction of CD73. In MaMel.15 and MaMel.71 we interfered with both most
relevant growth factor receptor ligation activated pathways, either MAPK signaling
by MEK inhibition (MEKi) or AKT-PI3K-signaling by PI3Ki in conjunction with the
co-stimulation procedure. Most surprisingly both, the separate inflammatory and the
mitogenic induction of CD73 expression were completely dependent on MAPK signaling,
while PI3Ki had no effect. (Figure 6.8, A). In addition, cooperative CD73 induction
under co-stimulation was completely abrogated in the presence of MEK. The findings
were reproducible on a total protein level in immunoblot analyses confirming abolished
ERK phosphorylation und MEKi despite stimulation and on a mRNA level in qPCR
analysis (Figure 6.8, B and C).
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6 Results
MEKi was also able to block TNFα dependent induction of CD73 in cell lines with
positive MAPK mutation status as tested for the NRAS mutant cell line MaMel.79blate
(Figure 6.8, D). Of note, MaMel.79blate was able to induce CD73 expression in re-
sponse to inflammatory TNFα stimulation whereas parental MaMel.79bearly harbor-
ing NT5E CpG island methylation was not. This finding nicely appends to previ-
ous investigation on the impact of epigenetic remodeling on inducibility of CD73 in
melanoma.
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Figure 6.8: MAPK cascade signaling orchestrates mitogenic inflammatory CD73 induction in
melanoma. (A): Representative CD73 FACS histograms of MaMel.15 (left) and MaMel.71 (right)
treated 5 days by 1000 U/ml TNFα, 50 ng/ml HGF or by combination together with 50 nM Trametinib,
1 µM BEZ235 or DMSO. (B): Representative immunoblot analysis of the experimental procedure as
described in (A) including DMSO and 50 nM Trametinib treatment. MaMel.15 and MaMel.71 in
upper and lower blots, respectively. (C): qPCR analysis of the experimental procedure from (A)
on MaMel.71 and MaMel.15 (upper and lower panels, respectively). Relative (rel.) NT5E mRNA
with values relative to UBC and referenced to unstimulated DMSO control (ctrl) shown as mean of
n = 3 with error bars as SD. Two-way ANOVA analysis. Post-hoc testing by Bonferroni’s multiple
comparisons test was either conducted to compare means across inhibitor treatment conditions or to
validate various stimuli in DMSO or Trametinib conditions against ctrl. *, P<0.05; **, P<0.01; ***,
P<0.001. (D): Immunoblots of MaMel.79blate (MaMel.79-l) with same experimental procedures as
in (A) but only 50 nM Tremetinib.
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6.2.5 Inflammatory macrophage supernatant constitutes a
source for melanoma cell CD73 induction
Next, we aimed to investigate on potential sources for mitogenic / inflammatory signals
in the tumor environment. We focused on inflammatory macrophages as a major source
for TNFα in the inflamed tumor tissue and during remodeling processes leading to cancer
progression and metastasis [190].
We translated this in our in vitro setting to stimulation of melanoma cells by inflamma-
tory macrophage supernatant. We used PMA in order to differentiate THP1 suspension
monocytes into adherent macrophages and harvested inflammatory THP1 cell super-
natant for melanoma cell stimulation according to the protocol shown in Figure 6.9, A.
In short term timeline stimulation experiments of MaMel.15 and MaMel.71 we found
robust activation of the MAPK cascade as visualized in high increase of ERK phosphory-
lation but also some impact on p38 and AKT signaling pathway (Figure 6.9, B). THP1
SN promoted melanoma cell dedifferentiation resulting in reduction of MITF, MLANA
and TYR expression levels in qPCR analysis (Figure 6.9, C). Remarkably, treatment of
MaMel.15 and MaMel.71 with THP1 SN resulted in a robust and very strong increase
of CD73 expression in both cell lines (Figure 6.9, D) and the induction could again be
blocked by Trametinib.
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Figure 6.9: THP1 macrophage secretome induces melanoma cell CD73 expression. (A): Outline
of the THP1 cell differentiation protocol for generating inflammatory supernatant. (B): Immunoblots
from MaMel.15 (left) and MaMel.71 (right) upon stimulation with pure THP1 SN for indicated pe-
riods of time. (C): qPCR analysis on indicated differentiation genes in MaMel.15 (upper blots) and
MaMel.71 (lower blots) treated by 50% v/v THP1 SN and THP1 medium for 5 days. Expression
normalized to UBC. Means of biological triplicates with error bars showing SD. Two-tailed, un-paired
Student’s T-Tests. *, P<0.05; ***, P<0.001.(D): CD73 FACS histogram analysis of a representative
experiment of MaMel.15 (left) and MaMel.71 (right) treated by THP1 SN as described in (B) and
co-inhibited by 50 nM Trametinib.
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6 Results
6.2.6 Baseline CD73 expression depends on MAPK signaling
in melanoma
So far we investigated the molecular pathways that account for CD73 de novo in-
duction in melanoma cells that do not or only marginally express CD73 on a baseline
level. We have consistently observed inflammatory/ mitogenic stimuli to converge on
MAPK cascade activation. This prompted us to downregulation of CD73 baseline ex-
pression in cell lines of the nascent imvasive or invasive cell state by blocking MAPK
signaling.
In this intention we treated CD73 positive melanoma cell lines from our panel with
the MEK inhibitor Trametinib and recorded CD73 expression by FACS analysis. We
observed a consistent and robust decrease of surface CD73 levels upon MAPK cascade
blockade for all cell lines except MaMel.54a with most effective downregulation observed
in SK.Mel28 (Figure 6.10, A). Immunoblot analysis confirmed inhibition of downstream
ERK phosphorylation in response to MEKi and proved reduction of CD73 on a total
protein level (Figure 6.10, B). Interestingly, partial reactivation of ERK signaling oc-
curred in those cell lines with a more dedifferentiated phenotype, i.e. MaMel.85 and
MaMel.65. This fits to reports stating a dedifferentiated phenotype to be prone to
primary targeted therapy resistance [167].
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Figure 6.10: Baseline CD73 expression is decreased by MAPK inhibition. (A): Representative
CD73 FACS analysis at baseline and after 4 days 50 nM Trametinib in a panel of CD73 positive
melanoma cell lines. (B): Representative immunoblot analysis on CD73 positive melanoma cell lines
after 96h of 50 nM Trametinib or DMSO (MaMel. = MM, SK.Mel28 = SK28).
MAPK signaling is a key signaling pathway for melanoma growth and survival [50]. In
order to exclude that reduction of CD73 expression is a secondary effect of therapy
induced cell cycle arrest we treated cells with the fungal antibiotic Aphidicolin that is
inhibiting eukaroytic replication, likewise similarly effecting cell growth than when ap-
plying MAPK signaling blockade. We found that Aphidicolin did not reduce, but rather
increase CD73 expression (Figure 6.11, A), excluding growth arrest related changes
to account for the downregulation of CD73 expression in melanoma. Interestingly, on
mRNA level Aphidicolin treatment slightly reduced NT5E expression, but still to a
lower extent when compared NT5E reduction mediated by MAPK blockade (Figure
6.11, B).
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Figure 6.11: Cell cycle arrest does not account for the reduction of CD73 expression (A):
Representative CD73 FACS analysis in SK.Mel28, MaMel.102 and MaMel.65 at baseline and after 4
days either 50 nM Trametinib or 1 µ/ml Aphidicolin (MaMel. = MM, SK.Mel28 = SK28). (B): NT5E
mRNA as mean of biological triplicates from diverse melanoma cell lines. Expression normalized to
UBC and DMSO control set as reference. Error bars show SD. Statistics by one-way ANOVA and
post-hoc testing by Bonferroni’s multiple comparisons test. **, P<0.01; ***, P<0.001.
We wondered whether prolonged inhibition of the MAPK pathway further reduced CD73.
Indeed, we observed progressive loss of CD73 from day 4, day 10 to day 18 of MEKi
(Figure 6.12, A). Vice versa, we next sought to address whether restoring ERK phos-
phorylation and MAPK signaling in a setting of previous MEKi would then also restore
CD73 expression on melanoma cells. For that, we withdrew MEKi after 4 days and
monitored CD73 expression over time. In SK.Mel28 and MZ7, CD73 expression was
fully restored after 12 days, MaMel.37a and MaMel.48a recovered most of CD73 surface
protein (Figure 6.12, B). Only MaMel.102 showed progressive loss of CD73 surface pro-
tein even after removal of Trametinib treatment, which was consistent with the strong
ablation of CD73 under long-term inhibition.
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Figure 6.12: Prolonged MAPK blockade further decreases - rehabilitating MAPK activity
restores CD73 expression (A): Representative timeline experiment showing CD73 FACS analysis at
day4, day10 and day18 of 50 nM Trametinib in the cell lines SK.Mel28, MZ7 and MaMel.102. (B):
CD73 FACS analyses after 4 days of 50 nM Trametinib and after additional 12 days upon removal of
inhibitor treatment in melanoma cell lines as indicated (MaMel. = MM, SK.Mel28 = SK28).
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Figure 6.13: Testing an inhibitor panel for CD73 regulation beyond MAPK signaling qPCR
for NT5E expression in melanoma cell line panel (n=9) after 4 days inhibitor treatment as indicated.
50 nM Trametinib (MEKi), 100 nM SCH772984 (ERKi), 1 µ/ml BEZ235 (PI3Ki), 1 µ/ml MK2206
(AKTi), 20 µ/ml SP600125 (JNKi) and 1 µ/ml Sotrastaurin (PKCi). Shown are means plus SD
of n=3. Data is normalized to UBC expression and DMSO control condition set as reference. For
statistical testing cell line wise comparison to DMSO ctrl by un-paired two-sided Student’s T-Test
with multiple comparison correction according to Benjamini and Hochberg (=FDR). *, P<0.05; **,
P<0.01; ***, P<0.001. (MaMel. = MM, SK.Mel28 = SK28).
Finally, we intended to reproduce our findings on CD73 regulation via the MAPK cas-
cade on mRNA expression level and further testing key pathways transmitting signaling
in melanoma. We found strong and consistent downregulation of NT5E mRNA in
our cell line panel upon MEKi (Figure 6.13). Comparable results were achieved by
SCH772984, which blocks ERK signaling. Interfering with PI3K/AKT-, JNK- and PKC
signaling showed varying effects on NT5E mRNA expression, depending on the individ-
ual cell lines and method of analysis. Whereas PI3K blockade (BEZ235) was able to
decrease NT5E mRNA in some cell lines such an effect was not seen for AKT (MK2206)
inhibition. JNK (SP600125) and PKC blockade (Sotrastaurin) also did not impact on
CD73 expression.
In summary, considering mRNA and FACS expression data across the cell line panel
tested, only MAPK signaling was consistently found to control melanoma cell CD73
expression.
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6.3 JUN/ AP1 complexes control transcription of
NT5E in dependence on MAPK activation
6.3.1 The search for transcription factors that correlate with
CD73 expression in melanoma points to JUN
In a next step, we were interested in finding the downstream molecular mechanisms
regulating CD73 expression in melanoma. For this, we made use of previously annotated
NT5E binding TFs from the ENCODE ChIPseq data of the ENCODE Human Feb.
2009 (GRCh37/hg19) assembly TF ChIPseq (161 TF of 91 cell types as at March
2012 Freeze). Figure 6.14, A visualizes the NT5E transcript sequence in the UCSC
genome browser together with regulatory tracks, such as H3K27 acetylation and H3K4
monomethylation indicating potential enhancer sites, as well as H3K4 trimethylation
for promotor sites and DNase cluster for regions of open chromatin. Due to the active
chromatin marks in an intergeneic region about 50 kb upstream of the NT5E locus
we expanded the region of interest to include this locus. In total, we covered a region
with 335 potential TF binding sites of 88 individual TFs (Figure 6.14, A) . Many
TF binding sites accumulated in this potential distant cis-regulatory element, another
fraction surrounded the transcriptional start site. Interestingly, we also found TFs
binding sites accumulating within an first intronic region of NT5E with additional high
H3K27 acetylation and H3K4 monomethylation.
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Figure 6.14: JUN is a transcription factor with ENCODE annotated binding in NT5E and
highly correlates with melanoma cell CD73 expression. (A): UCSC genome browser screenshot of
human GRCh37/hg19 assembly for genomic locus at NT5E. RefSeq transcript and ENCODE regulation
tracks layered H3K27Ac, H3K4Me3 and H3K4Me1. DNAseI hypersensitivity clusters and squish view
of ENCODE TF ChIPseq from 161 TFs in 91 cell types. (B): ENCODE NT5E binding TFs in ranked
order from positive to negative correlation with NT5E expression in the BROAD panel of melanoma
cell lines (n = 88). Correlation analysis performed for individual gene probe IDs against the NT5E
gene probe ID 203939-at. Probes with Pearson correlation > 0.4 highlighted.
For identification of TFs relevant for the regulation of CD73 in melanoma, we next
correlated mRNA expression of the selected candidate TFs with mRNA expression of
NT5E for the BROAD panel of melanoma cell lines (n = 88). Figure 6.14, B illustrates
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TFs with Pearson correlation ≥ 0.4 for this analysis. Among the top hits we found
IRF1, NR3C1 and JUN.
Finding JUN was highly interesting: We and others have recently described an im-
portant function of JUN/ AP1 complexes during stress- and inflammation mediated
invasive phenotype switching in melanoma, plus it is involved in adaptive therapy re-
sistance [201, 51, 69, 68, 249, 192]. JUN belongs to the heterodimeric AP1 TF family
acting downstream of the JNK and ERK-MEK signaling pathways [81, 233]. Dimeriza-
tion partners of JUN comprise FOSL1 (FRA-1), FOSL1 (FRA-2) and c-FOS [119]. It
essentially impacts on melanoma cell proliferation, progression, migration, and invasion
[64, 131, 224]. The fact that JUN/ AP1 complexes are capable of integrating both in-
flammatory and mitogenic triggers, makes it a highly promising candidate for mediating
CD73 induction during phenotype switching.
6.3.2 Cooperative upregulation of CD73 is accompanied by
the induction of JUN/ AP1 family members
Having found CD73 as an indicator of a nascent invasive phenotype and to be inducible
by inflammatory regenerative signaling, we speculated on the involvement of JUN in
the convergence of the signaling pathways. In accordance with previous findings on
JUN/ AP1 in melanoma plasticity, we found that JUN and the AP1 heterodimeriza-
tion partner FOSL1 were strongest expressed in invasive melanoma cell lines, which
were positive for CD73 and negative for MITF (Figure 6.15, A). We next wondered
whether cooperative induction of CD73 by mitogenic (HGF), together with inflamma-
tory (TNFα) stimulation is accompanied by the cooperative induction of JUN. For this,
we performed immunoblot analyses in both of our MAPK cascade associated mutation
status naïve model cell lines, MaMel.15 and MaMel.71, in response to prolonged mito-
genic/inflammatory co-stimulation. Indeed, we observed cooperative, stable induction
of JUN and to a lesser degree stabilization of additional factors of the JUN/ AP1 TF
family, such as FOSL1 and JUNB (Figure 6.15, B). Similarly, long term stimulation
by supernatant derived from differentiated THP1 cells, but not from undifferentiated
THP1 cells, established a CD73high, JUNhigh phenotype in both cell line models. Ad-
ditionally, we found upregulation of JUNB and FOSL1 primarily in MaMel.71 (Figure
6.15, C).
In summary, findings on JUN as ENCODE ChIPseq annotated TF showing enriched bind-
ing to the NT5E genomic locus and highly correlating with melanoma NT5E mRNA
expression in silico were supported by in vitro data on cooperative induction of JUN
alongside with elevation of CD73 expression levels by mitogenic together with inflamma-
tory stimulation. Based on those findings, we were prompted to the question whether
JUN is mediating CD73 expression in melanoma cells.
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Figure 6.15: Invasive cell state correlates with CD73 / JUN and induction of CD73 is accom-
panied by accumulation of JUN/ AP1 factors. (A): Immunoblot in the melanoma cell line panel
as introduced in Figure 6.5, B. (B): Representative immunoblots in MaMel.15 (left) and MaMel.71
(right) with 1000 U/ml TNFα, 50 ng HGF, or combinatorial treatment for 5 days. (C): Immunoblots
at 5 days 50% (v/v) SN from differentiated THP1 cells (diff) and 50% (v/v) SN from undifferentiated
THP1 cells (undiff) in MaMel.15 (left) and MaMel.71 (right).
6.3.3 JUN strongly induces melanoma cell CD73 in
dependence of MAPK activation
In order to evaluate the impact of JUN for CD73 induction, we stably overexpressed
JUN by retroviral infection of vector constructs carrying either JUN-citrine or citrine as
a control in MaMel.15. Surprisingly, overexpression of JUN under basal conditions was
not stable and no induction of CD73 was observed (Figure 6.16, A and B). As shown ear-
lier (Figure 6.6, A), MaMel.15 is negative for oncogenic driver mutations in the MAPK
signaling cascade and ectopic JUN stabilized upon mitogenic stimulation by EGF or
HGF. It is known that oncogenic MAPK cascade activation leads to post-translational
modification as well as transcriptional activation of JUN, thereby, increasing JUN pro-
tein stability and transcript abundance [242, 263, 146]. Indeed, upon MAPK activation
mediated stabilization, we observed induction of CD73 that was further increased in
cooperation with inflammatory TNFα stimulation in a magnitude that was not present
by control vector expressing cells (Figure 6.16, A and B). Additionally, CD73 induction
correlated with the induction of FOSL1 upon mitogenic stimulation, which is in line with
literature, stating in cancer cells by ERK-dependent phosphorylation [263]. It is known
that JUN induces FOSL1 expression by binding to promoter and first intronic elements
within the FOSL1 genomic locus [22, 36]. This is an interesting observation as in the
context of EMT transformation and tumor cell plasticity JUN/ FOSL1 heterodimers
play an important role [55]. Hence, data presume close connectivity of JUN function-
ality for melanoma cell CD73 regulation in heterodimers, orchestrated by inflammatory
stimulation, and stabilized by mitogenic signaling.
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Figure 6.16: Ectopic JUN induces CD73 in MaMel.15 upon stabilization by mitogenic stimula-
tion. (A): Immunoblots in MaMel.15 expressing citrine control or JUN-citrine vector after 72h 1000
U/ml TNFα, 100 ng/ml EGF and 100 ng/ml HGF in the indicated combinations. (B): Same as (A)
but CD73 FACS analysis at day 5 of stimulation.
Based on the above delineated results, we assumed that JUN overexpression in melanoma
cell lines with positive MAPK driver mutation status should lead to immediate induction
of CD73. We selected the nascent invasive melanoma cell lines MaMel.48a, MaMel.102,
MZ7, and MaMel.37a with positive BRAF or NRAS mutation status for JUN stable
overexpression. Remarkably, we observed stable expression of ectopic JUN and robust
upregulation for both CD73 protein and NT5E mRNA expression across all cell lines
tested (Figure6.17, A and B). JUN overexpression led to robust melanoma cell dedif-
ferentiation as visualized by the loss of MITF expression (Figure 6.17, A). Furthermore,
we again observed upregulation and stabilization of FOSL1 by ectopic JUN, in line with
our previous data.
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Figure 6.17: Ectopic JUN boosts CD73 expression in nascent invasive melanoma cells (A):
Immunoblots showing MaMel.48a, MaMel.102, MZ7 and MaMel.37a, transduced with citrine control
vector or JUN-citrine vector for the indicated proteins. (B): qPCR analysis on mean of NT5E expres-
sion across all cell lines transduced with JUN-citrine or citrine (n=4), normalized to UBC. Expression
in citrine vector set as reference. Error bars indicate SD. Two-sided paired Student’s T-Test. **,
P<0.01.
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6.3.4 A conditional expression system to study defined JUN
transcriptional activity on the NT5E genomic locus
Having found strong induction of CD73 by JUN, we were intrigued whether we can dis-
sect the regulation on a genomic level. As reported earlier, constitutive overexpression of
JUN does not only strongly impact and modulate the expression of its AP1 complex het-
erodimerization partners but also initiates remodeling and cell state transition. Hence,
for studying defined JUN transcriptional activity on the NT5E genomic locus, we aimed
to set up a JUN doxycycline(DOX)-dependent conditional expression system. For that
purpose, we selected the NRAS (p.Q61K) mutant cell line MaMel.79blate which shows
constitutive MAPK signaling activation enabling stabilization of ectopic JUN while at
the same time harboring baseline expression levels of the AP1 heterodimerization part-
ner FOSL1 (Figure 6.15, A). Furthermore, MaMel.79blate exhibits low levels of CD73
and is devoid of JUN (Figure 6.5, A), making it a good model system to study defined
effects of JUN on CD73.
As shown in Figure 6.18 A, inflammatory TNFα stimulation of the unmodified cell line
MaMel.79blate leads to immediate induction of JUN accompanied by MITF downreg-
ulation and furthermore is followed by strong accumulation of FOSL1 protein. Upon
prolonged TNFα stimulation, CD73 is robustly induced (Figure 6.8, D). Of note, as
a result of pre-activated MAPK signaling, we observed constitutive ERK phosphory-
lation that was not further increased neither by mitogenic HGF stimulation nor by
combinatorial treatment (Figure 6.18 A). Also, no further accumulation of FOSL1 and
JUN protein was found in the latter stimulation conditions which is in line with pre-
vious findings on absence of CD73 induction by mitogenic stimulation (Figure 6.8,
D).
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Figure 6.18: Establishment of a JUN conditional cell line system in MaMel.79blate. (A): Im-
munoblots showing MaMel79blate stimulated for the indicated periods of time with 1000 U/ml TNFα,
50 ng/ml HGF and combinatorial treatment. (B): Immunoblots on DOX titration in indicated con-
centrations after 24h in MaMel.79blateCitrineDOX (left) and MaMel.79blateJUN-CitrineDOX (right).
Following lenti- and retroviral transduction of the conditional expression constructs
into MaMel.79blate, DOX titration showed a concentration dependent increase of JUN-
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Citrine and Citrine protein expression in the screening cell line MaMel.79blateJUN-
CitrineDOX and the control cell line MaMel.79blateCitrineDOX, respectively (Figure
6.18, B), yielding a minimal effective concentration of 25 ng/ml DOX for future exper-
iments. JUN accumulation was accompanied by a successive increase in FOSL1 protein
and decrease in MITF protein (Figure 6.18, B).
6.3.5 Transient JUN induction establishes a MITFhigh /
CD73high phenotype in melanoma
In timeline experiments with a low dose pulse of DOX we observed only transient JUN-
citrine expression that was accompanied by transient suppression of MITF at peak
of JUN-citrine induction but still resulted in upregulation of CD73 expression (Figure
6.19, A). This generated a nascent invasive phenotype bearing CD73 expression along
with a positive MITF status in absence of JUN. On the contrary, induction of the
Citrine control construct was stable and had no impact on neither CD73 nor MITF
expression. We next evaluated the findings in more detail on a transcriptional level and
compared the effects of pulse JUN-citrine to durable expression of JUN-citrine (Figure
6.19, B). 48h post pulse DOX treatment MITF was depleted, NT5E induction was
not yet observed. At the same time, citrine induction in control cell population did
not effect MITF expression. For durable induction of JUN-citrine DOX treatment was
renewed for another 48h, whereas for pulse JUN induction medium containing remnants
of DOX was replaced.
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Figure 6.19: Transient JUN in MaMel.79blateJUN-CitrineDOX establishes a MITFhigh CD73high
phenotype. (A): Representative immunoblots for 10 ng/ml doxycycline (DOX) treatment in
MaMel.79blateJUN-CitrineDOX (left) and MaMel.79blateCitrineDOX (right) at indicated time points.
(B): qPCR experiments of n=3 showing cell lines as indicated in (A), but for 96 h with medium
replacement after 48 h and DOX at 100 ng/ml. DMSO (48 h medium + 48 h medium), 48 h DOX
(48 h medium + 48 h DOX), PULSE DOX (48 h DOX + 48 h medium), CONTIN. DOX (48 h DOX
+ 48 h DOX). Error bars showing SD. DMSO control set as reference. One-way ANOVA analysis with
post-hoc Bonferroni correction for multiple comparisons. ***, P<0.001.
Continuous JUN-Citrine expression led to comparably strong induction of NT5E mRNA
in the absence of MITF expression, as observed for transient JUN-citrine pulse, but here
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MITF expression was largely restored (Figure 6.19, B). Again, sole citrine induction did
not interfere with NT5E levels in any condition.
In summary, the data suggest the side-by-side generation of an invasive and a nascent
invasive phenotype from a proliferative cell state, with transient JUN promoting nascent
de-differentiation and incipient phenotype switching and stable JUN leading to full phe-
notype switching. Further mechanistically insights on melanoma plasticity might be
gained from RNAseq analysis on the above delineated experimental setting.
6.3.6 ChIP qPCR reveals prominent binding of JUN to AP1
consensus sites located in NT5E
Making use of our JUN-inducible melanoma cell line model, we were next interested in
finding the detailed binding sites of JUN in NT5E. We referred back to the ENCODE
ChIPseq dataset and searched for annotated JUN binding sites, plus additional intronic
control sites within H3K27Aclow regions of NT5E for designing a tiling approach for
ChIP qPCR (Figure 6.20, A). After DOX induction of the constructs, we used the
citrine tag to purify genomic binding regions for JUN-citrine and citrine only as a control.
Amplification on the immunoprecipitated DNA for the candidate JUN binding sites and
control sites yielded significant enrichment of JUN-citrine over citrine samples only for
two regions within NT5E that span the AP1 #1 and AP1 #2 sites, which are located
upstream of NT5E, and the first intronic AP1 #5 and AP1 #6 sites (Figure 6.20, B).
Indeed, binding of JUN in NT5E for those two regions coincided with elevated H3K27Ac
enhancer marks (Figure 6.20, A). Moreover, canonical AP1 binding motifs are centrally
located within the significantly enriched regions regions.
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Figure 6.20: Prominent binding of JUN to NT5E intronic enhancer region in ChIP qPCR.
(A): Screenshot of human GRCh37/hg19 assembly surrounding NT5E in the UCSC genome browser
with layered H3K27Ac and TF ChIP seq track for annotated JUN binding sites. JUN/ AP1 sites for
ChIP qPCR amplification indicated in red, control amplicon sites indicated in grey. (B): Means of %
input from biological triplicates of ChIP qPCR analysis performed in MaMel.79blateJUN-citrineDOX
after 24 h pulse by 25 ng/ml DOX. MaMel.79blatecitrineDOX as a reference. Error bars indicate SEM.
Significance tested by one-sided Student’s T-Test for enrichment. *, P<0.05.
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In summary, our findings substantiate the role of JUN in the direct regulation of
NT5E expression in melanoma by showing enriched binding of JUN to several ENCODE
ChIPseq predicted AP1 binding sites within the NT5E genomic locus.
6.4 A CRISPR/Cas9-FACSorting enhancer
screening approach for functional validation of
AP1 binding sites in NT5E
6.4.1 Development of the CRISPR/Cas9-FACSorting
enhancer screen
Having shown that JUN is recruited to defined binding sites within NT5E, we were next
interested if binding of JUN to those sites is of functional relevance for the induction
of CD73. For this purpose we designed an enhancer screening approach, that uses
CRISPR/Cas9 to disrupt JUN/ AP1 binding motifs of interest and subsequent functional
validation of CD73 expression by FACSorting in conjunction with deep sequencing of
the AP1 sites targeted in the fractions sorted. We assumed that when destructing an
AP1 site that was of functional relevance for the induction of CD73, we should see
decreased induction in response to JUN/ AP1 activation. In consequence, relevant
AP1 sites with a strong phenotype should be accessible by mere FACS analysis of
CD73. Additionally, we postulated that those cells that acquired insertions and deletions
(InDels) within a functional relevant AP1 binding motif should become enriched in the
CD73low inducible sub-fraction and vice versa depleted from the CD73high inducible sub-
fraction. Hence, the combination of FACSorting CD73high and CD73low expressing sub-
fractions followed by deep sequencing in an arrayed screening approach should allow to
causatively couple a phenotype observed to distinct genomic alterations. The schematic
overview in Figure 6.21, A introduces the screening approach and illustrates its main
principles.
Selection of the candidate sites throughout NT5E for CRISPR/Cas9-based targeting
was made based on significant enrichment of JUN binding to genomic DNA fragments
in ChIP qPCR analysis and yielded 8 potential sites. Subsequently, these sites were
matched to ENCODE annotated TFs binding in NT5E with a canonical AP1 binding
site, resulting in a final set of 5 candidate AP1 sites plus an extra control targeting site
within a H3K27Ac/ H3K4Me3/DNaseIlow region of the first intron of NT5E (Figure
6.21, B). sgRNAs were designed to cut most nearby the canonical AP1 binding motif
(Figure 6.21, C).
We used our model cell line MaMel.79blateJUN-citrineDOX and side-by-side transfected
the CRISPR/Cas9 constructs directed against the individual JUN/ AP1 and control sites
in NT5E. We induced CD73 for 5 days by DOX pulsed transient JUN-citrine expression
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and conducted FACS analysis. In parallel, FACSorting of the 10% lowest CD73 and 10%
highest CD73 fractions, as well as the total population of viable cells was performed
and AP1 and control site InDel formation quantified by deep sequencing (Figure 6.21,
A).
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Figure 6.21: Design of the CRISPR/Cas9-FACSorting enhancer screening approach. (A):
Schematic outline of the CRISPR/Cas9-based CD73 FACSorting approach for enhancer screening in
MaMel.79blateJUN-citrineDOX to identify JUN binding sites in NT5E relevant for CD73 induction.(B):
UCSC genome browser screenshot of NT5E locus with ENCODE regulatory tracks as indicated. JUN/
AP1 sites #1, #2a, #2b, #5, #6 and Control site targeted are mapped. (C): Target site sequences
for sgRNAs used. Protospacer adjacent motif (PAM) underlined, CRISPR/Cas9 cutting sites indicated
by // and canonical AP1 binding motifs highlighted in red.
6.4.2 JUN induces CD73 by binding to a specific AP1
consensus site in NT5E
Figure 6.22, A visualizes the results from biological triplicates of the screening ap-
proach, showing targeting efficiencies at individual sites in the CD73 sorted fractions
and the unsorted cell pools. Efficient genome editing with some minor individual vari-
ance across all sgRNAs used was observed in the unsorted cell pools. Interestingly,
AP1 site-specified editing, defined by the disruption of the canonical AP1 binding motif
nearby/in the sgRNA target sites, varied substantially in the unsorted cell pools for
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individual sgRNAs. This perfectly corresponds to the distance of target site cutting
from the respective AP1 motif (Figure 6.21, C). It cannot be avoided due to the lim-
itations given by sgRNA design rules [45, 80]. However, normalization of editing in
the sorted fractions to editing in the unsorted cell pool allows to compensate for this
effect.
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Figure 6.22: CRISPR/Cas9-based FACSorting approach for enhancer screening identifies AP1
#5 site for CD73 induction by JUN. (A): Pie charts showing successful genome editing by the
respective AP1 and control sgR As for target site and specified AP1 site editing. Sorting conditions
CD73 lowest and highest 10% and unsorted cell pool (Total) ar indicat d. Mean of biological trip-
licates consisting of technical triplicates shown. (B): Bar charts illustrating results as presented in
(B) but after normalization of AP1 site editing frequencies on AP1 site editing in the respective total
cell populations. Un-paired two-sided Student’s T-Test. *, P<0. 5. (C): Representative CD73 FACS
analysis of one biological replicate as shown in (A) and (B) of CRISPR/Cas9 (AP1/ctrl site) targeted
MaMel.79blateJUN-citrineDOX after 25 ng/ml DOX pulse at day 5.
The evaluation of the screening approach revealed one defined AP1 binding motif that
showed major functional relevance for the induction of CD73 by JUN: The AP1 #5
site. Quantification of AP1 site targeting prior normalization already demonstrates a
strong enrichment of 52% AP1 #5 site targeted mutagenesis in the 10% lowest CD73
sub-fraction (Figure 6.22, A). Vice versa, a strong depletion of AP1 #5 site targeting
in the 10% highest CD73 sub-fraction with only 4% AP1 #5 site editing is seen.
Following normalization, significant enrichment in of AP1 site disruption in CD73low
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versus CD73high sorted cells is again found only for the AP1 #5 site (Figure 6.22, B).
Intriguingly, we even observed reduced induction of CD73 in a sub-fraction of cells after
targeting the AP1 #5 site, which became apparent as a shoulder of CD73low inducible
cells in FACS analysis (Figure 6.22, C).
In summary, the results demonstrate that destructing the AP1 #5 site functionally im-
pairs CD73 induction in our cell line model. JUN/ AP1 complexes require binding to the
AP1 #5 site within the first intron of NT5E to stimulate its expression in melanoma.
Strikingly, the AP1 #5 site aligns perfectly to the region of strongest enrichment of JUN
binding to NT5E in our ChIP qPCR experiments presented above.
6.4.3 Positional mutation analysis constitutes a method for
the identification of previously unknown enhancer
elements with single base pair resolution
We used the CRISPR/Cas9-based FACSorting enhancer screening approach in the pre-
vious section to address the question whether specific predefined TF binding sites are
of functional importance for the expression of CD73. However, quite often, potential
enhancer regions and detailed TF binding sites remain elusive. Thus, a screening ap-
proach allowing identification of such sites and simultaneously proving their functional
relevance in an endogenous context would be highly desirable. We hypothesized that
in our approach the combination of FACSorting-based phenotype screening and subse-
quent genotyping of a polyclonal edited cell pool should qualify for the identification
of unknown enhancer elements. CRISPR/Cas9 genome editing by a single sgRNA re-
sults in a variety of genomic alterations leading to a polyclonal mutated cell population.
Those editing events that destroy the integrity of a functionally important enhancer
element will accumulate in low expressing fraction during FACSorting. In case the en-
hancer element has not been determined before, one can thus tile a potential enhancer
region via sgRNAs in an arrayed fashion and analyze for every sgRNA position-wise
enrichment of genome editing to retrieve functionally important enhancer motives with
resolution down to single basepairs (bp).
To survey this idea in a proof of principle approach, we developed positional mutation
analysis, comparing genome editing in CD73high and CD73low sorted cells position-wise
after targeting by the individual sgRNAs across the respective amplicons sequenced.
Figure 6.23 shows the results for sequences from 20 bp ahead to 20 bp past the
CRISPR/Cas9 cutting sites. Affirmative, we found highest editing frequencies at or
nearby the CRISPR/Cas9 cutting sites, 3 bps upstream of the protospacer adjacent
motif (PAM). We did not see any differences in position-wise deletion frequency for
CD73high and CD73low sorted cells targeted by the ctrl site sgRNA thus excluding arti-
facts from FACSorting procedure to influence the analysis.
Impressively, in line with our preceding analyses, we detected an increase of positional
mutation frequency specifically at the canonical binding motif TGACTCA of the AP1
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#5 site in CD73low versus CD73high FACSorted cells. In addition, we observed a com-
pensatory editing enrichment in CD73high FACSorted cells nearby the CRISPR/Cas9
cutting site but distal of the AP1 #5 site consensus binding motif. To this extent we
observed both of the effects only after targeting the AP1 #5 site but not for any other
candidate AP1 sites throughout NT5E.
In summary, we were able to unbiasedly retrieve the canonical AP1 binding motif
TGACTCA of the AP1 #5 site as a sequence motif that is required for the induc-
tion of CD73 by JUN in melanoma and thereby, validate our approach for functional
enhancer screening to uncover novel regulatory elements.
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Figure 6.23: Proof of principle positional mutation analysis identifies the canonical AP1 #5 site
motif for CD73 regulation by JUN Positional mutation analysis in MaMel.79blateJUN-citrineDOX,
CRISPR/Cas9 targeted at indicated sites, treated by 25 ng/ml DOX for 5 days, FACS sorted on 10%
highest (green lines) and 10% lowest (purple lines) CD73 expressing cells and fractions deep sequenced.
Positional mutation frequency (PMF) is normalized (norm.) to area under curve as divided by the sum
of all mutation frequencies. Data show means of n=3 with error bars indicating SD.
6.4.4 CD73 baseline expression depends on JUN binding to
the first intronic AP1 #5 site in NT5E
Having found that one defined AP1 site in NT5E significantly accounts for CD73 in-
duction by JUN, we next questioned whether CD73 baseline expression in melanoma
is subjected to similar regulation. Using our CRISPR/Cas9-based genome engineering
approach, we targeted the AP1 #5 site, the AP1 #2a site and the ctrl site in the
CD73 positive melanoma cell lines SK.Mel28, MaMel.65, MaMel.54a and MaMel.85
and continued by FACSorting and deep sequencing as described above. In this reduced
set of targeting sgRNAs we selected the AP1 #2a site as an AP1 site targeting control
sgRNA, in order to evaluate the effects of AP1 #5 site editing for baseline CD73 ex-
pression. sgRNA #2a had shown most similar editing freqeuencies compared to sgRNA
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#5 and both sgRNAs cut one bp apart from the respective AP1 canonical binding
motives.
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Figure 6.24: The AP1 #5 site is relevant for CD73 expression in SK.Mel28, MaMel.85,
MaMel.54a and MaMel.65. (A): SK.Mel28, (B): MaMel.85, (C): MaMel.54a and (D): MaMel.65
CRISPR/Cas9 targeted at AP1 #2a - , AP1 #5 - and ctrl site. Panels left: Relative mutagenesis
frequency at the respective AP1 sites for AP1 site targeting and at target site for ctrl site targeting
depicted in CD73low sorted cells (purple bars) and CD73high sorted cells (green bars) as normalized
to editing frequencies in total cell population is shown in bar charts as mean of n=3 with error bars
indicating SD. Significance tested by two-sided unpaired Student’s T-Test. *, P<0.05; ***, P<0.001.
Panels right: Pie charts illustrating genome editing frequencies as mean n=3 at the target sites and
for conditions as specified above.
Figure 6.24 illustrates AP1 site editing for sgRNAs #2a and #5 and target site edit-
ing for ctrl sgRNA in pie charts from 3 independent experiments for the total cell
populations as well as for the fractions sorted. Bar charts depict respective AP1 site
and ctrl site mutagenesis frequencies following normalization on the total cell pop-
ulation editing efficiency (Figure 6.24). Surprisingly, mutagenesis efficiencies highly
varied for the individual cell lines and sgRNAs. Reduced mutagenesis frequency in
MaMel.54a and MaMel.85 might be explained by limited transfectability of both cell
lines (Figure 6.24, B and C). We were highly intrigued that even though observing
such variation and limitation in editing efficiency, we consistently see a predominant
and significant enrichment of AP1 site editing in CD73low sorted cells when disrupting
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the AP1 #5 site in all cell lines analyzed and independent from CRISPR/Cas9 editing
activity.
In accordance with previous observations, the AP1 #5 site was the only relevant target
site that consistently impacted on CD73 expression. In SK.Mel28 we detected a 20
fold enrichment of AP1 #5 site editing in the CD73low sorted compared to CD73high
sorted fraction (Figure 6.24, A). MaMel.85 that exhibited the most limited mutagenesis
frequency of only 1.1% in sgRNA #5 targeted cells, still held an 18 fold enrichment of
editing at the AP1 #5 site of CD73low sorted cells (Figure 6.24, A). Similarly, MaMel.54a
and MaMel.65 showed a 18 fold and 5.5 fold enrichment for sgRNA #5 targeted CD73low
sorted cells, respectively. Destruction of the ctrl site did not majorly change CD73
expression in the cell lines, some minor enrichment was observed for MaMel.85 and
MaMel.65 (Figure 6.24, B and D). Likewise, editing by the sgRNA # 2a did not lead to
an enrichment of AP1 #2a disruption in CD73low sorted cells in a dimension that was
perceivable from AP1 #5 site editing. Some minor enrichment was observable again
for MaMel.85 and MaMel.65 CD73low sorted cells, with a 1.5 fold and 1.4 fold increase,
respectively.
We next recapitulated positional mutation analysis again in this context as illustrated in
Figure 6.25. Position-wise distribution of genome editing for a 40 bp sequence surround-
ing the CRISPR/Cas9 target sites of sgRNAs #2a, #5 and ctrl has been calculated for
CD73low and high sorted SK.Mel28, MaMel.85, MaMel.54a and MaMel.65. We affirma-
tively observed enrichment of editing in the CD73low sorted fraction of cells at specifically
the AP1 #5 canonical binding motif TGACTCA for SK.Mel28 and MaMel.54a (Figure
6.25, A and C). In line, those cell lines showed most prominent enrichment of AP1 #5
targeting in the CD73low sorted fraction in previous analyses. Enrichment of editing in
an AP1 binding motif other than the AP1 #5 canonical binding site was not found in
CD73 depleted cells in any cell line investigated.
As a side note, in this instance genome editing efficiency is impacting on the potency
of positional mutation analysis which can be readily observed for MaMel.85 targeted
by sgRNA #5 (Figure 6.25, B) and should be considered and sgRNAs optimized for
future analysis, in especially when designing screens for the identification of unknown
enhancer elements.
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Figure 6.25: Positional mutation analysis confirms the relevance of AP1 #5 for baseline CD73
expression Positional mutation analysis for (A): SK.Mel28, (B): MaMel.85, (C): MaMel.54a and
(D): MaMel.65, CRISPR/Cas9 targeted at the AP1 #2a - , AP1 #5 - and ctrl site. Green and purple
lines show FACSorted fractions of 10% highest and 10% lowest CD73 expressing cells, respectively,
that are deep sequenced for genome editing and analyzed on positional mutation frequency (PMF).
PMF is normalized (norm.) to area under curve as divided by the sum of all mutation frequencies.
Data show means of n=3 with error bars indicating SD.
6.4.5 Disruption of the first intronic AP1 #5 site in NT5E
leads to long term depletion of CD73
In a final experimental setting, we aimed to check whether CD73low expressing subpop-
ulations that arise in CD73 positive melanoma cell lines after targeting the AP1 #5
site, exhibit persistent downregulation of CD73 surface expression. For that referred
to SK.Mel28 as a representative cell line model. We FACSorted CD73high and CD73low
subpopulations of cells targeted by CRISPR/Cas9 at the AP1 #2a, AP1 #5, and ctrl
site and tracked CD73 surface expression for up to one week (day 0, day 3, and day 7 af-
ter FACSorting) as illustrated in Figure 6.26, A. As expected, we found stable depletion
of CD73 surface expression only for CD73low sorted cells in the AP1 #5 sgRNA target-
ing condition (Figure 6.26, B). CD73low sorted cell populations targeted by the sgRNA
#2a and ctrl sgRNA restore baseline CD73 expression levels already after 3 days. Of
note, CD73high sorted cells of the AP1 #5 site targeting condition also restored parental
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CD73 surface and total protein expression levels at day 7 post sorting. This finding was
corroborated by mRNA and total protein expression analyses (Figure 6.26, C). At 24h
post FACSorting, we found strong depletion of NT5E mRNA only when sorting on the
CD73low fraction of sgRNA #5 transfected cells which persisted for at least one week
after FACSorting. Interestingly, we already noticed some decrease in NT5E mRNA in
the unsorted total cell population of AP1 #5 site CRISPR/Cas9 targeted cells (Figure
6.26, B). On a total protein level, the effect of FACSorting on CD73low and CD73high
expressing fractions was well-detectable by a decrease and an increase of total protein
after 24h. Only cells targeted at the AP1 #5 site kept the differential expression after
7 days.
In summary, we identify a first intronic enhancer within NT5E that critically regulates
CD73 baseline expression via JUN binding to a canonical AP1 site motif, here named
AP1 #5 site. JUN promotes upregulation of CD73 in CD73low expressing melanoma cell
lines via this JUN/ AP1 signaling axis and is also involved in CD73 baseline expression
as demonstrated in various melanoma cell lines.
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Figure 6.26: SK.Mel28 show long term depletion of CD73 when enriching on AP1 #5 site
disruption by FACSorting. (A): Schematic overview on the experiemental procedure for long term
monitoring of CD73 post FACSorting in AP1/ Ctrl site CRISPR/Cas9 targeted SK.Mel28. (B): CD73
FACS histograms in SK.Mel.28 CRISPR/Cas9 targeted at AP1/ Ctrl sites as indicated and FACSorted
on 10% lowest and 10% highest CD73 expressing cells in re-FACS at day 0, day 3 and day 7 post sorting.
CD73low and CD73high sorted cells are depicted in purple and green in the follow-ups, respectively.
(C): Same as (B) but showing qPCR analysis at top and immunoblot analysis at bottom at 24 h post
sort (left) and at day 7 post sort (right). Relative NT5E expression as normalized to UBC is shown
in mean values from 3 independent experiments with error bars indicating SD. One-way ANOVA and
multiple comparison testing within sorted fractions corrected according to Bonferroni. *, P<0.05; ***,
P<0.001; n.s.=none significant.
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Phenotypic plasticity of cancer cells has evolved as a novel hallmark of cancer [79].
It is a major cause for melanoma cell aggressiveness and difficulty to sustainably fight
melanoma [110]. So far, models of melanoma phenotype switching are based on two
alternative cell states, defined by the presence or absence of MITF [34]. In order
to increase the understanding and provide further knowledge for future therapeutical
targeting of melanoma cell plasticity, we have investigated additional transitional cell
states and novel plasticity markers in the present study. We found a nascent invasive
cell state, which can be described by expression of the 5’ectonucleotidase CD73 in the
MITFhigh fraction of melanoma cells, and which exhibits an early inflammatory, early
invasive gene expression signature. Intriguingly, CD73 expression was cooperatively
induced by mitogenic and inflammatory signaling and depended on the MAPK signal-
ing cascade. We found the transcription factor JUN being as a main transcriptional
regulator, activating CD73 expression via an intronic JUN/ AP1 binding site. CD73
constitutes an upcoming target in checkpoint immune blockade of melanoma [7], hence
knowledge about CD73 regulation in melanoma phenotype switching provides essen-
tial insights into the reciprocal interactions of therapeutic interventions and melanoma
plasticity.
7.1 The trajectory of melanoma cell state
transitions
Melanoma phenotype switching has been established as a binary decision between a
stem cell like invasive and a differentiated proliferative phenotype [34, 107]. Mechanis-
tic analyses on melanoma phenotype switching focussed on comparing transcriptional
profiles and epigenetic regulations between those two cell states, and concepts were
adapted from the well-defined transitions between epithelial and mesenchymal cells,
EMT and MET. However, the comparison of phenotypes of maximal dissimilarity ham-
pers a decoding of the process of interconversion. Here, we expand the known two
alternative melanoma cell states by the identification of an early intermediate pheno-
type, and thereby allow novel insights into the mechanisms of cell state interconversions.
We term it a nascent invasive phenotype, as it can be characterized by a nascent in-
vasive and nascent inflammatory transcriptional signature and can be identified by the
co-expression of CD73 along with MITF (Figure 6.1, E-H).
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The identification of an intermediate cell state is in line with reports on partial or
incomplete EMT of epithelial cells, that evolve by progressive loss of epithelial features
and cooperative gain of mesenchymal traits, resulting in an intermediate transition
phenotype, sharing characteristics of both traits [170]. Stable and metastable partial
EMT phenotypes play an important role during embryonic development, fibrosis, wound
healing, and, most interestingly, have been highlighted for carcinoma progression [170].
As an example, in wound healing keratinocytes undergo partial EMT gaining migratory
capacity while retaining epithelial characteristics, such as cell-cell adhesion, and migrate
in clusters along the wound edges in order to close the wound [274]. Importantly,
partial EMT and collective cell migration is also frequently observed during metastatic
dissemination of carcinoma cells [214, 197, 205, 279, 237]. Additionally, the co-existence
of epithelial and mesenchymal traits was associated with increased aggressiveness and
poor outcome in breast cancer [209].
Already 20 years ago, a negative prognosis has been described for human melanoma,
co-expressing epithelial kreatin and mesenchymal vimentin [100]. Moreover, partial
EMT-like phenotypes and collective cell migration are well accepted features of neu-
ral crest cells during the early developmental process of delamination and migration
to distant sites [244]. Disseminating melanoma cells with a bi-phenotypic nature have
been described during the process of perivascular mimicry. For example, strongly pig-
mented melanoma cells have been reported to migrate along perivascular routes in
response to UV-induced neutrophilic inflammation in a melanoma mouse model [13].
Other studies analyzing perivascular mimicry showed the presence of melanosomes, a
feature of the proliferative phenotype, to coincide with vasculogenic networks, which
is marking invasive melanoma cells [152, 101]. Such data are indicative for a role of
an intermediate melanoma cell state during metastasis formation. In line, CD73 ex-
pression in melanoma, which our data suggest as a maker for nascent invasiveness,
has been associated with metastasis formation in several melanoma mouse models
[275, 235, 268].
The development of therapy resistance constitutes an additional aspect that a par-
tial EMT phenotype has been shown to contribute to. In their study of targeted
drug resistance in lung cancer, Sharma et al. observed stochastic and, importantly,
reversible occurrence of drug-resistant precursors at low frequency within PC9 cells,
which persisted therapy and gave rise to a sub-fraction of expanding fully drug-resistant
progeny [223]. Intriguingly, the authors observe global transcriptional differences be-
tween all three subpopulations: The parental culture, the drug-persistent progenitors,
and the drug-resistant cell population, indicating nascent phenotype switching in the
early drug-persistent cells. Interestingly, full phenotype switching and expansion of resis-
tant cells was observed to descent from only a fraction of drug-persistent progenitors.
The establishment of full drug resistance seems to depend on both the susceptibil-
ity of the drug-persistent cancer cell to progress and on the prolonged exposure to
therapeutic stress stimulation. On a mechanistic level, Sharma and colleagues identi-
fied epigenetic remodeling during phenotype switching, which depends on the histone
demethylase JARID1a and begins in drug-persistent progenitor cells. Complementary,
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we showed that expression of the nascent invasive cell state marker CD73 required global
epigenetic remodeling in addition to inflammatory mitogenic stress stimulation in our
panel of melanoma cell lines (Figure 6.5, A and Figure 6.7), indicating that chromatin
modifications are an early event in the process of melanoma phenotype switching as
well.
Based on the broad evidence for a partial EMT phenotype and its role in carcinoma, sim-
ilar concepts presumably apply for cell state interconversions in melanoma. It is unclear
why an intermediate phenotype in melanoma has not been identified earlier by the nu-
merous previously published large scale transcriptome analyses.
The predominance of metastable interstates in a cell type with an intrinsic low threshold
for phenotype switching, such as neural crest-origin melanoma cells, might provide a
possible explanation. The highly plastic nature of melanoma cells has been demon-
strated by metastatic melanoma cells that were transplanted and reprogrammed within
the developing chicken embryo to reconstitute a neural crest phenotype migrating along
environmental gradients to finally contribute to a plethora of neural crest derived lin-
eages [135]. In support, our data show that inflammatory and invasive gene expression
signatures are not increasing linearly, but exponentially upon progressive melanoma cell
dedifferentiation. Thus we see only moderate induction of inflammatory and invasive
signature genes in the nascent invasive phenotype (Figure 6.1), which can still exhibit
a priming effect on further melanoma cell dedifferentiation upon inflammatory stimu-
lation. Indeed, we have shown that nascent invasive melanoma cells are more prone
to inflammation-induced dedifferentiation and show a stronger inflammatory response
than proliferative melanoma cells when treated with TNFα (Figure 6.3, B). This is also
strongly reminiscent of our previous findings on varying penetrance of TNFα-mediated
induction of JUN and invasive phenotype switching, resulting in the classification of poor
switching and strong switching melanoma cell lines [201].
Another theory relates to the aspect that cell state transitions may not only follow one
route along a sequential transition process but may exist in many facets with multiple,
and even co-existing intermediate states. In our data such a hypothesis is supported
by the finding that individual genes of the invasive and inflammatory gene expression
signature highly vary across different cell lines belonging to the same phenotype (Figure
6.1, B). Confirmatively, CD73 is steadily expressed upon a nascent invasive phenotype
but with high individual variance (Figure 6.1, E).
Finally, even though the concept of melanoma cell plasticity is based on EMT, and
even though EMT-like processes are common during neural crest development, one
has to keep in mind that EMT of epithelial origin is highly complex and shaped by
a plethora of tissue specific extracellular signals converging on multiple tissue specific
EMT TFs, even exerting tissue specific roles. [169]. As an example, whereas SNAIL
promotes EMT and metastasis in breast cancer [252], such an effect has not been ob-
served for pancreatic cancer [283], but here ZEB1 has been described as a main factor
for EMT induction [133]. In melanoma, members of the ZEB family even hold an-
tagonistic functions, as ZEB1 and ZEB2 have been involved in tumor promotion and
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reduction of aggressiveness, respectively [53, 33]. As a consequence, single mesenchy-
mal markers are often insufficient to characterize EMT processes in cancer and the
adaptation of EMT-like plasticity in melanoma to epithelial EMT has to be done with
caution.
Currently, the establishment of scRNA-seq technologies are advancing the field of can-
cer plasticity, allowing novel insights into the variability of single cell phenotypes within
a tumor mass. Initial exciting publications are supporting a concept of multi-stage
melanoma cell plasticity. At the end of last year, Ennen and colleagues published
scRNA-seq data of 472 cells from 5 primary melanomas. In line with the nascent in-
vasive phenotype emerging from our bioinformatic analyses, the authors found some
MITFhigh melanoma cells co-expressing invasive signature genes. Interestingly, when
they validated their results for a selection of candidate co-expressed markers by immuo-
histochemical stainings they found both intertumoral, as well as intratumoral differences
in co-expression of proliferative and invasive cell state markers [66]. In another recent
work, Shaffer and co-workers showed an involvement of an intermediate, slow-cycling
melanoma cell state in the development of non-genetic resistance against targeted ther-
apy [221]: Vemurafenib pre-resistant cells majorly differed from the plenum of sensi-
tive melanoma cells with respect to their transcriptome and expression of resistance
markers. In a subsequent phase of expansion followed by drug-treatment, resistant
melanoma cells underwent additional massive epigenetic rewiring. Interestingly, the
final switch for therapy resistance is driven by an activation of JUN/ AP1 signaling
fitting to our observations of inflammatory stress signaling via JUN to drive invasive
phenotype switching in melanoma. However, in contrast to our model of an early inflam-
matory and invasive gene expression signature marking the nascent invasive phenotype
in a fraction of differentiated cell lines, the authors found cellular reprogramming to
be initiated by down-regulation of SOX10 and associated differentiation programs. In
a further study, an interesting R-based tool for cell state identification from scRNA-
seq data was published lately [3], emphasizing the rising interest in using single cell
transcriptome data for elucidating cellular plasticity. The presented algorithm identifies
gene regulatory networks based on integration of cis-regulatory networks in so-called
regulons. Cell types or phenotypes are determined by shared binary regulon activity,
creating regulatory subnetworks. In line with previous literature, Aibar et al. show data
on 1200 single cells from 14 melanoma lesions, which cluster according to predefined
MITFhigh proliferative and MITFlow invasive cell states. Shared MITFhigh regulatory
subnetworks with MITF/STAT/IRF constitute central TFs on the one hand and in-
vasive regulatory subnetworks harboring high expression of WNT5A/LOXL2/ZEB1 on
the other hand. Affirmatively, MITFhigh regulatory subnetwork activity is completely
absent in the invasive phenotype (Figure 7.1). Intriguingly, even though the authors
are not highlighting it in their paper, their data show activity of invasive regulatory
subnetworks in a fraction of MITFhigh cells, which also form a separate population in
t-SNE analysis (Figure 7.1), and fits our description of an MITFhigh nascent invasive
phenotype.
A very recent publication, which similar to ours, investigated further transition cell
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Figure 7.1: Nascent invasive phenotype switching becomes apparent in single cell RNAseq
data by Aibar et al. for coinciding MITF and invasive regulon activity]. (A): T-SNE plot
based on the expression matrices, colored by tumor of origin. (B and C): T-SNE plots based on the
binary regulon activity, colored by gene regulatory network activity. (D): Single-cell regulatory network
clustering map. Data adopted from Aibar et al., Figure 3 [3].
stages by means of bioinformatic analyses of melanoma expression datasets, suggests
a 4 stage phenotype switching model, which is imitating stages of melanocyte devel-
opment in a reverse route of dedifferentiation, starting from a melanocytic cell state,
followed by a transitory cell state and a neural crest-like cell state, resulting in a fi-
nal undifferentiated cell state [255]. Strikingly, Tsoi et al. confirmed the importance
of mitogenic signaling along with inflammatory signaling on this route of melanoma
cell dedifferentiation, which we pointed out in our study as well. Furthermore, the
authors provide an online-tool, allowing visualization of genes of interest within PCA
analysis data to annotated melanoma cell phenotypes. As shown in Figure 7.2, visu-
alization of CD73 in sub-phenotypes clearly shows that CD73 expression distinctively
overlaps with the proposed transitory cell state, and is increased overall in the neural
crest-like and the dedifferentiated phenotype. In contrast, classical invasive markers
AXL and WNT5a are negative in this early dedifferentiated cell population which is
fitting to the analysis presented in Figure 6.2 of this study and hinting on an overlap
of the nascent invasive phenotype of our work and the transitory phenotype of Tsoi et
al.
In contrast to the commonly preferred trajectory of cell state transitions with prolifera-
tive melanoma cells undergoing dedifferentiation into a final neural-crest stem cell-like
invasive phenotype, Tsoi et al. describe a trajectory of melanoma phenotype switching
that passes an intermediate neural crest precursor fate and results in a dedifferentiated
omnipotent stem cell-like phenotype with more mesenchymal, inflammatory character-
istics. In support of this concept, we observed that the sub-population of most dediffer-
entiated melanoma cells are indeed negative for the neural-crest marker NGFR (Figure
6.2, A). Moreover, based on the fact that CD73 represents a well-established marker
for mesenchymal stem cells [32], our observation of elevated CD73 expression starting
in nascent invasive melanoma cells and increasing to robust CD73 expression in a fully
dedifferentiated phenotype reinforces the importance of mesenchymal cell traits in full
dedifferentiated melanoma cells. In addition to that, expression of CD73 on melanoma
cell lines has been described to correlate with expression of mesenchymal markers be-
fore, yet the molecular mechanisms remained unclear [207]. Also, during embryonic
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Figure 7.2: Nascent invasive phenotype switching in comparison to the plasticity model pro-
posed by Tsoi et al. (A): Data adopted from Tsoi et al., Figure 1C [255]. Panel of human
melanoma cell lines (n=53) shown as PCA, assigned to 4 subtypes by consensus hierarchical clus-
tering. Stages of melanocyte differentiation are specified by comparative analysis to in vitro in-
duction of embryonic stem cells into melanocytes. (B): Web tool, provided by Tsoi et al. on
http://systems.crump.ucla.edu/dediff/ for visualization of gene of interest superimposed on the anal-
ysis as presented in (A), showing expression of NT5E. (C): Same as (B), but illustrating WNT5A,
AXL and NGFR expression from left to right.
stem cell reprogramming towards a neural crest lineage, the occurrence of mesenchy-
mal features and subpopulations have been repetitively observed [49, 138], hinting on a
close cross-talk of those two stem cell types during reprogramming events. Summariz-
ing currently available data, one can postulate, that melanoma stem cells, which have
been characterized as a rare fraction of cancer cells expressing neural crest markers, are
forming a metastable intermediate cell state, and that therapeutic intervention, stress
and inflammation may lead to a shift of balances, promoting switching to a more sta-
ble, fully dedifferentiated cell type. Hence, intermediate melanoma cell states, such as
above described pre-resistant melanoma cells, might endow melanoma with the capacity
of priming for environmental changes, such as development of therapy resistance. In
support of this hypothesis, a recent publication on renal cell carcinoma suggested CD73
as a marker for CSCs with increased tumorigenicity and resistance to therapeutic stress
[232]. It will be interesting to investigate whether pre-resistant melanoma cells are in-
deed positive for CD73, implying nascent invasive phenotype switching as a resistance
mechanism.
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7.2 CD73, a melanoma plasticity marker with an
important role in tumor immunosuppression
So far, melanoma plasticity markers were identified on the basis of mutual exclusive
expression in the proliferative or the invasive cell state. In the present study we in-
vestigated intermediate cell states and retrieved a previously unknown nascent invasive
phenotype, which can be identified by the co-locatisation of MITF, the bona fide pro-
liferative cell state marker, and CD73, a novel marker of invasive and nascent invasive
melanoma cells.
Intriguingly, CD73 constitutes a novel target for cancer immunotherapy. Physiologically,
CD73 expression can be found on a variety of immune cell subtypes, like T cells, B cells
and myeloid cells, but also on mesenchymal stem cells, as well as bone marrow stro-
mal cells, endothelial and epithelial cells in many diverse tissues [44]. The function of
CD73 has mostly been attributed to its extracellular enzymatic activity in the cascade
of adenosine triphosphate (ATP) breakdown, hydrolyzing adenosine monophosphate
(AMP) into adenosine, which is modulating various cellular responses via adenosine
receptors. Among other functions, CD73 can regulate vascular integrity and ischemic
re-perfusion [284], but it also controls immune responses in a negative feedback loop in
order to limit excessive inflammation [44, 177], which has emerged as a key mechanism
of tumor immunosupression [9]. An effective anti-tumor immune response is accompa-
nied by destruction of tumor cells, leading to release of pro-inflammatory ATP. Here, the
presence of CD73 in the tumor microenvironment acts as a molecular switch, that turns
an ATP-rich anti-tumor immune response into an adenosine-rich broad immunosup-
pression [9]. Hematopoietic and non-hematopoietic host cells as well as tumor cells can
express CD73 to provide sources of adenosine, which interferes locally and suppresses
many types of immune cells: Immunosuppressive adenosine receptors are up-regulated
upon T cell activation [281] and adenosine ligation impairs both T helper cell and
cytotoxic T cell functions [281]. Furthermore, adenosine inhibits NK cell activation
[193]. It impairs phagocytosis and at the same time promotes alternative macrophage
polarization [48], as well as expansion of myeloid derived suppressor cells (MDSCs)
[206]. Additionally, adenosine stimulation causes abnormal dendritic cell maturation
into a pro-tumorigeneic, pro-angiogenic phenotype, characterized by secretion of vas-
cular endothelial growth factor (VEGF) [172] and supports expansion of regulatory T
cells [178]. Another interesting aspect, which has only been appreciated recently, is the
impact of chronic adenosine signaling to render tumor endothelial cells anergic, which
means that the tumor vasculature is not responsive to stimuli up-regulating adhesion
molecules and allowing extravasation of lymphocytes, but at the same time myeloid
cell infiltration is still supported [243, 268]. As a consequence, adenosine signaling not
only impairs immune cell function within the tumor microenvironment but also prevents
entrance of anti-tumoral immune cells. Lastly, adenosine signaling in breast cancer cell
line models was found to also directly promote cancer cell migration and metastasis
formation [162]. The broad spectrum of CD73 expression and adenosinergic signaling
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in mediating immunosuppression and promoting tumor progression has put pharmaco-
logical inhibition of CD73 and adenosine receptors into the focus to develop novel ways
of immune checkpoint blockade [7, 11, 10]. Numerous pre-clinical studies have demon-
strated A2A adenosine receptor inhibition to limit tumor growth [282, 8]. Based on the
success of pre-clinical A2A adenosine receptor studies, phase I clinical trials involving
antibody mediated blockade of CD73 (NCT02503774) and small molecule interference
with A2A adenosine receptor (NCT02503774 and NCT02655822) in solid cancer are
currently ongoing [98].
Previous studies have revealed mechanisms of how full dedifferentiation of melanoma
cells in response to inflammation and therapeutical stress promotes resistance. For
example, the attack of anti-tumor T cells can be bypassed by the down-regulation of
melanocytic target antigens [136] and a stem cell-like dedifferentiated transcriptional
program allows uncoupling of melanoma cell survival and proliferation signaling from
oncogene driver activity [129, 167]. Our work provides novel insights into melanoma cell
phenotype switching and links it to the acquisition of an immunosuppressive phenotype
by expression of CD73. According to our model, full melanoma cell dedifferentiation
might not coercively be required for the establishment of an immunosuppressive tu-
mor microenvironment. On the contrary, CD73 expression is present in differentiated
melanoma cells upon nascent increase of invasive and inflammatory signature gene ex-
pression. For example, inflammatory macrophages, which form a first line of immune
defense, provide a source of TNFα for the induction of CD73 in our model system
(Figure 6.9). Based on this observation, we assume that melanoma up-regulate CD73
in vivo when exposed to acute or chronic stress conditions, which is the case dur-
ing uncontrolled tumor growth, leading to hypoxia and starvation stress, as well as
during therapeutical interventions accompanied by tissue destruction and inflammation
[108, 136, 70]. Importantly, only transient activity of AP1/ JUN signaling is required
for the induction of CD73 (Figure 6.19), and we postulate that expression of CD73
on tumor cells indicates previous exposure to cellular stress and memorizes preceding
inflammation. Following this assumption, a switch to a nascent invasive phenotype is
primed to counteract further inflammatory triggers by remodeling the tumor microen-
vironment via the adenosinergic axis, which could be a maladaptive modus exploiting
the physiological role of CD73 in shutting down excess inflammation. Hence, resistance
to cancer immunotherapy might rather constitute an early event during melanoma phe-
notype switching. Of note, a cancer stem cell-like phenotype associated with evasion
from immune recognition has recently been attributed to tissue resident stem cells [1].
Agudo et al. showed that quiescent tissue stem cells of various origin can bypass cyto-
toxic T cell recognition and destruction by down-regulation of various components of
the antigen presentation machinery.
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7.3 Survey on the functional relevance of CD73
expression for EMT and inflammatory
phenotype switching
Common invasive cell state markers, among them AXL and WNT5a, are not only mark-
ing, but also participating in progressive dedifferentiation [57, 218]. Having observed
CD73 expression to be up-regulated upon nascent invasive phenotype switching raises
the question, whether CD73 is functionally involved in that process. Indeed, a recent
study showed that CD73 plays a role for EMT switching of ovarian carcinoma cells [148].
Lupia and colleagues showed, that in ovarian carcinoma spheroid cultures shRNA me-
diated knock-down of CD73 or CD73 inhibitor treatment impaired the formation of
tumorigenic spheres, led to a down-regulation of key EMT genes, and, most impor-
tantly, hampered the acquisition of a stem cell-like phenotype. Inversely, adenosine
stimulation further up-regulated those stemness associated TFs. Similarly, in neuroen-
docrine pancreatic tumors, CD73 was reported to be over-expressed in the fraction of
CSCs and to be relevant for sphere formation as well as motility of cancer cells [120].
Endogenous plastic somatic cells constitute another interesting CD73 expressing cell
population endowed with a functional role of CD73 for cell plasticity: Pan et al. have
analyzed this rare and highly plastic population of cells, which is exhibiting omnipotent
stem cell capabilities and can be found at very low frequency in adult tissue [182].
Interestingly, the stem cell phenotype was dependent on expression of 4 factors, among
them is CD73. CD73 was found to be relevant for adenosine generation and signaling
via the A2B adenosine receptor inducing expression of stem cell TFs. The fact that
rare adult neural crest stem cells in the skin, adipose tissue and bone marrow express
CD73 [46] may hint to a similar role. It remains to be determined whether the same
function is involved in melanoma cell plasticity. The fact that melanoma cell lines of
the nascent invasive phenotype show stable expression of CD73 along with MITF differ-
entiation signature, but otherwise only nascent dedifferentiation marks, suggests that
further factors are required for initiation of full dedifferentiation. From another perspec-
tive, priming of dedifferentiation and inflammation in melanoma cells upon expression
of CD73 in the nascent invasive cell state raises the question whether CD73 is causative
for this effect. Preliminary transcriptome data of CD73 CRISPR/Cas9 KO and control
melanoma cell lines however did not indicate changes of invasive phenotype-associated
gene expression (data not shown). Further analyses will be needed in order to answer
this question.
In recent years, it has become clear that inflammation and chronic regenerative stress
signaling are key triggers of melanoma phenotype switching, converging on AP1/ JUN
as a central axis promoting dedifferentiation of melanoma cells [201]. A study by
Schwitalla and colleagues revealed a direct role of TNFα mediated NFκB activation in
intestinal epithelial cells for directed dedifferentiation and tumorigenicity [216]. Wound
healing has been assigned the mechanistic counterpart for processes occurring during
chronic inflammation in cancer. Indeed, inflammation-induced dedifferentiation repre-
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sents a key mechanism for re-establishing tissue integrity after injury and similar growth
factors, which we have highlighted for for melanoma cell dedifferentiation and induc-
tion of melanoma cell phenotype switching in the present study are involved [15]. For
example, TNFα is an important mediator of keratinocyte EMT during the process of
wound healing [274]. Keratinocytes of c-Met deficient mice were not able to close
shin wounds [41]. Furthermore, key signaling events during keratinocyte EMT and
wound healing have been identified to include JUN/ AP1 signaling and the MAPK
cascade [196]. Ample literature exist on the influence of metabolic, oxidative and hy-
poxic stress, as well as inflammation on the induction of EMT in cancer [147, 239]. A
plethora of cytokines with EMT inducing properties in carcinoma have been discovered,
such as TNFα, TGFβ, IL1β, IL6, IL8, CCL-2/-5/-18/-20/-21, IL23 and IL17 [239].
The modulation of cancer cell states by microenvironmental inflammatory triggers is
not a one way route, but rather shaped by reciprocal interactions of cancer cells and
cells of the tumor microenvironment. In melanoma we showed that phenotype switching
towards an invasive cell state is associated with a progressive increase in inflammatory
capacity, and inflammatory melanoma cells promote the conversion of an immune re-
sponse within the tumor towards chronic pro-tumorigeneic inflammation. Furthermore,
the melanoma inflammatory secretome was revealed to foster an invasive cell state
in an autocrine manner [256, 272, 231]. In addition, also for CSCs of other cancer
entities, the auto-regulation of stemness has been attributed to the inflammatory secre-
tome of tumor cells [250, 87]. With respect to this notion, the induction of CD73 on
melanoma cells upon inflammation-induced dedifferentiation might exploit the function
of negative feedback regulation towards a pro-tumorigenic regenerative inflammatory
environment and thereby might further support invasive phenotype switching. Direct
impact of CD73 expression on melanoma cells and adenosine signaling on shaping the
pro-tumorigenic inflammatory capacity of melanoma cells has to be investigated in fu-
ture studies.
7.4 Melanoma CD73 expression links to primary
and acquired resistance towards cancer
immunotherapy
During tumor growth, nutrient deprivation and hypoxia create an environment of chronic
inflammation and regenerative mitogenic signaling, which is even enforced under therapy
[136, 70, 175, 38]. Hence, the question arises whether melanoma cell CD73 induction
in response to therapy-induced stress and inflammation is causally involved in ther-
apy resistance. Pre-clinical mouse models showed non-redundant immunosuppressive
mechanisms in the tumor microenvironment playing an important role for primary resis-
tance towards immune checkpoint blockade [174]. To this effect, depletion of tumoral
MDSCs or regulatory T cells was shown to improve anti-PD-L1 therapy [102, 261].
Interestingly, gene signatures of chronic inflammation, hypoxia and dedifferentiation
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have been associated with a poor response to PD-1 immune checkpoint blockade [113],
which might hint to the induction of CD73 in this context and, in the following, its
involvement in therapy resistance. Another interesting study reported the recurrence of
MDSCs upon acquired resistance to BRAFi, which could not be overcome by CTLA-4
or PD-1 immune checkpoint blockade [236]. With MDSCs expressing CD73 and being
a major source of adenosine in the tumor microenvironment, this might hint on a role
of CD73-adenosinergic signaling also in this context of resistance to targeted therapy.
Pre-clinical studies in a syngeneic transplanted B16F10 melanoma mouse model have
demonstrated effective combinatorial treatment by either CTLA-4 or PD-L1 immune
checkpoint therapy together with A2A adenosine receptor signaling blockade [163, 114].
PD-1 blockade has been shown to up-regulate A2A adenosine receptors on tumoral CD8
positive T cells. In the presence of CD73 this is limiting effective T cell reactivation,
thereby leading to the suggestion of CD73 as a biomarker for impaired responsiveness
to PD-1 blockage [18, 19].
An additional implication of adenosine signaling in primary therapy resistance is CD73
immunosuppressive pre-conditioning in conjunction with therapy-induced cell death and
obligatory release of excessive ATP. Extracellular ATP is promoting a pro-inflammatory
tumor environment and an anti-tumor immune response. On the other hand, high abun-
dance of enzymes breaking down ATP during an initially effective anti-tumor therapy
could eventually boost tumor immune escape. In line, regulatory T cells expressing
CD39 and CD73 and substantially contributing to purinergic breakdown in the tumor
have been shown to provide their own substate when encountering oxidative stress,
undergoing apoptosis and releasing ATP [151].
Direct evidence for acquired resistance of melanoma against immunotherapy due to
up-regulation of melanoma cell CD73 expression is still pending. In a mouse model of
syngeneic HCMel3 melanoma cell inoculation and PMEL-directed ACT, our lab has pre-
viously shown that melanoma initially undergo remission in response to immunotherapy,
however they relapse later due to inflammation-induced dedifferentiation [136]. In our
recent publication, we examined changes in melanoma phenotypes in this model prior to
therapy, early during therapy and during late escape. Indeed, we observed progressive
induction of CD73, which was strongly and stably induced upon full dedifferentiation,
supporting the in vivo relevance of CD73 induction by inflammatory mitogenic stress
conditions, and furthermore hinting to an involvement in therapy-induced immune es-
cape [195]. In collaboration with Antony Ribas, we have analyzed expression of CD73 in
serial metastatic melanoma biopsies from patients who received an ACT directed against
MART-1 together with DC vaccination (NCT00910650). Affirmatively, one patient’s
metastasis, which lost MART-1 target antigen expression and showed dedifferentiation,
revealed emerging CD73 expression under therapy, resulting in high expression upon
progression and failure of therapy [195]. A very recent case study published by the
group of Antony Ribas on the same patient further substantiated our findings, showing
that therapy escape was mediated by inflammation-induced dedifferentiation and can
be mimicked by TNFα treatment of patient-derived melanoma cell lines [160]. Fu-
ture studies will be required to finally decipher the relevance of CD73 up-regulation for
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acquired resistance against cancer immunotherapy.
7.5 Prognostic implications of CD73 marker
expression on nascent invasive melanoma
CD73 was identified as a negative prognostic marker in several types of cancer: In
triple-negative breast cancer tumoral CD73 expression correlated with poor prognosis
and promoted therapy resistance [144, 29]. In colorectal and ovarian cancer, expres-
sion of CD73 was associated with reduced survival [181, 257]. However, the asso-
ciation of melanoma cell CD73 expression and disease progression seems to be less
clear.
In our work we found that melanoma cell CD73 expression is highly heterogenous, and
regulation of melanoma cell CD73 under anti-PD-1 therapy is highly dynamic, even
though we did not observe down-regulation of CD73 in patients after therapy failure
[195]. The dynamic regulation of CD73 might reflect its expression in a nascent invasive
cell state and discloses plastic responses of melanoma during treatment. Interestingly,
a soluble enzymatic active form of CD73 (sCD73) can be generated by cleavage from
the plasma membrane of predominately lympocytes and tumor cells under pathologic
conditions, making it an interesting potential biomarker for serum diagnostics [4, 130].
Based on this technology, a recent publication provided data in a study cohort of 37
patients suffering from metastatic melanoma, which suggested sCD73 as negative prog-
nostic marker for anti-PD-1 therapy based on decrease of progression free survival from
14.2 to 2.6 months in case sCD73 was detectable in patients’ serum prior to therapy
[166]. Clearly, data are supporting a role of CD73 expression for acquired therapy resis-
tance, and targeting the CD73-adenosinergic axis has high potential for combinatorial
immunotherapies. Still, variable expression of CD73 prior to therapy and dynamic regu-
lation of CD73 under therapy points to a critical assessment of CD73 as a pre-treatment
biomarker for therapy success and suggests that combinatorial immunotherapies involv-
ing A2A adenosine receptor and CD73 blockade should be considered independently
from pre-treatment expression of CD73.
7.6 The relevance of MAPK signaling for CD73
expression on melanoma cells
Another important therapeutically relevant aspect is the MAPK-dependent expression of
CD73 in melanoma cells. In the present study we found that CD73-positive melanoma
cell lines strongly down-regulate CD73 expression upon interference with MEK/ERK
signaling (Figure 6.10). In line, a recent study has provided similar results showing
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decreased NT5E transcript levels in A375 melanoma cells upon inhibition of MAPK
cascade signaling [143].
MAPK dependency of CD73 expression is a favorable point of attack for targeting
melanoma cell CD73 expression, as MAPK hyper-activation is a central oncogenic driver
of melanoma. BRAFi and MEKi are already successfully used to limit melanoma growth
and improve patient outcome [5, 132]. Indeed, in a combined effort together with the
group of Mark Smyth, we were able to show that patients with BRAF mutations show
decreased expression of CD73 in all cases upon BRAFi and in more than half of all cases
upon combinatorial treatment with BRAFi and MEKi [277]. Moreover, re-expression
or increase of CD73 expression post BRAFi correlated with rapid disease progression
[277].
MAPK blockade has various immune activating activities in melanoma [62, 111, 143,
31]. Showing that MAPKi blocks tumoral CD73 expression and thereby limits adeno-
sine generation by tumor cells provides further insights on how targeted therapy may
strengthen anti-tumor immune responses. Combinatorial treatment of CD73 inhibi-
tion and A2A adenosine receptor blockade has shown promising results in preclini-
cal trials superior to mono-therapy [276], and it implies potential benefits for com-
bined MAPK blockade together with A2A adenosine receptor inhibition. According
to our findings, one might assume synergistic anti-cancer immunity from the increase
of tumor immunogenicity by the direct effects of MAPKi, together with dual resolu-
tion of the CD73-adenosinergic immunosuppressive axis by decreasing the source of
adenosine due to MAPK-dependent down-regulation of CD73, while in parallel in-
hibiting adenosine receptor signaling. Intriguingly, our studies indeed provided in-
sights into a significantly improved treatment outcome achieved by MAPKi together
with A2A adenosine receptor blockade in relation to the respective mono-therapies
[277].
Hyper-activation of the MAPK signaling cascade in melanoma is known to have an
important role for melanoma invasive phenotype switching [33]. Given that melanoma
cell CD73 expression upon nascent invasive cell state is driven by MAPK signaling, the
question arises whether positive MAPK driver mutation status correlates with CD73 ex-
pression on melanoma cells. In our collaborative study we only found a non-significant
trend of positive BRAF mutation status beeing associated with high CD73 expression
[277]. Our finding of epigenetic silencing leading to absence of CD73 expression in
BRAF mutant melanoma cell lines (Figure 6.5, A), which can be resolved upon global
demethylation (Figure 6.7), provides a plausible explanation for the missing link be-
tween positive MAPK mutation status and CD73 expression in melanoma. In contrast
to melanoma, a previous publication supports this concept in other tumor types: Neve-
domskaya and coworkers analyzed BRAF and NRAS mutation status as well as expres-
sion of CD73 in the NC-60 cell line panel, revealing and a significant correlation across
all cancer entities tested [168]. Along these lines, rare BRAF-mutant serous ovarian
carcinomas were found to express elevated levels of CD73 in comparison to BRAF-WT
tumors [273].
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7.7 Conclusion
Stress signaling and inflammation guides melanoma phenotype switching in a recipro-
cal interplay of tumor cells and microenvironmental co-actors. This has detrimental
consequences for the treatment of cancer. Efficient treatment schemes have to be
specified to target tumor cells in their environment rather than establishing therapies
that concentrate on interference with tumor cell specific signaling mechanisms. The
failure of MAPK targeted therapies to achieve long term benefits for patients is one
example.
In this work, we provide novel link of melanoma phenotype switching in a regenerative
inflammatory environment to the upregulation of a key immunosuppressive molecular
switch: The 5’ectonucleotidase CD73. Transient mitogenic and inflammatory stimula-
tion converges on JUN/ AP1 central stress signaling nodes to induce nascent invasive
phenotype switching, marked by the expression of CD73. Continous stress signaling
results in full invasive phenotype switching and the expression of classical invasive
markers along with high levels of CD73 (summarized in Figure 7.3). Importantly, the
identification of an intermediate cell state beyond the current classification of oppos-
ing invasive and proliferative cell states will allow a more detailed understanding of
cell state transitions in the future. For epithelial cancer, the importance of transi-
tory, partial EMT cell states for the development of therapy resistance and metastatic
progression is beginning to be understood. Most likely transitory phenotypes play an
even more important role in highly plastic neural crest-derived cancers. Moreover, the
up-regulation of CD73 in that context uncloses insights on how phenotype switching
and tumor immune evasion are orchestrated in an interplay of tumor cell - immune
cell - microenvironment interactions. Finding invasive phenotype switching coupled to
MAPK-dependent regulation of an upcoming target for cancer immunotherapy fosters
approaches of combinatorial therapy targeting the CD73-adenosinergic axis in combi-
nation with immune checkpoint blockade. The fact that sCD73 can be measured by
serum diagnostic in patients even holds potential for staging patients’ responses to
immunotherapies.
Still open questions remaining comprise whether there is a functional relevance of
CD73 for melanoma cell phenotype switching and, more importantly, whether CD73 up-
regulation by inflammation and constitutive stress signaling during therapy contributes
to acquired therapy resistance.
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Figure 7.3: A model of Nascent invasive phenotype switching in melanoma in comparison to the
Waddington’s landscape of partial EMT. (A): Model of a Waddington’s landscape for melanoma
phenotype switching in the style of partial EMT of epithelial cancer. Stable phenotypes reside within
valleys of a certain gene expression signature, interjacent hills represent the threshold that has to be
overcome for phenotype switching, a process that is governed by environmental stress signals. Stable
and metastable interstates are highlighted during the transition process. (B): Schematic representation
on melanoma phenotype switching with implementation of the nascent invasive cell state marked by
the expression of CD73, modified from Reinhardt et al [195].
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Abbreviations
Prefixes
p pico (10−12)
n nano (10−9)
µ micro (10−6)
m milli (10−3)
c centi (10−2)
k kilo (103)
Units
A ampere
Da dalton
g gram
h hour
l liter
m meter
M mol/l
min minute
OD optical density
s second
U unit
v/v volume per volume
w/v weight per volume
°C degree celisius
Chemicals and solutions
APS ammonium persulfate
DPBS Dulbecco’s phosphate-buffered saline
DMEM Dulbecco’s Modified Eagle’s Medium
DMSO dimethyl sulfoxide
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
EtBr ethidium bromide
LB lysogeny broth
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PMA phorbol 12-myristate 13-acetate
SDS sodium dodecyl sulfate
TEMED tetramethylethylenediamine
Proteins, biomolecules and cell types
AMP adenosine monophosphate
APC antigen presenting cell
AP-1 activator protein-1
ATP adenosine triphosphate
BSA bovine serum albumin
Cas9 CRISPR-associated protein 9
C cytosine
CAF cancer-associated fibroblast
CSC cancer stem cell
CTLA-4 cytotoxic T-lymphocyte-associated protein 4
DC dendritic cell
ECM extracellular matrix
EDN3 endothelin-3
ERK extracellular signal?regulated kinase
Escherichia coli e. coli
dNTP desoxynucleoside triphosphate
FAK focal adhesion kinase
FBS fetal bovine serum
FGF fibroblast growth factor
GFP green fluorescence protein
GPCR G protein coupled receptor
HEK human embryonic kidney
HGF hepatocyte growth factor
IFN interferon
IL interleukin
LPS lipopolysaccharide
MAPK mitogen-activated protein kinase
MEK MAPK/ERK kinase
MDSC myeloid derived suppressor cell
MITF microphthalmia-associated transcription factor
mRNA messenger RNA
NF-κB nuclear factor-kappa B
NGFR nerve growth factor receptor
PBMC peripheral blood mononuclear cell
PI3K phosphatidylinositol-3-kinases
PD-1 programmed cell death protein 1
PD-L1 programmed cell death protein 1 ligand 1
RB retinoblastoma protein
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RNA ribonucleic acid
RTK receptor tyrosine kinase
sCD73 soluble CD73
TNF tumor necrosis factor
TGF transforming growth factor
VEGF vascular endothelial growth factor
WNT wingless Int 1
Other Abbreviations
ACT adoptive T cell transfer
AP1 activator protein 1
bHLH basic helix-loop-helix
BS bottom strand
bp base pair
BRAF rapidly accelerated fibrosarcoma protein kinase B
BRAFi BRAF inhibition
CAR chimeric antigen receptor
CD cluster of differentiation
ChIP chromatin immunoprecipitation
ChIPseq chromatin immunoprecipitation sequencing
CPD cyclobutane pyrimidine dimer
CRISPR clustered regularly interspaced short palindromic repeats
DNA deoxyribonucleic acid
DOX doxycycline
ECL enhanced chemoluminescence
EMT epithelial-mesenchymal transition
ERKi ERK inhibition
FACS fluorescence-activated cell sorting
FDR false discovery rate
fwd forward
gDNA genomic DNA
GEO gene expression omnibus
GSEA gene set enrichment analysis
InDel insertion and deletion
KO knockout
MAPK mitogen-activated protein kinases
MAPKi MAPK inhibition
MEKi MEK inhibition
MET mesenchymal-epithelial transition
MFI mean fluorescence intensity
MITF microphthalmia-associated transcription factor
movAVG moving average algorithm
MSigDB Molecular Signature Database
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NES normalized enrichment score
NGS next generation sequencing
NHEJ non-homologous end joining
O/N over night: 16-20 h
ORF open reading frame
PAGE polyacrylamide gelelectrophoresis
PAM protospacer adjacent motif
PCR polymerase chain reaction
PI3Ki PI3K inhibition
qPCR quantitative real-time PCR
PFA paraformaldehyde
rev reverse
RGF radial growth phase
RNAseq RNA sequencing
ROS reactive oxygen species
RT room temperature
rpm rounds per minute
S1 security level 1
scRNA-seq single cell RNA sequencing
sgRNA single guide RNA molecule
SN supernatant
T thymidine
TF transcription factor
TS top strand
UV ultraviolet
VGF vertical growth phase
WT wild type
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